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As we age, skeletal integrity becomes compromised due to a decrease in bone mineral 
density. Bone formation is mediated by osteoblast (OB) cells which originate from 
mesenchymal stem cells (MSC). MSCs, a rare stem cell population within the bone marrow, 
possess self-renewal and multi-lineage differentiation potential. In aging or diseased states, 
such as osteoporosis, there is a reduction in osteoblastic differentiation potential of MSCs in 
favour of differentiation toward fat storing adipocytes (AdC). Several signalling pathways 
have been shown to regulate osteogenic commitment of MSCs as well as the subsequent 
processes of osteoblast differentiation and skeletal formation. The mammalian target of 
rapamycin complex 1 (mTORC1) has been implicated as a master regulator of cell 
metabolism that integrates signals which control MSC commitment and OB function. 
However, the direct role of this complex in these functions remains to be determined. To 
definitively address the role of mTORC1 in MSC fate determination, OB differentiation and 
bone accrual, this project utilised the Cre-loxP system of targeted transgenesis, which enabled 
the tissue-specific and temporal inactivation of Rptor, the gene encoding for the mTORC1 
complex-specific protein raptor. 
In this study Rptor-deficient MSCs cultured under osteogenic and adipogenic-
inductive conditions displayed a reduced capacity to form lipid-laden AdCs and an increased 
capacity to form a mineralised matrix. Consistent with the increased osteogenic 
differentiation, deletion of Rptor in MSC resulted in an up-regulation in the expression of the 
osteogenic growth factor BMP2, a known inducer of RUNX2 expression, OB maturation and 
mineral formation. 
To examine the role of raptor in skeletal development, Rptor was deleted in pre-
osteoblastic cells marked by their expression of the osterix (Osx) gene, by crossing Rptorfl/fl 
mice with Osx-cre transgenic mice. Deletion of Rptor lead to a reduction in limb length at 
birth and post-natally and was associated with smaller epiphyseal growth plates. Deletion of 
Rptor caused a marked reduction in pre- and post-natal bone acquisition in both 
 
Page ii 
intramembranous and endochondral ossification leading to skeletal fragility. The decrease in 
bone acquisition was not due to a reduction in OB numbers but a reduction in OB function. In 
vitro, primary OBs from knockout animals failed to respond to extracellular factors that 
promote bone formation including insulin and BMP2 and assessment of bone development 
markers in Rptor knockout OBs revealed a transcriptional profile consistent with an immature 
OB phenotype suggesting that OB differentiation was hindered early in osteogenic 
development. These findings demonstrate that mTORC1 plays an important role in skeletal 
development by controlling OB differentiation and hence function. 
Taken together, these studies show that mTORC1 plays an important role in MSC fate 
determination and bone accrual. Notably, deletion of raptor in pre-osteoblasts blocked 
osteoblast differentiation causing defective intramembranous and endochondral ossification 
resulting in a low bone mass phenotype and skeletal fragility. 
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Skeletal diseases associated with excessive bone loss and skeletal fragility, such as 
osteoporosis and osteopenia, are currently estimated to affect 66% of Australians over the age 
of 50 years 1. In 2012, osteoporosis, osteopenia and bone fractures in older Australians cost 
the Australian Health System an estimated $2.75 billion per annum, with this figure projected 
to rise to $3.84 billion per annum by 20221. Alarmingly, studies have shown that in recent 
years, little progress has been made in preventing and managing osteoporosis in Australia. 
With an increasingly aging population, the prevalence of this disease is expected to increase 
exponentially in coming decades, highlighting the necessity for research into new 
therapeutics. 
Osteoporosis is associated with a decrease in bone mineral density and an increase in 
intramedullary adiposity 2. Adipocytes (fat cells) and osteoblasts (bone cells) are derived from 
a common mesenchymal stem cell (MSC) progenitor, and the differentiation toward either 
lineage is a mutually exclusive and transcriptionally controlled process governed by 
transcriptional cues. It has been hypothesised that the shift in the osteoblast (OB) to adipocyte 
(AdC) ratio observed in osteoporosis arises from increased adipogenic differentiation at the 
expense of osteoblastic differentiation in osteoporotic individuals 3, 4.  
While the mechanisms underlying these changes in MSC behaviour remain to be 
determined, it is possible that as we age, key signalling pathways responsible for determining 
MSC fate become aberrantly regulated in this cell population. To date, several signalling 
pathways including Wnt/β-catenin 5, 6, BMP/SMAD 7, 8, Indian hedgehog (IHH) 9-11, MAPK 
12, 13 and insulin/IGF1 14, 15 have been implicated to play a role in MSC fate determination. 
Furthermore, recent studies have also implicated mammalian target of rapamycin (mTOR) as 
being important in MSC fate determination, with inhibition of mTOR promoting OB 
differentiation 13, 16-18 and suppressing AdC differentiation 19-23. However, contradictory 
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studies have shown that inhibition of mTOR inhibits OB differentiation 24-29, and therefore the 
precise role of mTOR in MSC lineage determination and skeletal development remains 
unclear. 
The following introduction presents a brief overview of the literature regarding (i) the 
process of skeletal development and bone accrual, (ii) MSC commitment and differentiation, 
(iii) the role of mTORC1 in MSC commitment and (iv) the role of mTORC1 in skeletal 
development and bone accrual. 
1.2 Bone structure and composition 
Bone is the main support structure of vertebrate animals and serves several important 
functions. Structurally, the skeleton serves as a protective cage for vital organs such as the 
brain, lungs and heart, provides mechanical support to soft tissues and aids movement by 
acting as a lever in muscle action. Bones also house and protect the bone marrow, responsible 
for the production of red and white blood cells and serve as a reservoir for calcium and 
phosphate for the maintenance of mineral homeostasis 30-33. 
Bones consist of both organic and inorganic elements. The inorganic mineral 
component, composed mostly of calcium and phosphate in the form of hydroxyapatite 
[Ca10(PO4)6(OH)2], provides stiffness and structure and serves as a metabolic reserve for 
mineral homeostasis. The organic component is formed of collagen, proteoglycans, matrix 
proteins, cytokines, growth factors and bone cells, which collectively maintain skeletal 
integrity and provide tensile strength and elasticity 31, 34. Structurally, there are two types of 
bone tissue: cortical bone and trabecular bone. These tissues are biologically identical, 
however as described in detail below, the different arrangements of their respective 
microstructures mean that they perform vastly different functions.  
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1.2.2 Cortical bone 
Most bones consist of a dense outer layer known as cortical bone. Also known as 
compact bone, cortical bone is made up of densely-packed mineral covered by a vascular 
layer of connective tissue containing progenitor cells capable of maturing into bone forming 
cells. The outer bone surface connective tissue layer is termed the periosteum and the inner 
surface layer adjacent to the medullary cavity is the endosteum. Cortical bone tissue provides 
strength and hardness to the bone and contributes approximately 80% of the weight of a 
human skeleton. Structurally cortical bone facilitates many of the skeleton's main functions: 
to support the body, protect organs, provide levers for movement and store and release 
chemicals. Canals in the compact mineral allow for nerves, blood vessels and lymph vessels 
to interact with the marrow cavity and periosteum 31 (Figure 1.1).  
1.2.3 Trabecular bone 
Trabecular or cancellous bone accounts for approximately 20% of the human skeleton 
and provides structural support and flexibility to the skeleton without the weight of cortical 
bone. It exists in a three dimensional, lattice-like formation (Figure 1.1), which gives it a 
much higher surface area to mass ratio and softer, weaker and more flexible characteristics 
than the dense cortical bone. Trabecular bone makes up much of the enlarged ends 
(epiphyses) of the long bones, and is a major component of the ribs, skull, shoulder blades 
and various other short, flat bones that comprise the skeleton. Depending on the need for 
strength or flexibility, different bones contain varying proportions of space relative to bone 
within their trabecular region. The open structure of trabecular bone also enables it to dampen 
sudden stresses, and its greater surface area facilitates metabolic activity (e.g. exchange of 
calcium and phosphate for mineral homeostasis). As it is more highly involved in the 
elasticity of the bone structure, trabecular bone constantly requires repair and maintenance.  
Figure 1.1 - Trabecular and cortical bone: Cross sectional image of bone illustrating the 
cortical and trabecular bone structure. Adapted from Junqueira’s Basic Hisology: Text and 







1.3 Bone development 
Bone development occurs via two distinct processes termed intramembranous 
ossification and endochondral ossification. Intramembranous ossification is responsible for the 
formation of most of the craniofacial skeleton and flat bones, whereas endochondral ossification 
is responsible for the formation of the long bones, ribs and vertebrae of the appendicular and 
axial skeleton (reviewed by 35). In both processes, osteoblasts (OBs), the bone forming cells of 
the skeleton, play an essential role. 
1.3.1 Intramembranous ossification 
During embryonic development, intramembranous ossification begins with 
proliferation of embryological mesenchymal stem cells (MSCs) that condense to form a sheet 
of connective tissue termed the mesenchyme. These MSCs then differentiate into bone-forming 
OBs which secrete osteoid, an extracellular matrix composed primarily of type-I collagen fibrils 
which provide the initial scaffold for mineralised bone formation. Following osteoid synthesis, 
OBs deposit hydroxyapatite crystals forming woven bone matrices in small mineral masses of 
bone called spicules. OBs continue the synthesis of osteoid and mineral lengthening, connecting 
adjacent spicules to form the lattice-like network. Some OBs become embedded within the 
matrix and undergo terminal differentiation to become osteocytes, creating a signalling network 
within the bone and to the bone surface.  New bone is invaded by blood vessels enabling the 
formation of the haematopoietic bone marrow. The periosteum is then formed around the 
trabeculae which consist structurally of an inner layer of bone lining OB precursors held 
together by an outer layer of fibroblasts. Osteogenic precursors from the periosteum mature 
into OBs leading to the further deposition of osteoid and mineral, creating layer upon layer of 
ossified bone. This mineral layering occurs until an optimal density is achieved, forming the 
cortical bone in a process known as appositional bone formation (Figure 1.2) 36. 
  
 
Figure 1.2 - Intramembranous ossification: A) Ossification centres appear within a sheet of 
dense fibrous connective tissue when clusters of mesenchymal stem cells begin differentiating 
into osteoblasts and start secreting osteoid. B) Osteoblasts mature and synthesise calcified 
bone matrix to replace the fibrous membrane in small masses called spicules. During the 
ossification process, osteoblastic cells trapped within the matrix form osteocytes. C) Spicules 
expand until they fuse in a lattice-like structure, known as the trabeculae, around blood 
vessels. The layer of mesenchyme condenses on the external surface leading to the formation 
of the periosteum. D) As the structure matures, trabeculae near the periosteum thicken 

























1.3.2 Endochondral Ossification 
Unlike intramembranous ossification, endochondral ossification is preceded by the 
formation of a cartilage structure 37, 38. As outlined in Figure 1.3, endochondral ossification 
begins with the condensation and differentiation of MSCs into chondrocytes which produce a 
cartilaginous matrix scaffold, or anlage, composed predominantly of type II collagen and 
chondroitin sulphate proteoglycan (aggrecan) aggregates 39, 40. The anlage acts as a template for 
the subsequent formation of the bony elements of the skeleton and is covered by the 
perichondrium, a fibrous dense layer of tissue which, once vascularised, becomes the  
periosteum. Ossification centres appear first in the centre of the anlage followed by the 
extremities. In these centres, the chondrocytes enlarge and mature, coinciding with an increase 
in intracellular calcium concentrations. Then, as chondrocyte apoptosis occurs, a calcified 
scaffold appears. Simultaneously, neo-vascularisation of the perichondrium leads to the 
formation of the periosteum which delivers the OB progenitors. Capillaries and osteogenic cells 
then invade the calcified scaffold, initiating the deposition of the osteoid that is subsequently 
ossified by mature osteoblasts to form mineralised bone 30, 37, 41.  
1.3.2.1 Chondrogenesis and the growth plate 
During skeletal growth, long bone elongation occurs in specialised regions known as 
growth plates. At the cellular level, the growth plate is organised into three layers of 
morphologically and actively distinct chondrocytes termed the resting-, proliferative- and 
hypertrophic zones 42-45 (Figure 1.4).  
The rate of longitudinal bone growth is primarily dictated by the rate of chondrocyte 
proliferation and hypertrophy 45, 46. During childhood and adolescence, growth plate activity is 
at its peak velocity which progressively declines following sexual maturation and ceases in 
adulthood. The decline in activity is accompanied by a steady reduction in growth plate width.  
  
Figure 1.3 - Endochondral ossification: A) Endochondral ossification begins with the 
condensation of MSCs into chondrocytes which produce a cartilaginous scaffold or anlage for 
subsequent mineral formation. B) MSCs within the perichondrium undergo OB differentiation 
and synthesise a collar of bone around the anlage. C) Chondrocytes within the anlage 
proliferate and hypertrophy. Invading blood vessels deliver OBs which replace the 
cartilaginous scaffold with bone mineral. D) Chondrocytes at the epiphyses continue to 




















Figure 1.4 - The growth plate: Longitudinal bone growth is dependent upon the activity of 
the growth plates located in the epiphyses of long bones. Chondroblasts form the resting zone 
and function as a reserve for proliferative clones. Resting chondrocytes, located near the 
metaphases mature and enter the proliferative-zone where they align in column, parallel to the 
axes of the bone and synthesise a cartilaginous matrix. Farthest from the epiphyses, in the 
hypertrophic zone, chondrocytes cease proliferation and increase in size which increases the 
width of the cartilage scaffold. Hypertrophic chondrocytes then undergo apoptosis and the 
remaining cartilage scaffold is vascularised. OBs and OCs are recruited to the scaffold which 















In adult humans, the active cellular components of the growth plate are replaced by inorganic 
mineral, which stops further long bone growth 47, 48. 
The resting zone, positioned nearest the epiphyses, is formed of closely grouped and 
irregularly arranged chondroblasts which rarely divide and function as a reserve of stem-like 
cells capable of generating proliferative clones44, 45. Chondroblasts located near the metaphyses 
mature and begin the formation of the proliferative zone. Here chondrocytes flatten and align 
into columns parallel to axes of the bone. Chondrocyte proliferation within the columns 
facilitates organised elongation of the growth plate. Simultaneously, proliferative zone 
chondrocytes begin anlage synthesis 42-45, 49. Farthest from the epiphyses is the hypertroic 
zone,where proliferative chondrocytes cease dividing and increase in size via both dry mass 
and fluid accumulation 50. It is the proliferation and hypertrophy of the chondrocytes which 
increases the width of the cartilage scaffold. The enlarged hypertrophic chondrocytes undergo 
apoptosis creating crevasses within the anlage.  
Concurrent to chondrocyte hypertrophy, surrounding perichondrial MSCs differentiate 
into OBs and begin the initial stages of mineral deposition. Crevasses are invaded by blood 
vessels in the formation of the medullary cavity42, 51. The cartilage scaffold is digested and 
replaced with mineral in the initial formation of the epiphyseal trabecular bone (spongiosa). 
The spongiosa is digested and reformed in the process termed bone remodelling.  
1.4 Bone remodelling 
Bone remodelling is the homeostatic process required to build and maintain skeletal 
integrity. Remodelling is orchestrated by the actions of two cell types, namely the bone-forming 
OBs and bone-resorbing osteoclasts (OCs) 30, 52. Bone remodelling alters the microarchitecture 
of the skeleton to form an optimal structure, repairs micro-fracture-related damage, changes 
bone density and facilitates the management of systemic calcium and phosphate levels.  
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In the healthy adult skeleton, bone remodelling is tightly-coupled in time and space, 
with OC activity and OB activity maintained in equilibrium. As outlined in Figure 1.5, bone 
remodelling is a cyclical process beginning on a quiescent bone surface covered in bone lining 
cells. In response to signals, usually originating from osteocytes, bone lining cells retract and 
expose the bone surface 53. Haematopoietic precursors are recruited to the exposed bone surface 
and mature into bone-resorbing OCs. OCs fuse to the bone surface and secrete proteolytic 
enzymes and acids which digest bone mineral through the breakdown of hydroxyapatite and 
organic components. This process increases cytosolic Ca2+ signalling, which in turn signals  
OCs to detach from the mineral matrix and expose the resorbed surface 54. During resorption, 
factors sequestered within the mineralised bone, such as transforming growth factor β (TGFβ), 
platelet derived growth factors (PDGFs), insulin-like growth factor (IGF1) and bone 
morphogenic proteins (BMPs), are released and signal the recruitment of OBs. OBs assemble 
on the resorbed bone surface and initiate the synthesis of new mineralised bone matrix 
(Figure1.5) 55-58. 
Uncoupling of normal bone remodelling results in pathological changes to the skeleton. 
In diseases such as osteoporosis, there is a reduction in the number and bone forming capacity 
of OBs. This results in an imbalance between the rate of resorption and the rate of formation, 
resulting in reduced bone mineral density 3, 4. In Paget’s disease, abnormal bone growth occurs 
as a result of increased bone resorption due to increased OC numbers 55, 59. The increase in OC 
activity increases bone activating factors which, in turn, signal the limited numbers of OBs to 
rapidly form bone and as a result, this bone is of poor structural integrity and lacks the strength 




Figure 1.5 - Bone remodelling: In the resting state, the bone surface is covered by bone 
lining cells which retract at activated sites. Osteoclasts are recruited to active sites to digest 
mineral matrices in the process of resorption. Resorption of bone releases factors that lead to 
the chemotaxis of osteoprogenitors to the site of the resorption pits. The osteoprogenitors 
differentiate into the osteoblasts, which  form the osteoid matrix that is subsequently 
mineralized. The osteoblasts trapped in the matrix from osteocytes and osteoblasts become 













OBs are mature, non-proliferative cuboidal cells with a single nucleus, an intensely 
basophilic cytoplasm and a prominent golgi apparatus. Derived from multipotent MSCs in 
response to a variety of stimuli (described in detail in section 1.5), they are responsible for the 
synthesis of an uncalcified osteoid matrix consisting of Type I collagen, osteonectin, 
osteopontin, bone sialoprotein and serum-derived globular proteins 55. The osteoid matrix is 
then mineralised by OBs through the deposition of hydroxyapatite crystals which are 
composed of calcium and phosphate 60. At the bone surface, OBs facilitate active transport of 
Ca2+ ions to the bone formation space through nucleated vesicles and increase phosphate 
levels at the mineralisation front via the enzymatic cleavage of phosphate ions. 
Hydroxyapatite crystal nuclei are synthesised from which further mineral deposition is 
founded. 
1.4.2 Osteocytes 
Osteocytes are terminally differentiated, non-proliferative cells derived from mature 
OBs that become embedded in lacunae of the bone matrix during bone formation. They act as 
a mechanosensory network deep within the bone by forming a syncytium with other 
osteocytes, OBs and bone lining cells via the canalicular network and intercellular gap 
junctions 51, 61. In 
response to extracellular events such mechanical strain, fluid flow and micro-fracture damage, 
osteocytes produce factors such as IGF-1 and nitric oxide, which act as signalling molecules 
to influence bone remodelling62-65. 
1.4.3 Osteoclasts 
OCs arise from mononucleated precursors of haemopoietic origin 51, 66-68. OCs are 
recruited to the bone surface through the recognition of binding matrix proteins which 
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facilitate OC adhesion to the bone surface via the formation of an actin ring sealing zone 51, 69, 
70. Adhesion of OCs to the bone surface is mediated predominantly via integrins 71. Following  
adhesion to the bone surface, OCs polarize and undergo cytoskeletal organisation, allowing 
them to spread along the bone surface. Fusion occurs via a process involving the formation of 
a ruffled membrane which fuses to the bone surface facilitating the transport of intracellular 
microtubules and vesicles containing proteases and protons to the bone surface 51, 70, 72-76. 
Proton pumps along the ruffled membrane, within the sealing zone, reduce the pH and 
solubilise the mineral component of bone 76, 77. Enzymes such as cathepsin K are then 
released to solubilise the collagen matrix 78. Both the solubilised mineral and collagen type I 
fragments are released into the systemic circulation and the OC unseals before undergoing 
apoptosis or are recruited to bone remodelling sites by signals generated from osteocytes79, 80.  
1.5 Mesenchymal Stem Cells 
OBs originate from a pool of precursor stem cells, MSCs which have a capacity for 
self-renewal and multi-lineage differentiation. MSCs are the precursor for a number of cell 
types including, but not limited to OBs, adipocyes (AdCs), chondrocytes and myocytes for the 
regeneration of bone, cartilage, tendons, muscle, ligaments, adipose and stroma 81-83. MSCs 
have been identified in numerous adult tissue including bone marrow 81, adipose tissue 84, 
dental pulp 85 and muscle 86. Isolated MSCs can be cultured ex vivo without significant 
changes in their general properties making them ideal for tissue regenerative therapies. 
As the precursor of OBs, MSCs are essential for the development and homeostasis of 
bone. In aging and diseased states, MSCs undergo behavioural changes often resulting in a 
reduction in their self-renewal and differentiation capacities. For example, osteoporosis is 
characterised by both a decline in MSC pools and a reduction in their osteogenic capacity 3, 4. 
Initial commitment of MSC to each lineage is a tightly-regulated process governed by 
extracellular cues driving intracellular signalling cascades which promote the commitment 
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and multistep maturation stages. During the differentiation process, MSCs progress through 
developmental stages both morphologically and functionally, which can be identified by the 
expression of functional markers specific to each lineage 87, 88. 
1.5.1 Osteoblast differentiation 
OB differentiation is the process by which MSC mature into bone forming OBs. This 
is a linear process which can be simplified into three stages of development, namely; the 
formation of OB progenitors, pre-OBs and OBs. Each step is characterised by the temporal-
spatial expression of OB gene markers required for their maturation and function. 
OB differentiation is regulated by two primary transcription factors; Runt-related 
transcription factor 2 (Runx2) and Osterix (Osx). Both transcription factors are essential for 
OB differentiation, as mice lacking Runx2 or Osx are devoid of a mineralised skeleton due to 
complete absence of mature OBs87, 89. Runx2 regulates the expression of OB genes including 
osterix (Sp7) 90, integrin-binding saloprotein (Ibsp), osteopontin (Spp1), osteonectin (Sparc) 
and osteocalcin (Bglap) 91, 92. Together, Runx2 and Osx regulate the expression for OB genes 
encoding collagen type I (COL1A1), and alkaline phosphatase (ALPL)34. 
The expression of Runx2, Osx and other OB genes occurs in a stage-dependant 
manner which is commonly utilised in the quantification of the differentiation process. 
Widely considered to be the master regulator of osteogenesis, Runx2 signifies the 
differentiation of multipotent MSCs into the precursors of both OBs and chondroctyes 
(osteochondroprogenitors) 93. Runx2 is a central mediator in bone morphogenic protein 
(BMP) and Wingless-related integration site (Wnt) signalling, which function to promote cell 
lineage commitment and osteogenesis.  
Progenitor cells are morphologically indistinct from their MSC predecessors and 
expansion and maturation of progenitor cells are regulated by both fibroblast growth factors 
(FGF) and parathyroid hormone (PTH/PTHrP) 94. Both the expression of Osx and canonical 
Wnt signalling activation mark the end of the proliferative precursor stage and are essential 
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for progression into the subsequent developmental stage of a pre-OBs. Wnt proteins, BMPs 
and transforming growth factor beta (TGFβ) families are involved in early skeletal 
development and act as mitogenic factors for MSC proliferation. At this time, cellular 
morphology shifts into the cuboidal shape of the mature OB cell, and pre-OBs begin 
synthesising extracellular matrix (ECM) proteins. Composed primarily of collagen type I 
(COL1A1), the synthesis of ECM by pre-OBs requires the expression of the COL1A1 and 
BSP proteins 95. Progression into the mature OB stage is marked by decreased levels of 
Runx2 and increased levels of alkaline phosphatase (ALP). At this stage, OBs continue the 
synthesis of ECM and initiate mineralisation with upregulation of osteopontin (OPN) and 
osteocalcin (OCN). Mature stage mineralisation is facilitated by the OB-specific protein 
OCN, which binds the calcium and phosphate components of hydroxyapatite crystals 95. 
1.5.2 Chondrocyte differentiation  
Chondrocytes, also arising from MSCs, are responsible for the production of 
cartilaginous matrices during endochondral ossification (as outlined in section 1.3.2), for the  
synthesis of on the epiphyseal surfaces of long bones and the intervertebral discs of the spine, 
and form structural components of the rib cage, ear, nose and bronchial tubes 96. 
Chondrogenic differentiation is facilitated by the expression of key transcription 
factors Runx2 and sex determining region Y box 9 (Sox9) 35. As mentioned in section 1.5.2, 
chondrogenic differentiation begins with the initial expression of Runx2 in MSCs, which 
drives the initial stages of commitment to the osteochondroprogenitor lineage. Secondary to 
Runx2 upregulation and in the absence of Osx, commitment to the chondrocyte lineage is 
facilitated by the expression of Sox9. Expression of Sox9 and its downstream targets Sox5 
and Sox6 stimulates the expression of genes encoding cartilaginous extracellular matrix 
proteins including collagens II, IX and XI and aggrecan 97-99. Unlike osteogenesis, where 
Runx2 expression decreases in mature osteoblasts, Runx2 is expressed in mature pre-
hypertrophic and hypertrophic chondrocytes and promotes hypertrophic differentiation. The 
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necessity of Runx2 in these later stages is  evidenced by a decrease in the number of 
hypertrophic chondrocytes in Runx2 null mice 89, 100-102.  
1.5.3 Adipocyte differentiation 
AdCs, also arising from MSCs, control the systemic balance of energy and lipid 
homeostasis through the storage and expenditure of energy via lipid accumulation and release 
and the production of adipokines 103.  
The main transcription factors involved in the commitment and maturation of AdCs 
from multipotent cells are the nuclear hormone receptor, peroxisome proliferator-activated 
receptor γ (PPARγ) and the CCAAT/enhancer binding protein α, C/EBPα 104. PPARγ is the 
master regulator of adipogenesis 88 and is required during both the initial commitment and in 
the maintenance of an adipogenic state as its expression can be detected throughout the 
lifespan of the AdC 105. PPARγ promotes the expression of CAAT-enhancer binding proteins 
(C/EBP) including C/EBPα, C/EBPβ and C/EBPδ, which are also essential in adipogenesis 
106, 107. Like PPARγ, C/EBPα expression is maintained throughout the lifespan of an AdC 108. 
Together, their expression is essential for both the regulation of early adipogenesis and the 
expression of adipogenic genes such as insulin-responsive glucose transporter (GLUT4), 
Stearoyl-CoA desaturase–1 (SCD1) and leptin 109. PPARγ and C/EBPα then form a positive 
feedback loop to maintain and enhance their expression and activate adipogenic genes 
required for function and maintenance of differentiated AdCs and accumulation of 
triglycerides 108, 110. 
1.6 Inverse relationship between adipocytes and osteoblasts 
The aging skeleton is characterized by a reduction in bone mineral density and an 
increase in intramedullary adiposity 3, 111. At the cellular level, these age-related changes are 
associated with an increase in bone marrow AdCs and a decrease in bone-forming OBs 2. At 
the cessation of longitudinal bone growth, the requirement for bone development is limited to 
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micro- and macro-damage repair resulting in a reduction in MSC proliferation and a decrease 
osteogenic capacity.  
As AdCs and OBs originate from a common MSC progenitor 112-115, the shift in the 
AdC:OB ratio is thought to occur in response to increased AdC differentiation at the expense 
of OB differentiation 116, 117. This is associated with a decrease in response to bone stimulating 
factors favouring the upregulation of genes involved in adipogenesis 118, 119. In support of this, 
functional comparisons of MSCs isolated from osteoporotic and healthy individuals show that 
while similar in morphology, size and cell surface antigen expression, MSCs from 
osteoporotic individuals exhibit a reduced propensity for osteogenic differentiation 3, 4.  
Key transcription factors for each lineage not only promote lineage commitment but 
prevent commitment to the opposing lineage. Runx2, the master regulator of osteogenesis, has 
been shown to inhibit PPARγ expression and AdC differentiation 120. Conversely, PPARγ, has 
been shown to inhibit Runx2 expression and OB differentiation 108, 121-123.  
1.6.1 Signalling pathways governing OB and AdC differentiation 
The balance between OB and AdC differentiation requires the coordinated 
communication of extracellular stimuli activating complex intracellular signalling cascades. 
Activation of these cascades regulats the expression of lineage-specific genes. Specific to the 
AdC:OB ratio, several signalling pathways, including Wnt/β-catenin, BMP/SMAD, Indian 
hedgehog (IHH) and Insulin/IGF1 have been shown to direct MSC to either or both lineages33, 
124-127. 
1.6.1.1 Insulin 
The role of insulin and insulin-like growth factor-1 (IGF-1) in MSC differentiation has 
been well documented, with both shown to have both pro-osteogenic and pro-adipogenic 























Figure 1.6 - Osteogenic and adipogenic MSC Differentiation: Activation of signalling 
pathways drive the initial commitment of MSCs to lineage precursors by promoting the 
transcription of genes essential in cell maturation and function. (Green arrows = stimulate; red 






The binding of IGF-1 to the IGF1-R receptor activates insulin receptor substrate (IRS) 
proteins and mediates OB maturation via upregulating Osx expression in pre-OBs. 
Furthermore, bone formation has been shown to be mediated by IGF-1 signalling as it 
mediates OCN transcription 124. Insulin and IGF-1 indirectly regulate Runx2 to promote post-
natal bone accrual. Insulin down-regulates Twist1 and Twist2 expression 124 which inhibit 
Runx2 activity 124. IGF-1 and Insulin also inhibit Foxo1-mediated suppression of Runx2 
activity by promoting Foxo1 phosphorylation and nuclear exclusion 128. IGF-1 signalling is 
also necessary for the proliferation of pre-AdCs and essential for expression of PPARγ and 
C/EBP and the activation of the adipogenic cascade129, 130. 
1.6.1.2 Wnt Signalling 
Wnt/β-Catenin signalling is crucial for bone formation and is involved in pre-OB 
replication, induction of OB differentiation 131 and inhibition of OB apoptosis 132, 133. Wnt 
signalling is activated following the binding of ligands such as Wnt1, Wnt3a and Wnt8 to 
membrane receptor complexes composed of Frizzled and LRP5/6 (low density lipoprotein 
receptor-related protein 5 and 6) 134. Activation results in the stabilisation and translocation of 
β-catenin to the nucleus where it regulates gene expression 135. In vitro studies show that Wnt 
signalling is significantly upregulated during OB differentiation and enhances OB 
differentiation at the pre-OB stage through the upregulation of Runx2 33, 125, 136. Studies also 
show that Wnt signalling suppresses AdC differentiation by downregulating C/EBPα and 
PPARγ whilst increasing Osx and Runx2 expression 137. 
1.6.1.3 BMP Signalling 
BMPs are part of the TGFβ superfamily and play a crucial role in the formation of 
cartilage and bone as well as postnatal bone formation. BMPs have been found to play 
important roles in both embryonic development and adult tissue homeostasis 138-141. Notably, 
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BMP-2 expression is involved in both osteogenic MSC differentiation 142 and induces OCN 
expression in mature OBs 143. During osteogenic MSC differentiation, BMPs bind to type I 
and type II BMP receptors and form a multimeric receptor-ligand complex 144. This leads to 
the phosphorylation and translocation of SMADs to the nucleus 145. SMADs then induce 
Runx2 expression, directing MSCs to differentiate towards the OB lineage. BMP-2 is known 
to promote OB differentiation by inducing the expression of both Runx2 and Osx 146, 147 
1.7 The mammalian target of rapamycin (mTOR) pathway 
The mTOR pathway is a key nutrient-sensing pathway that controls cell growth and 
metabolism. Mammalian target of rapamycin (mTOR) functions as a nutrient sensing 
checkpoint integrating several environmental cues including energy levels, growth factors, 
amino acids and cellular stress 148-152. Compared to other effectors, mTOR has only recently 
become recognised as a regulator of MSC differentiation and bone development. The target of 
rapamycin (TOR) gene was first identified in yeast as recently as 1991 by collaborators of this 
project at the Biozentrum, Basel, Switzerland 153. The mammalian ortholog, mTOR, was 
identified several years later in 1994 148 has since been recognised as the primary protein 
kinase in two multiprotein complexes; mTOR complex 1 an 2 (mTORC1 and mTORC2) 154-
156. mTORC1 and mTORC2 are structurally distinct and both complexes localise to different 
subcellular compartments with differing effectors and downstream targets 157. mTORC1 
consists of Raptor (regulatory associated protein of mTOR), PRAS40, mLST8 and mTOR, 
and controls protein synthesis, ribosome biogenesis and nutrient transport 150, 158. mTORC2 
consists of Rictor (rapamycin insensitive companion of mTOR), mSIN1, mLST8 and mTOR 
and is involved in cytoskeletal organisation 156.  
The distinct mTOR complexes were originally distinguished by their sensitivity to 
mTOR kinase inhibition by the macrolide, rapamycin. Notably, rapamycin readily inhibits 
mTORC1 activity but only inhibits mTORC2 activity following prolonged exposure and 
Chapter 1 
Page 23 
mediates its inhibitory effect on mTORC1 by blocking substrate recruitment. Rapamycin 
forms a complex with cytosolic 12kDa FK506-binding protein (FKB12) which binds directly 
to mTORC1 via the FKBP12-rapamycin binding (FRB) domain 159, 160. It is thought that by 
binding to the FRB domain, the FKRBP12-rapamycin complex exerts an allosteric influence 
on substrate alignment to mTOR159, 161. Conversely, while the FKBP12-rapamycin complex 
readily binds to mTORC1, it cannot bind to pre-formed mTORC2 155, 157. However, it does 
bind to free mTOR, destabilising both mTORC1 and mTORC2 formation 150, 162. 
Rapamycin studies, both in vivo and in vitro, have identified mTORC1 as being a key 
regulator in MSC lineage commitment and skeletal development. As detailed in section 1.7, 
both complex-specific studies and studies targeting mTORC1-effectors have provided further 
evidence that mTORC1 is a mediator in these processes. For these reasons, the focus of this 
study is to better define role of mTORC1 independently of mTORC2 in these processes. 
(Figure 1.7).  
1.7.1 mTORC1 
mTORC1 is ubiquitously expressed in all cell types and has been established as a 
master regulator of cell growth, metabolism and proliferation by activating translation of 
proteins 163. The mTORC1 signalling network is activated by growth factors including IGF-1, 
Wnt signaling, energy status, oxygen and amino acids (Figure 1.7).  
1.7.1.1 Upstream activators of mTORC1 
Activation of mTORC1 is mediated primarily through the ras homolog enriched in 
brain (Rheb) which is modulated via TSC1/2 complex activity. Other direct effectors of 
mTORC1 include RagA family of small GTPases (Rag) and mitogen-activated protein kinase 
(MAPK), AMPK. Extra-cellular factors that control skeletal development and bone accrual 
activate mTORC1 (Figure 1.6). 
 
 
Figure 1.7 - Simplified schematic representation of the mammalian target of rapamycin 






































Growth factors including insulin and IGF-1 activate mTORC1 through stimulation of 
the PI3K/Akt signalling cascade. Binding of insulin to its receptor promotes the recruitment 
of IRS1 causing the subsequent activation of PI3K and recruitment of AKT to the plasma 
membrane. This leads to suppression of the negative regulator of mTORC1, TSC1/2, which is 
a GTPase activating protein for Rheb, a small GTPase. In its GTP-bound state, Rheb binds to 
and activates mTORC1 152, 164, 165. 
mTORC1 is also activated by Wnt ligands. Wnt proteins activate mTORC1 via Akt-
mediated suppression of GSK-3β. In the absence of Wnt signalling, GSK-3β phosphorylates 
and enhances the activity of TSC2 promoting the conversion of Rheb-GTP to Rheb-GDP 
thereby inhibiting mTORC1 function 166, 167. 
Cellular energy status regulates mTORC1 activity via AMP-activated protein kinase 
(AMPK) to modulate cellular proliferation and function in at least three separate ways. 
Firstly, AMPK is activated under low glucose influx, causing the phosphorylation and 
activation of TSC2 and the inhibition of mTORC1 activity 168. Secondly, activation of AMPK 
also directly inhibits mTORC1 through the phosphorylation of Raptor 169. Thirdly, recent 
studies have shown that AMPK is involved in the regulation of Rheb, which binds to and 
activates mTORC1 in its GDP-bound form. 
Reduced cellular oxygen levels modulate mTORC1 activity through multiple channels 
to decrease mitochondrial function and cellular apoptosis 170. Hypoxic conditions (i.e. 
conditions of reduced oxygen availability) reduce cellular ATP, which activates AMPK and 
decreases mTORC1 activity 171, 172. TSC1/2 is also activated in response to low oxygen levels 
through transcriptional regulation of the DNA damage response 1 (REDD1) protein 173.  
Finally, sufficient amino acid availability is required for mTORC1 activity which is 
independent of its association with TSC1/2 163. Evidence suggests that amino acid signalling 
regulates mTORC1 activity through the RagA family of small GTPases and mitogen-
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activated protein kinase 3 (MAPK) 174, 175. While the mechanisms by which this occurs are yet 
to be fully elucidated, studies show that amino acid availability is essential for the re-
localisation of cytoplasmic mTORC1 to a perinuclear region in order for it to associate with 
the coactivator, Rheb 152, 176. 
1.7.1.2 Downstream of effectors of mTORC1 
The two best characterised targets of mTORC1 are p70-S6 Kinase 1 (S6K) and the 
eukaryotic initiation factor 4E binding protein 1 (4E-BP1) 177(Figure 1.6). mTORC1 
phosphorylates at least two residues of S6K including threonine T389, which stimulates 
subsequent phosphorylation of S6K by PDK1. Once activated, S6K is known to mediate 
several roles in the regulation of cellular processes including translation initiation, ribosomal 
biogenesis 178 and in a positive feedback loop activates mTOR translation 179.  
4E-BP1, also a direct target of mTORC1, controls cap-dependent translation initiation 
together with S6K1. Phosphorylation of 4E-BP1 causes its dissociation from eukaryotic 
initiation factor 4E (eIF4E) allowing for its subsequent association with the eIF4G complex 
177, 180. Simultaneously, S6K1 acts on the formation of the eIF4G complex through the 
activation of eIF4B181. This complex binds to the 5’ cap of mRNA and once assembled, 
facilitates cap-dependant translation and elongation, mRNA biogenesis and the translation of 
ribosomal proteins 182, 183.  
mTORC1 regulates starvation-induced autophagy via direct interaction with unc-51-
like kinase 1 (ULK1). Active mTORC1, phosphorylates and inactivates ULK1. In response to 
decreased amino acid levels, mTORC1 activity is reduced, and ULK1 is activated. 161, 184-187. 
While the mechanisms by which mTORC1 inhibits autophagy remain unclear, studies show 
that ULK1 activation regulates the formation of autophagosomes for the degradation of 
intracellular proteins and organelles 188. 
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mTORC1 also has a central role in homeostatic regulation of protein synthesis via 
feedback loops whereby downstream effectors of mTORC1 also act as upstream regulators. 
For example, growth factor initiated Akt/mTORC1 signalling is negatively regulated by the 
phosphorylation IRS-1 by S6K. Activated S6K interacts directly with IRS-1, promoting its 
degradation, thereby inhibiting its sensitivity to insulin and subsequently inactivating 
PI3K/Akt signalling 183, 189-191. Additionally, S6K also participates in a positive feedback loop 
by phosphorylating mTOR resulting in the stimulation of mTOR activity 179, 192. Additionally, 
growth factor receptor-bound protein (Grb10), a negative regulator of IGF-1 signalling, has 
been identified as a direct target of mTOR leading to the inhibition of mTORC1 activity via 
interaction with both the insulin receptor and Raptor 193, 194.  
1.7.1.3 Raptor is an essential component of mTORC1 
Raptor is essential in mTORC1 activity as it integrates both upstream and downstream 
signalling events. Raptor is a scaffold protein which recruits phosphorylation targets of 
mTORC1 including S6K and 4EBP1 186, 195-198. This is facilitated by the direct binding of 
Raptor to a short amino-acid sequence referred to as the TOS (mTOR signaling) motif present 
in both S6K and 4EBP1 197, 199, 200. Raptor also works as a signal receiver via interaction with 
upstream regulators of mTORC1. Multiple phosphorylation domains have been recognised on 
Raptor which interact directly with Rheb201, RagA152 and MAPK activated ribosomal protein 
S6 kinase (RSK) 174 to stimulate mTORC1 activity. Conversely, during cellular energy stress, 
activation of AMPK results in the direct phosphorylation and inactivation of Raptor inhibiting 
mTORC1 activity169. Raptor has been identified as both a unique component of mTORC1 189 
and an essential in mTORC1 function202. It is for these reasons that Raptor is the target of 
functional studies of mTORC1.  
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1.8 Evidence for a role of mTORC1 in MSC lineage commitment 
Established in vitro protocols have identified mTORC1 as a mediator of lineage 
specific gene expression during MSC differentiation. As mentioned previously (Section 
1.5.5.1), activation of insulin signalling is required for adipogenesis. Constitutive activation of 
mTORC1 through loss of TSC1/2 function increases mRNA and protein expression of PPARγ 
which, in turn, leads to increased triglyceride levels in pre-adipocyte cells23. Additionally, 
inhibition of mTORC1 via rapamycin results in reduced AdC differentiation and lipid 
accumulation by mature AdC. Inhibition of mTOR decreases expression of most adipogenic 
genes including PPARγ, adipsin and ADD1/SREP1c, stalling adipogenic MSC differentiation 
resulting in reduced lipid accumulation 20-22, 203, 204.  
Observations indicate that mTORC1 signalling is required in the proliferative stages 
of OB differentiation with rapamycin inhibition reducing the proliferative capacity of 
osteogenic mouse cell lines, primary mouse bone marrow cells 25 and human embryonic stem 
cells 205.  However in vitro inhibitor studies investigating the role of mTOR in differentiation 
and bone formation have produced conflicting evidence depending largely on cell type and 
inhibitory method used. In differentiating OBs, OB-like cells and primary bone marrow 
stromal cells (BMCs) display reduced OB differentiation in response to rapamycin 
administration25.  Rapamycin treatment blocks the expression of osteoblastic gene expression 
and mineral matrix production in rat BMCs 24 and osteogenic protein-1-induced ALP activity 
in primary rat calvarial OBs 27. 
However, studies have also indicated that rapamycin treatment increases expression of 
osteoblastic genes during differentiation of MSC to bone forming OBs 18, 205 and in 
differentiated OBs 27. Rapamycin promotes osteogenic differentiation of hESCs by blocking 
proliferation and stimulating BMP signalling resulting in increased expression in Rux2, OCN, 
BMP2, osteonectin and osteoprotegerin 205. Rapamycin increases mRNA expression of 
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osteopontin and osteocalcin in terminally differentiated osteosarcoma cell line resulting in 
increased mineral matrix deposition 17. Inhibition of both PI3K and mTOR using the 
compound, BEZ235, also promoted the differentiation of hMSC by upregulating the 
expression of osteogenic markers including BMP2, ALPL, and BGLA and increasing mineral 
matrix production. BEZ235 also enhanced de novo bone formation in calvarial cultures. 
Knockdown of mTOR in OB like cells also promoted osteogenesis by increasing the 
expression of osteogenic markers including BMP2, ALPL, and BGLA 18. 
1.9 Evidence for an in vivo skeletal role for mTORC1: clinical 
observations in humans 
Although limited in nature, clinical observations provide evidence for a role for 
mTORC1 in the regulation of bone density and development in humans. To this end, a recent 
meta-analyses of genome-wide association studies have identified a link between mTOR 
signalling and heritability for adult height 206.  It has also been established that several 
upstream effectors of mTORC1 are associated with skeletal disorders. For example, the low 
bone mass phenotype of patients with Osteoporosis Pseudoglioma syndrome is associated 
with loss of function mutations in the Wnt co-receptor LRP-5 207. Conversely, a high bone 
mass phenotype is presented in humans harbouring gain of function mutations in LRP5 208, 209. 
Humans with tubercular sclerosis exhibit loss of function mutations in upstream effector 
TSC1 and/or TSC2 and present with scelrotic and lytic bone changes 210. Additionally, 
systemic deficiency of IGF-1 is common in several conditions which are associated with low 
bone mass including osteoporosis 211, 212, diabetes type 1 213, 214 and anorexia nervosa 215, 216. 
Rapamycin and analogues thereof, have been used clinically as immunosuppressants 
to prevent organ rejection following transplant 217-222 as well as preventing mTORC1-
mediated cancer cell proliferation 223-230. Rapamycin is used clinically as bone-sparing 
alternative to commonly administered immunosuppressant cyclosporin A (CsA) for 
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suppression of T-cell and B-cell activation in graft-versus-host-disease. While CsA 
administration is associated with rapid bone loss resulting in severe osteopenia, clinical 
evidence has indicated that rapamycin administration preserves bone mass while still 
maintaining immunosuppressive activity 231-235. Furthermore, rapamycin has also been 
identified as a bone sparing agent for patients suffering from osteoporosis and/or bone loss 
which is exacerbated as a result of chemotherapy 236, 237. 
While these observations highlight a potential role mTORC1 signalling in human 
skeletal development and bone accrual, knowledge of what aspects of bone formation that it 
regulates remains largely unknown. 
1.10 Evidence for an in vivo skeletal role for mTORC1: knockout mouse 
models 
Early studies targeting mTORC1 in vivo, were limited by their use of traditional global 
KOs of mTOR which revealed that Rptor KO confered embryonic lethality shortly after 
implantation 202, 238, 239 due to cellular degeneration and vascularisation defects 202. To 
minimise the unintended consequences of traditional KO strategies, conditional KO models, 
which make use of the Cre-loxP system, have been developed202. The Cre-loxP system 
provides a means to “knock-out” and “knock-in” genes in a tissue-targeted manner and as 
described below, has enabled the effects of tissue-specific ablation of Rptor to be assessed. To 
this end, the function of mTORC1, has been investigated in mice with conditional deletion of 
Rptor in adipose tissue 240, skeletal muscle 241, liver 242, neural cells 243, oligodendrocytes 244, 
T-cells 245, oocytes 246, intestinal epithelial cells 247 and haematopoietic cells 248. Notably, the 
adipose-specific KO of Rptor resulted in a substantial reduction in adipose tissue,240 
supporting in vitro evidence that mTORC1 is essential in adipogenesis 20-22, 203, 204. However, 
prior to this study, bone-specific conditional targeting of Rptor had not been reported. 
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Numerous Cre-transgenic lines have been generated for skeletal tissue-specific 
knockout of genes including; The PRX1-Cre line, utilised in the targeting of mesenchymal 
cells with recombination occurring in chondrocytes, osteoblasts, periosteal, and perichondrial 
cells249. The OSX-Cre line, targeting committed OB progenitors 33 and the OCN-Cre line, 
targeting mature, differentiated osteoblasts 250. As described below, for this study, the OSX-
Cre line was selected to investigate the role of mTORC1 in OB maturation and function. 
1.10.1 mTORC1-related knockout models 
Some insight into the role of mTORC1 in skeletal development has been revealed in 
studies where genes encoding for proteins that utilise the mTORC1 pathway have been either 
deleted globally or in OBs. 
Homozygous deletion of genes encoding IGF1, IGF2 or the IGF receptor (IGF1R) all 
conferred abnormal embryonic skeletal development resulting in dwarfism 251-253. While 
postnatal survival of IGF1-/- mice was reduced, progeny were infertile and exhibited delayed 
bone development 251. Furthermore, heterozygous deletion of IGF-1 resulted in reduced 
cortical bone mineral density 254. IGF1r-/- embryos showed delayed ossification that was 
thought to be due to a failure of Igflr null OBs to fully differentiate into mature 
osteocalcin-positive cells 251. 
Bone-specific IGF-1 knockout mice, in which IGF-1 deletion was restricted to mature 
Col1a2-expressing OBs, displayed reduced bone formation and decreased bone mass 255. 
Furthermore, IGF-R ablation via OCN-Cre also caused decreased bone formation at 6 weeks 
of age, due to an impairment of OB activity 256. In contrast, over-expression of IGF-1 in 
Col1a1-expressing cells increased thickness of cortical bone 257. Taken together, these studies 
highlight the importance of IGF signalling, which occurs upstream of mTORC1, in bone 
formation. 
Downstream of IGF signalling, mice harbouring a global knockout of Akt1 developed 
an osteopenic phenotype at 8 weeks of age, as a result of suppressed OB differentiation and 
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function 258. In addition, mice lacking both Akt1 and Akt2 showed neonatal lethality, dwarfism 
259 and delayed bone ossification 166, 260 
The role of the negative regulator of PI3K/Akt/mTOR signalling, PTEN, on skeletal 
development was investigated in conditional knockout mice. Pten deletion in mature OBs, 
driven by Col2a1:Cre, resulted in increased skeletal formation and an increase in both AKT 
and mTOR activity 261. In other studies, mice lacking Pten in mature OBs via OCN-Cre also 
displayed a progressive increase in bone mineral density, attributed to decreased OB 
apoptosis and increased mTOR activity 262. 
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1.11 Summary and project aims 
Recently, a growing body of evidence has emerged suggesting that mTORC1 signalling 
is critical for the regulation of both the differentiation of MSCs and accrual of bone mass. While 
overwhelming evidence suggests mTORC1 is an essential mediator of adipogenic MSC 
differentiation 19-23, conflicting observations have been made in relation to its role in OB 
differentiation and function 13, 16-18, 24-29. The differences in the results of previous studies may 
be attributed to the types of cell used and/or their stage of differentiation. The results of inhibitor 
studies are also confounded by a lack of specificity making it difficult to attribute function to 
mTORC1 or mTORC2. Therefore, the role of mTORC1 in MSC differentiation remains 
unclear. Furthermore, while both clinical and animal studies have suggested a role for mTORC1 
in bone formation, no definitive studies that target bone-specific mTORC1 have been 
performed.  
To address the limitations of previous studies, the Cre-LoxP system of targeted 
transgenesis was utilized to target Rptor, an essential component of mTORC1, in mice. To 
examine the role of mTORC1 in MSC fate determination, primary multipotential MSCs 
deficient of Rptor were generated for in vitro differentiation assays. Additionally, to examine 
the role of mTORC1 in skeletal development, pre-OB specific deletion of Rptor was achieved 
through Cre-mediated targeted deletion in osterix-expressing cells.  
The studies presented in this thesis were designed to address the following aims: 
Aim 1: To determine the role of mTORC1 in MSC fate determination. 
Aim 2: To determine the role of mTORC1 in embryonic and postnatal skeletal 
development. 
 




2.1 Commonly used reagents 
Table 2.1: Reagents and Suppliers 






Acetic acid Merck 6.10001.2500 
Acetone Ajax Finechem, Taren Point, 
NSW 
6-2.5L 
Acrylamide (30% bis 
solution) 
BioRad, Gladesville, NSW 161-0148 
Agarose Sigma-Aldrich A9539 
Alcian blue Sigma-Aldrich A5268 
Alizarin red Sigma-Aldrich A5533 
Calcein Sigma-Aldrich C0875 
Calcium chloride Sigma-Aldrich C1016 
Chromium (III) potassium 
sulphate dodecahydrate 
Sigma-Aldrich 243361 




Table 2.1: Reagents and Suppliers 
Reagent Supplier Catalogue Number 
Citric acid solution Sigma-Aldrich 91-S 
Dexamethasone Sigma-Aldrich D4902 
D-glucose Sigma-Aldrich G8270 
Dimethyl sulphoxide 
(DMSO) 
Ajax Finechem 225-2.5L 
Dithiothreitol (DTT) Invitrogen, Mulgrave, VIC P2325 
Eosin Y Merck 1.15935.0025 
Ethylenediaminetetraacetic 
acid (EDTA) 
Chem Supply, Gilman, SA EA023 
Ethanol (analytical grade) Merck 6.10107.2511 
Fast green Sigma-Aldrich F7252 
Foetal calf serum (FCS) SAFC 12003C 
Formaldehyde, 40% (w/v) Merck 10113 
Gelatine Sigma-Aldrich G9391 




Table 2.1: Reagents and Suppliers 
Reagent Supplier Catalogue Number 
Haematoxylin ProSciTech, Thuringowa 
Central, QLD 
C1071 
Hanks buffered saline 
solution (HBSS) 
SAFC 55021C 
Indomethacin Sigma-Aldrich I7378 
Isoporopanol Ajax Finechem, Taren Point, 
NSW, Australia 
ACR327272500 
L-ascorbate-2-phosphate Wako Pure Chemical 
Industries, Osaka, Japan 
013-12061 
L-glutamine, 200 mM SAFC 59202C 
Hoescht 33258 Sigma-Aldrich B61405 
Hydrochloric acid (HCl), 
35% 
Merck 6.10307.2511 
Methanol Chem Supply MA004-P 
Methyl green Sigma-Aldrich M8884 




Table 2.1: Reagents and Suppliers 
Reagent Supplier Catalogue Number 
Neutral buffered formalin 
(NBF, 10%) 
Fronine Laboratory Supplies, 
Riverstone, NSW 
JJ01810 
Oil Red O MP Biomedicals, Solon, OH 215598425 
Paraformaldehyde Merck 296474L 
Penicillin 5000 U/mL, 
streptomycin 5mg/mL 
Sigma-Aldrich P4458 
Perkadox 16 AkzoNobel, Tullamarine, 
VIC 
1552-11-3 
Phosphate buffered saline 
(PBS) 
20x Media Production Unit 
IMVS 
N/A 
Polyethylene glycol 300 
(PEG 300) 
Sigma-Aldrich 81162 
Proteinase K  Invitrogen 25530-015 
Safranin O Sigma-Aldrich S8884 
Salmon sperm DNA Sigma-Aldrich 31149 




Table 2.1: Reagents and Suppliers 
Reagent Supplier Catalogue Number 
Sodium bicarbonate McKenziees, Altona, VIC N/A 
Sodium carbonate Merck 10240 
Sodium chloride Sigma-Aldrich S9625 
Sodium dodecyl sulphate 
(SDS) 
Merck 444464T 
Sodium hydroxide, pellets Merck 567530 
Sodium hypochlorite 
(12.5% w/v) 
ACE Chemical Company F386 
Sodium iodate Sigma-Aldrich S4007 
Sodium-L-tartrate Sigma-Aldrich 228729 
Sodium nitrite solution Sigma-Aldrich 91-4 
Sodium phosphate Sigma-Aldrich S342483 
Sodium pyrophosphate Sigma-Aldrich S9515 
Sodium pyruvate Sigma-Aldrich P5280 




Table 2.1: Reagents and Suppliers 
Reagent Supplier Catalogue Number 
Tartrate solution Sigma-Aldrich 387-3 
Toluidine blue Sigma-Aldrich T3260 
Tris Roche 1185-53-1 
TRIzol Invitrogen 15596-018 
Trypan blue (0.4%) Sigma-Aldrich T8154 
Trypsin-EDTA (0.5%) Gibco 15400-054 
Tween-20 Sigma-Aldrich P9416 
Type I collagenase 
(400U/mL) 
Worthington Biochem, 
Lakewood, NJ, USA 
LS0004196 
WST-1 Tanaka, Madison, USA 11644807601 







Table 2.2: Antibodies 
Antibody Supplier Catalogue Number 
B220 Biotin BioLegend 103204 
CD11b Biotin eBioscience 13-0112-82 
CD3 Biotin BioLegend 100304 
CD31 PerCP/Cy5.5 BioLegend 102420 
CD4 Biotin BioLegend 100404 
CD45 APC-eFlour 780 eBioscience 47-0451-82 
CD51 PE eBioscience 12-0512 
Gr1 Biotin BioLegend 17-5931-82 
Sca-1 PECy7 BD Bioscience 561021 





2.3 Real time PCR primers 
Table 2.3: Real time PCR primers 
Gene  Forward Primer (5’-3’) Reverse Primer (5’-3’) 




Adipoq TGTTCCTCTTAATCCTGCCCA CCAACCTGCACAAGTTCCCTT 
Alpl GCCTTACCAACTCTTTTGTGC GGCTACATTGGTGTTGAGCTT 
Bmp2 GGGACCCGCTGTCTTCTAGT TCAACTCAAATTCGCTGAGGAC 
Col10a1 CATCTCCCAGCACCAGAATC GCTAGCAAGTGGGCCCTTTA’ 
Col2a1(II) GCGACCGGGAGCATATAACT GCCCTAATTTTCGGGCATCC 












Table 2.3: Real time PCR primers 




Runx2 ATGATGACACTGCCACCTCTG ATGAAATGCTTGGGAACTGC 













All mice were bred and housed at the SA Pathology Animal Care Facility and studies 
were performed with Institutional Ethics approval (SA Pathology Animal Ethics Committee 
approval Project #63/10). Rptorfl/fl mice 241, Osx1-GFP::cre mice 33 and R26-stop-EYFP mice 
263 were used in this study.  
2.4.2 Genotyping 
Routine genotying was performed on DNA isolated from tail biopsies. Briefly, genomic 
DNA was isolated by placing the tail biopsy into 300µL lysis buffer and 4µL proteinase K and 
incubating overnight at 56ºC with agitation. Samples were  subsequently incubated at 95ºC for 
10mins and centrifuged at 16,000g for 10 mins. Supernatant, containing the genomic DNA was 
isolated and PCR was performed using the following primers; Rptorfl/fl, 
5'-ATGGTAGCAGGCACACTCTTCATG-3' and 5'-GCTAAACATTCAGTCCCTAATC-3'; 
Osx1-GFP::cre, 5'-CGCGGTCTGGCAGTAAAAACTATC-3' and 
5'-CCCACCGTCAGTACGTGAGATATC-3'; R26-stop-EYFP, 
5'-AAAGTCGCTCTGAGTTGTTAT-3' and 5'-GCGAAGAGTTTGTCCTCAACC-3'. 






2.5 Cell culture solutions, buffers and media 
2.5.1 Adipogenic media 
D-MEM was supplemented with 10%FCS, 10mM 2mM L-glutamine, 1mM sodium 
pyruvate, 15mM HEPES, 50U/mL penicillin and 50Pg/mL streptomycin, 60PM indomethacin 
and 1PM dexamethasone. Media was stored at 4qC until use. 
2.5.2 Complete D-MEM/20%FCS for murine MSC culture 
D-MEM was supplemented with 20% FCS, 2mM L-glutamine, 1mM sodium pyruvate, 
15mM HEPES, 50U/mL penicillin and 50Pg/mL streptomycin, 100PM ascorbate-2-phosphate 
and filter-sterilised using a 0.2Pm syringe filter. Media was stored at 4qC for up to two weeks. 
2.5.3 Osteogenic Media 
D-MEM was supplemented 2%FCS, 2mM L-glutamine, 1mM sodium pyruvate, 15mM 
HEPES, 50U/mL penicillin and 50Pg/mL streptomycin, 10-7M dexamethasone and 1.8mM 
KH2PO4. Media was stored at 4qC until use. 
2.5.4 Trypsin, 0.05% 
0.5% Trypsin-EDTA (1mL) was thawed at 37qC and mixed with 9mL HBSS and was 
stored for up to one week at 4qC. 
2.5.5 Type I Collagenase DNase 
A Type I collagenase(400U/ml)/DNase (50U/ml) solution was made by dissolving type 




2.5.6 EDTA, 0.5M 
EDTA solution (0.5M, pH 8) was made by dissolving EDTA in RO water and the pH 
was adjusted to 8.0 by the addition of sodium hydroxide pellets. Solution was stored at room 
temperature. 
2.6  In vitro techniques 
2.6.1 Cell counts and viability staining 
Trypan blue staining was used to obtain viable cell counts. Cells in suspension were 
diluted in 0.4% (w/v) trypan blue and cells were incubated at room temperature for 3-10mins. 
Cells were then loaded onto a haemocytometer (Weber Scientific International, Teddington, 
England) in duplicate. Viable cells were counted using a light microscope (Olympus BX40, 
Tokyo, Japan) and cell concentration and viability were calculated. 
2.6.2 Standard culture conditions. 
All tissue culture techniques were performed in a Class II Biological Safety Cabinet 
(Top Safe 1.2, Bio Air, Siziano, Italy). Cell lines were maintained in a humidified environment 
at 37qC in hypoxic invitro cabinet (Coy Laboratory Products). All media was warmed to 37qC 
before use. All tissue culture plates were obtained from BD Biosciences (North Ryde, NSW). 
2.6.3 Trypsinisation of adherent cells lines 
Cells were washed with pre-warmed HBSS and treated with 0.05% trypsin-EDTA for 
3-5mins. Cells were dislodged by agitation of the flask. The trypsin was inactivated by the 
addition of culture media containing FCS. Cells were pelleted by centrifugation at 800g for 
5mins at 4qC in an Eppendorf 5810 centrifuge (Eppendorf South Pacific, North Ryde, NSW). 




in an appropriate volume of culture media. Cells were transferred at an appropriate density into 
a new tissue culture flask. 
2.6.4 Cryopreservation and storage of cells 
Cells were preserved in FCS containing 10% DMSO and stored long term in liquid 
nitrogen storage (-196qC). The cell suspension was pelleted by centrifugation at 800g for 5mins 
in an Eppendorf 5810R centrifuge. Supernatant was aspirated and the pellet was resuspended 
in FCS (1mL) filter-sterilised using a 0.2Pm syringe filter. FCS containing 20% DMSO (1mL) 
was added to the cell suspension. 1mL volumes containing 5-10 x 106 cells were aliquoted into 
cryovials (Greiner, Kremsmuester, Germany) and cryovials were transferred to a 4qC 
cryopreservation freezing container (Mr Frosty; Nalgene, USA) catalogue number 5100-0001) 
and were cooled to -80qC for at least 3 hours before being transferred to liquid nitrogen storage 
tanks. 
2.6.5 Thawing of Cryopreserved Cells 
Cell suspensions were thawed rapidly from liquid nitrogen in a 37qC water bath. Cells 
were rapidly transferred to a 14mL round-bottom polypropylene tube. Pre-warmed culture 
media (1mL) was added dropwise to thawed cell suspension and incubated at room temperature 
for 5mins. The cell suspension was topped up to 10mL with pre-warmed culture media and 
cells were pelleted by centrifugation at 800g for 5mins in an Eppendorf 5810R centrifuge and 
the supernatant discarded. Cells were resuspended in 10mL culture media and seeded in a 
75cm2 culture flask. Cells were passaged at least once before use in experiments. 
2.6.6 Compact bone digestion for long bone and calvarial MSC isolation 
Compact bone isolation of MSCs was conducted as previously described264. Briefly, 
mice were humanly killed by CO2 asphyxiation and cervical dislocation and for long bone 




plates were recovered. All bones were excised from the animals and cleaned thoroughly to 
remove excess muscles and tendons. Bones were gently cracked open with a mortar and pestle 
and washed in ice cold PBS/2% FCS/2mM EDTA to remove marrow. Bones were digested in 
PBS containing 3mg/mL collagenase/50units/mL DNase for 45mins at 37qC with gentle 
agitation. 
Following digestion, bone chips were left to settle in ice cold PBS / 2% FCS / 2mM 
EDTA for 5mins. Supernatant was removed, strained using a 70Pm cell strainer and transferred 
to a 14mL round-bottom polypropylene tubes. This was repeated and the supernatant 
centrifuged at 400 x g for 10mins at 4qC. Supernatants were then aspirated and cells were 
resuspended and combined in a 5mL polypropylene tube. Cell number and viability was 
assessed by trypan blue staining and haemocytometer assessment as described above. Cells 
were resuspended at 2 x 107 viable cells/mL in PBS/2% FCS/2mM EDTA.  
2.6.7 Isolation of R26eYFP-Rptorfl/fl MSCs 
Cells obtained following compact bone digestion (described in section 2.6.6) were 
incubated with mouse gamma globulin at 1:1000 and the cell suspension incubated on ice for 
30mins in the dark. Cells were washed twice with PBS/2% FCS/2mM EDTA. Cells were 
pelleted at 400g for 10mins and supernatant was aspirated. Cells were resuspended at 2 x 107 
cells/mL in the antibody cocktail comprised of biotinylated lineage (Lin) antibodies (CD3, 
CD5, B220, CD11b, Gr-1, Ter119, CD4, CD8) and streptavidin-APC, CD45, CD31, CD51 and 
Sca1. FloroGold was used to distinguish between dead and living cells. Cells were incubated 
with the antibody cocktail for 30mins on ice, in the dark. Cells were washed twice with PBS/2% 
FCS/2mM EDTA as described above. Cells were resuspended in 300PL PBS/2% FCS and 
sorted by fluorescence activate cell sorting (FACS) using Epics Altra HyPer Sort FACS 





2.6.8 Isolation of eYFP+ cells 
Compact bone isolated MSCs in PBS/2% FCS/2mM EDTA cells were isolated based 
on eYFP+ expression by fluorescence activate cell sorting (FACS) using Epics Altra HyPer 
Sort FACS machine (Beckman Coulter, Miami, Florida, USA).  
2.6.9 Generation of RapKO cells 
In order to generate primary MSC populations, devoid of raptor, compact bone isolated 
cells were infected with a lentivirus harbouring a tamoxifen-inducible self-deleting Cre 
recombinase (LEGO-CreERT2-iG2), or vector control (LEGO-iG2) in the presence of 4Pg/mL 
polybrene as previously described 265.  
Briefly, HEK239-T cells were grown to confluence before being transfected with the 
lentiviral vector as previously described 266, 267. Successful transfection was assessed by 
examining the cells for green fluorescence protein using a UV fluorescent microscope 
(Olympus, Tokyo, Japan.) as previously described 268. 
Once transfection was verified, supernatant containing viral particles was removed from 
HEK293-T cells and the supernatant diluted with 1:1 with D-MEM + additives supplemented 
with Polybrene (4Pg/mL; Sigma Aldrich, Castle Hill, Australia). This mixture was then added 
drop wise to the target MSC population which were then cultured in the presence of the viral 
particles for 48hrs. After infection, GFP expression was verified using a UV microscope. Cells 
were reinfected in the same manner described above to increase the number of infected cells. 
After a further 48hrs the viral supernatant was removed and replaced with appropriate growth 
media, D-MEM + additives. 
Infected MSCs were cell sorted based on GFP expression using an Epics Altra HyPer 
Sort FACS machine (Beckman Coulter, Miami, Florida, USA). The brightest 30% of cells in 
the positive fraction were selected using Expo 32 Multi-comp software (Software version 




described. Following in vitro expansion, cells were treated with 0.5mM 4-hydroxytamoxifen 
(4-OHT, Sigma-Aldrich) or vehicle (0.05% ethanol) for 8 days.  
2.6.10 BrdU Assay 
Cells (1.25x104/cm2) were seeded into 24-well plates in growth media, allowed to 
adhere overnight then incubated with 5-bromo-2'-deoxyuridine (BrdU) for 16 hours. 
Incorporated BrdU was detected using a colourimetric assay according to the manufacturer’s 
instructions (Roche, NSW, Australia). 
2.6.11 Cell Proliferation WST-1 Assay 
Cells were seeded at 4x103 cells per well in a 96-well flat bottom plate in 100PL of the 
appropriate media and cultured in a humidified environment at 37qC in the presence of 5% CO2. 
The relative number of viable cells in each well was determined at days 1, 3, 5 and 7 using the 
colorimetric assay reagent WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulphonate, Roche, USA) according to manufacturers’ instructions. Briefly, 10μl 
of WST-1 was added to each well (and to wells containing medium alone, to enable background 
subtraction) and incubated for 90 minutes at 37oC. The optical density of the dye solution was 
measured with a plate reader (Bio-Rad Model 3550, USA) at 450nm wavelength. 
2.6.12 7AAD/Annexin V assay 
The Annexin V-PE Apoptosis Detection Kit I (BD Biosciences, San Diego, CA, USA) 
was used to analyse apoptosis in cell populations. Briefly, cells were resuspended in binding 
buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2 ) and incubated in the presence 
of Annexin V-PE and 7-AAD in the dark at room temperature for 15 mins. Cells were 
subsequently resuspended in binding buffer and analysed by flow cytometry using Epics Altra 




apoptotic and dead cells were defined by their distribution in a fluorescence Annexin/7-AAD 
dot plot. 
2.6.13 Assessment of adipogenic differentiation potential 
Adipogenesis assays were performed as previously described 81, 269. MSCs were seeded 
at 8x103 per cm2 in 24 well plates and cultured for 28 days in the presence of adipogenic media 
with media changes twice a week. At 28 days, the wells were washed 3 times with 1xPBS and 
cells fixed in 10% NBF for 1 hour at room temperature. Oil Red O staining solution and further 
diluted 3:20 in RO water. Formation of lipid-laden fat cells was determined by Oil Red O 
staining. 
2.6.14 Assessment of osteogenic differentiation potential 
In vitro mineralization assays were performed as previously described 269. Briefly, 
MSCs were seeded at 8x103 cells per cm2 in 96 well plates and cultured in mineralization 
induction media for 28 days with media change twice weekly. At 28 days, the wells were 
washed three times with 1x PBS and the mineralized matrix dissolved in 100PL of 0.6M HCl 
for 1 hour at room temperature. The dissolved mineral solution was then transferred to 96-well 
microtitre plates and calcium levels were quantitated by the Cresophthalein Complexone assay 
(Thermo Electron Corporation, Melbourne, VIC, Australia). Briefly, 5PL of each supernatant 
was transferred to a single well of a fresh microtitre plate. A calcium chloride standard curve 
was also established in triplicate. Equal volumes of reagent A (cresophthalein complexone 
0.10mmol/L, 8-hydroxyquinoline 5.2mmol/L, polyinlpyrolidine 0.07 mmol/L) and reagent B 
(2-amino-1-methylpropanol 260mmol/L) were mixed and 200PL was added per well. The 
plates were incubated at room temperature for 2 mins and the absorbance was read at 540nm 




Following dissolution of the mineral with HCl, the wells were washed with 1x PBS and 
the cells were digested with 100PL of proteinase K for 2 hours at room temperature or overnight 
at 4qC. The cells were then mixed thoroughly to ensure complete disruption and 50PL volumes 
were transferred to a while 96-well microtitre plate (Costar, Corning, New York, NY, USA). 
DNA content per well was then quantified using the Picogreen assay. 
2.6.15 Osteogenic potential of isolated MSCs 
Assessment of osteogenic potential was conducted on cavarial MSCs isolated as 
previously described in section 2.6.6. Osteogenic assays were conducted for 21 days and 
mineral quantified described in section 2.6.14. 
2.6.16 Insulin stimulation response 
Assessment for response to insulin stimulation was assessed on isolated calvarial cells. 
The assessment of osteogenic potential was conducted (as previously described 2.6.14) for 14 
days in the presence or absence of 10mM insulin. Mineral quantitation was conducted as 
described in section 2.6.14. 
2.6.17 CFUF  
Mice were humanely euthanized using CO2 gas followed by cervical dislocation. The 
tibiae were surgically removed and cleared of soft tissue in a Class II laminar flow hood (Top 
Safe 1.2, Bio Air Siziano, Italy), using sterile instruments. The distal and proximal ends of each 
femur were removed using sterile forceps and a surgical blade (#22). A 10mL syringe attached 
to a 21-gauge needle was then inserted into either end of the bone with a screw motion. The 
bone marrow was flushed then stored on ice in a 50mL Falcon tube, before being transferred to 
a 6cm culture dish with enough complete D-MEM media to cover the bones (~500PL). The 
bone was then crushed into small pieces with a sterile scalpel blade and transferred to a 10mL 




45mins-1hr at 37qC with shaking at 200rpm. Once digested, 10mL complete D-MEM media 
was added to the bone chips. The digested bone chips were then strained through a 70Pm cell 
strainer and combined with the flushed bone marrow. The filtered bone chip/marrow solution 
was then centrifuged at 800g at 4qC for 10 mins. Once centrifuged, cells were counted in white 
cell fluid and diluted to concentrations of 9, 18 and 36 x 105 cells per well (3mL per well) and 
plated in duplicate in 6 well plates. Both plates were then incubated for 9 days in a hypoxic in 
vitro cabinet (Coy Laboratory Products) at 37oC before staining for CFU-F colonies with 0.1% 
(w/v) toluidine blue in 1% paraformaldehyde as previously described 269. Aggregates of >50 
cells were scored as CFU-F-derived colonies and aggregates of >10 and <50 cells were scored 
as clusters. 
2.6.18 BMP2 assay 
Calvarial bone organ cultures established from 4 day-old mice were cultured in the 
presence of rhBMP-2 (50ng/mL) or media alone for 10 days as previously described 18. 
Calvariae were then fixed in formalin for 24 hours, decalcified overnight (14% EDTA, pH 7.2) 
and embedded in paraffin. Sections (5µm) were cut 1200µm into the specimen parallel to the 
midline suture and stained with Haematoxylin and Eosin. The average width of new bone 
formed relative to the length of calvarial bone specimen analysed was quantitated using the 
Osteomeasure XP system (OsteoMetrics Inc.) 
2.7 Molecular Biology Buffers and Reagents 
2.7.1 DNA Standards for cDNA quantitatioin 
A 1mg/ml stock solution was made by dissolving salmon sperm DNA in RO water 
overnight at 4qC. Aliquots of 100PL were stored at -20qC. Salmon sperm DNA was diluted in 





2.7.2 Calcium standards 
Calcium chloride (11.098g) was dissolved in RO water (100mL) and stored at room 
temperature. A standard curve for the Cresolphthalein Complexone assay was prepared by 
diluting calcium stock solution from 2.5-0.25mM in RO water. 
2.7.3 EDTA, 0.5M 
EDTA (93.05g) was dissolved in RO water (500mL) and sodium hydroxide pellets were 
used to adjust the pH to 8.0. The solution was stored at room temperature. 
2.7.4 Flow cytometry fixative (FACS Fix) 
1xPBS was supplemented with 1% (v/v) formalin, 2% (w/v) D-glucose, and 0.02% 
(w/v) sodium azide and stored at 4°C. 
2.7.5 Proteinase K 0.01%(w/v) 
Proteinase K solution 1%(w/v) was made by dissolving proteinase K in RO water. 
500PL aliquots were stored at -20qC. 
2.7.6 Lysis buffer 
Lysis buffer was comprised of 1% Nonidet P40, 20mM Tris, 150mM sodium chloride, 
1mM ethylenediaminetetraacetic acid, 25mM sodium fluoride, 10mM sodium phosphate, 2mM 
vanadate and 0.5mM phenylmethylsulfonyl fluoride supplemented with complete protease 
inhibitors in RO water. Solution was stored at -20ºC for up to 3 months. 
2.7.7 Blocking buffer 
Blocking buffer was comprised of 5% Amersham block (Amersham Biosciences UK 




2.7.8 TBS /Tween 
Tween 20 (1% v/v) was added to TBS and stored at room temperature. 
2.8 Molecular Biology Techniques 
2.8.1 Preparation of protein lysate 
Whole cell lysates were prepared on ice from 3 x 106 MSC. Cells were washed once 
with 10mL of ice cold PBS before 300PL of lysis buffer was added and cells were scraped off 
the dish using a cell scraper and the cells transferred to an eppendorf tube and vortexed. This 
preparation was incubated on ice for approximately 30 minutes and cells were lysed by 
sonication for 10 seconds at 3 watts using a probe sonicator (XL2007, Misonix Inc., Farmingale, 
NY, USA). Cell lysate was then centrifuged for 30 minutes at 16,000g at 4qC. Centrifugation 
was sufficient to separate out the nuclear proteins and other cellular debris which formed a 
pellet at the bottom of the tube. The supernatant was transferred to a new tube from which an 
aliquot was taken and protein concentration quantitated using the RC/DC protein assay kit (Bio-
Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. 
Once protein concentrations were determined, 50Pg of protein per lane was loaded onto 
a 12% polyacrylamide gel and electrophoresed at 15mA and 30mA through the stacking and 
separating gels, respectively. Gels were transferred to a Hybond-P 0.45Pm PVDF membrane 
(Amesham Bioscience UK Limited, Little Chalfont, UK)using the SEMI-PHORTM Hoefer 
Semi Dry blotter (Hoefer Scienific Instruments, San Fransisco, USA) and blocked with 50mL 
blocking buffer overnight at 4qC. After blocking, the membranes were washed three times using 
TBS/Tween to remove any residual blocking buffer solids. 
The membrane was submerged in this solution of primary antibody and probed 
overnight at 4qC on a rocker. The membrane was washed three times in TBS/Tween. Following 




affinity isolated alkaline phosphatase conjugated, P326A, Chemicon Australia Pty. Ltd., 
Melbourne, Australia) diluted 1 in 2000 into % BSA TBS/Tween. The secondary antibody was 
incubated with the membrane for 1 hour at room temperature on a rocker. The membrane was 
washed a further three times with TBS/Tween, rinsed three times with TBS, developed using 
ECF substrate and visualized using a Typhoon 9410 variable model imager (GE Healthcare, 
Europa Bio Producs, RPN5785). 
2.8.2 Preparation of total RNA 
Total cellular RNA was prepared using TRIzol (Life Technologies, Carlsbad, Canada). 
Up to 1 x 106 MSC were lysed in 1mL TRIzol. Chloroform (200PL per mL) was added to this 
solution and tubes were shaken vigorously for 15 seconds before a 3min incubation at 30qC. 
The mixture was centrifuged at 12,000g for 15 mins at 2qC and resulted in phase separation. 
The lower two layers contained protein and DNA while RNA remained in the upper aqueous 
phase. This aqueous phase was transferred to a fresh tube and total RNA was precipitated using 
isopropanol (500PL per mL) and glycogen (1PL per mL; Sigma Aldrich, Castle Hill, Australia). 
This preparation was incubated for 1hr on ice to ensure maximum RNA precipitation. RNA 
was pelleted by centrifugation at 12,000g for 10 mins at room temperature. Supernatant was 
removed and the pellets washed in 1mL of 75% ethanol before being centrifuged at 7,500g for 
5 minutes at 4qC. Ethanol was removed and the RNA was air dried for approximately 10 
minutes. The dried RNA was then dissolved in RNAse free water at room temperature for 10 
minutes before being quantitated using NanoDrop Mass spectrometer (NanoDrop ND-1000 
Spectrophotometer, Biolabgroup, Clayton, Victoria, Australia) and stored at -20qC. 
2.8.3 Quantification and purity analysis of RNA 
The NanoDrop mass spectrometer was used for the quantification and purity analysis of 




of the NanoDrop. Absorbance at 260nm was measured to determine the quantity of the RNA 
and purity was measured by the ratio of A260:A280. Ratios between 1.85 and 1.95 were 
commonly obtained. Samples with values within this range were considered of high purity and 
were either used immediately to generate cDNA or stored at -20qC for future use. 
2.8.4 Complementary DNA (cDNA) synthesis 
Complementary cDNA was generated using the SuperScript III Reverse Transcriptase 
kit (Invitrogen, Carlsbad, Canada. Briefly, 1PL oligo(dT), 1-5Pg total RNA, 1PL dNTP mix 
and distilled water to a total volume of 13PL was added to each microcentrifuge tube. This 
mixture was heated to 70qC for 5 minutes and then incubated on ice for 1min to denature the 
RNA. The tube was then briefly centrifuged before 4PL 5x first-strand buffer, 2PL 0.1M DTT 
and 1PL of SuperScript III RT (200 units / PL) was added. This solution was mixed with gentle 
pipetting before being incubated at 42qC for 1hr to allow for primer extension and first strand 
synthesis. The reaction was stopped by incubation at 70qC for 15 minutes leading to 
deactivation of the reverse transcriptase enzyme. RNAse free water was added to a volume of 
50x the number of Pg template RNA added originally. The resulting cDNA was used as a 
template for PCR reactions and stored a -20qC. 
2.8.5 Real-time PCR 
Real-time PCR was used to assess the levels of RNA expression for genes of interest. 
Beta-actin (E-actin) was used as a housekeeping control gene and samples were normalized 
against this control. A reaction mixture containing 2PL of sample cDNA, 7.5PL cyber green 
(Jomar Diagnostics, Adelaide, Australia), 0.75PL (10PM) mixed primer pairs and 4.75PL 
DEPEC water was mixed to generate a 15PL reaction. Iterative amplifications were performed 




2.8.6 Confirmation of osteoblast specific Rptor deletion 
Genomic DNA was isolated from multiple tissues (bone, liver, spleen, heart, kidney, 
lung) and PCR used to amplify a product generated by Cre-mediated recombination of the Rptor 
gene as described in section 0. 
Compact bone cells were isolated as described in section 2.6.6. RNA was isolated and 
quantification of changes in gene expression were conducted (described in section 2.10.7.). 
Amplified products were resolved on 2% agarose gels stained with Gel Red. 
2.8.7 Serum biochemistry 
Animals were anaesthetised with isoflurane and blood was collected by cardiac 
puncture, prior to sacrifice by CO2 overdose. Cardiac blood samples were collected, spun at 
800g for 15 minutes and the collected sera were stored at -20°C until analysis. The serum levels 
of osteocalcin, P1NP and TRAcP5 were measured by ELISA in accordance to the 
manufacturer’s instructions (Biomedical Technologies). 
2.9  Histological stains and buffers 
2.9.1 Acetate-tartrate buffer 
On the day of use, sodium acetate and sodium tartrate were dissolved in RO water and 
the pH was adjusted to 5.2 with 1.2% acetic acid final concentration of 200mM sodium acetate 
and 100mM sodium tartrate. 
2.9.2 Acid Alcohol 
A 70% (v/v) ethanol, 0.3% (v/v) hydrochloric acid solution was made by mixing RO 
water, ethanol and hydrochloric acid and stored at room temperature. The solution was used to 




2.9.3 Alizarin red stain 2% (w/v) 
Alizarin Red S was dissolved in RO water for a final concentration of 2% (w/v) and pH 
was adjusted to 4.1-4.3 using 0.5% ammonium hydroxide. Solution was stored at room and pH 
adjusted prior to use. 
2.9.4 Citrate/acetone/formaldehyde fixative 
On day of use, citric acid solution, acetone, and formaldehyde were mixed thoroughly 
for a final concentration of 4.6M citric acid, 66.3% (v/v) acetone and 3.3% (v/v) formaldehyde 
solution.  
2.9.5 Decalcification Buffer 
Decalcification buffer was made to a final concentration of 0.5M EDTA and 
paraformaldehyde 5% (w/v) in PBS. Sodium hydroxide pellets were added as required to adjust 
the pH to 8.0. Solution was stored at 4qC for up to 1 month. 
2.9.6 Eosin 
An 11% (w/v) eosin, 1.1% (w/v) phloxine and 83% (v/v) ethanol solution was made by 
combining RO water, ethanol, eosin Y, phloxine and acetic acid. The solution was stored at 4qC 
until use. 
2.9.7 Fast green stain 0.2% (w/v) 
Fast green 0.2% (w/v) solution was made by dissolving fast green in RO water. The 
solution was stored at room temperature until use. 
2.9.8 Gelatin/chromic potassium sulphate solution 
A gelatine 1% (w/v), chromic potassium sulphate 0.05% (w/v) solution was made by 




dodecahydrate was added and stirred until dissolved. The solution was stored at room 
temperature until use. 
2.9.9 Mayer’s haematoxylin 
A 5% (w/v) aluminium ammonium sulphate, 0.5% (w/v) haemotoxylin, 1% (v/v) 
ethanol, 0.1% (w/v) sodium iodate, 2% (v/v) acetic acid and 30% (v/v) glycerol solution was 
made by dissolving aluminium ammonium sulphate in RO water on a heated stirrer. The 
solution was cooled and haematoxylin, ethanol, sodium iodate, acetic acid and glycerol were 
added. The solution was stored at room temperature until use. 
2.9.10 Methacrylate embedding mixture 
On day of use, methacrylate embedding mixture was made by mixing methyl 
methacrylate and polyethylene glycol (PEG) at a 10:1 ratio. 
2.9.11 Oil red O 0.5%(w/v) 
Oil Red O 0.5%(w/v) staining solution was prepared by dissolving Oil Red O in of 
isopropanol. 
2.9.12 Safranin O stain, 0.1% (w/v) 
Safranin O 0.1% (w/v) stained was made by dissolving Safranin O in RO water. Solution 
was stored at room temperature until use. 
2.9.13 Sodium carbonate, 5% (w/v) 
Sodium carbonate 5% (w/v) was dissolved in RO water and the solution was stored at 




2.9.14  Sodium thiosulphate, 5% (w/v)  
Sodium thiosulfate 5% (w/v) was dissolved in mL RO water and the solution was stored 
at room temperature until use. The solution was used neat or was diluted 1:1 in RO water prior 
to use.  
2.9.15 Sodium bicarbonate, 0.1% (w/v)  
Sodium bicarbonate 0.1% (w/v) was dissolved in RO water on the day of use. Solution 
was used as a blueing agent for haematoxylin staining.  
2.9.16 Sodium phosphate/citrate buffer  
Citric acid and sodium phosphate were dissolved in RO water for a final concentration 
of 8.22mM citric acid and 4.575mM sodium phosphate. The pH was adjusted to 3.7 and the 
solution stored at room temperature until use.  
2.9.17 Toluidine blue stain, 2% (w/v)  
Toluidine blue 2% (w/v) was dissolved in sodium phosphate/citrate buffer. The pH was 
adjusted to 3.7, and the solution was filtered through a 0.45μm syringe filter. The solution was 
stored at room temperature until use. 
2.10 Histomophometric techniques 
2.10.1 Methacrylate processing 
Samples were fixed in 10% NBF for four days at 4qC before being transferred to PBS 
at 4qC. Tissue was trimmed from one side of the excised tibia to ensure correct orientation. 
Samples were transferred to 25mL polypropylene tubes and filled with 70% acetone at 4qC for 
1hr. The samples were sequentially transferred into 90% acetone for 1hr, 100% acetone for 1hr 
hour and 100% acetone for an additional hour. At this stage, the samples were fully dehydrated 




Samples were placed with lid loosened under vacuum for one week to allow for 
complete infiltration of the embedding mixture. Following complete infiltration, the embedding 
mixture was transferred to a waste container and replaced with 11mL methacrylate embedding 
mixture with Perkadox (0.04g/11mL). With lids tightened, samples were places into a glass tray 
containing ~3cm water and kept in an incubator at 37qC until completely polymerized. Tubes 
were cut open with a band-saw to remove the plastic block, which was sanded and attached to 
an aluminium block using Araldite® epoxy resin. 
Using a Leica SM2500 motorised sledge microtome (Leica Microsytems), 5µm sections 
were taken from each block and attached to gelatine-coated slides using spreading solution. 
Slides were clamped together overnight and incubated at 42ºC to dry. Sections were 
deplasticised in 100% acetone for 15mins prior to staining. 
2.10.2 Paraffin Processing 
Excised tibiae were fixed in 10% NBF for four days at 4qC before being transferred to 
PBS and stored at 4qC. Samples were transferred to decalcification buffer and stored at 4qC. 
Samples were considered decalcified by the absence of X-Ray-detectable mineralised bone 
material. Once completely decalcified, samples were processed overnight for paraffin 
infiltration in the Neuropathology Laboratory (Hanson Institute, South Australia). Infiltrated 
samples were embedded into paraffin blocks using a Leica embedding station (Leica, North 
Ryde, NSW, Australia) and embedding cassettes (Techno-Pls, St Marys, South Australia). 
Longitudinal sections (5µm) were cut and were mounted on Snowcoat X-tra slides (Surgipath, 
Richmond, USA). Sections were dewaxed through xylene and rehydrated through 100% 




2.10.3 Haematoxylin and Eosin Staining 
Slides were stained in haematoxylin for 5 mins. Once stained, slides were rinsed in 
running tap water, immersed in bicarbonate solution for 10 second differentiated in 0.3% acid 
alcohol for 5 seconds, rinsed in running tap water, immersed in bicarbonate solution for 10 
seconds and rinsed in running tap water. Slides were counterstained with eosin for two minutes 
before being dehydrated in three ethanol washes and two xylene washes. Slides were then 
cover-slipped. 
2.10.4 Safranin O Staining 
Slides were rinsed twice in dH2O and stained with Fast Green for 5 minutes. Following 
staining, slides were immersed once in 1% acetic acid before being counter-stained in Safranin 
O for 3 minutes. Slides were immersed in 1% acetic acid and thoroughly blotted on both sides 
before being differentiated and dehydrated by transferring quickly through three changes of 
ethanol and two changes of xylene. Slides were then cover-slipped. 
2.10.5 Toluidine Blue Staining 
Slides were rinsed twice in dH2O and stained with 2% toluidine blue stain for 3 minutes. 
Following staining, slides were dipped twice in sodium thiosulphate and thoroughly blotted on 
both sides before being differentiated and dehydrated by transferring quickly through three 
changes of ethanol and two changes of xylene. Slides were then cover-slipped. 
2.10.6 Imaging slides 
Digital images of stained slides were generated using the NanoZoomer 2.0-HT scanner 
(Hamamatsu, Shizuoka, Japan). Briefly, slides were wiped clean with 70% ethanol and loaded 
into NanoZoomer trays. Focal points were selected manually for each slide and each slide was 




2.10.7 Histomorphometric analyses of osteoblasts and osteoclasts 
Histomorphometric analyses were conducted in duplicate on blind-coded slides using 
OsteoMeasure XP (OsteoMetrics, Decatur, USA). Analyses of osteoblast numbers 
(N.Ob/B.Pm), osteoblast-occupied bone surface (Ob.S/BS), osteoclast numbers (N.Oc/B.Pm) 
and osteoclast-occupied bone surface (Oc.S/BS) in the proximal mouse tibiae were performed 
on toluidine blue-stained slides (described in section 2.10.5) in a designated region of primary 
and secondary spongiosa distal to the growth plate.  
2.10.8 Growth plate analysis 
Assessment of the width of the resting-, proliferating- and hypertrophic-zones were 
performed on safranin O/fast green-stained methacrylate sections (as described in section 
2.10.4)  along a central 2.32 mm region of the proximal tibial growth plate. Analyses were 
conducted in duplicate on blind-coded slides using OsteoMeasure XP (OsteoMetrics, Decatur, 
USA). 
2.10.9 Histological analyses of intramedullary adipose 
Histomorphometric analyses were conducted in duplicate on blind-coded slides using 
OsteoMeasure XP (OsteoMetrics, Decatur, USA). Histomorphometric analysis of 
intramedullary adipose in mouse tibiae was performed on toluidine blue- stained slides (as 
described in section 2.10.5) in region of the proximal trabecular region of the bone excluding 
cortical bone.  
2.10.10Immunohistochemistry 
Paraffin-imbedded sections (5Pm) (described in section 2.10.2) were subjected to 
antigen retrieval (10mM citrate buffer (pH6.0), 95°C) for 10 min then cooled to room 
temperature. Endogenous peroxidase was quenched with 0.5% H2O2 (v/v) in methanol for 30 




primary antibody at 4°C overnight. Sections were washed in PBS then incubated with species-
specific biotinylated secondary antibodies (anti-goat (BA-5000) and anti-rabbit (BA-1000) 
(Vector Laboratories, CA, USA) for 1 hr at room temperature followed by a 30-minute 
incubation with streptavidin-HRP (Vector Laboratories). Antibody binding was visualized 
using DAB as per the manufacturer’s instructions (Vector Laboratories). Antibodies used for 
IHC: osterix (ab22552; Abcam, Cambridge, UK); eGFP (A600-101-215; Rockland, PA, USA); 
eYFP (A600-401-215; Rockland); osteocalcin (sc-18319; Santa Cruz Biotechnology, TX, 
USA) and PCNA (sc-7907; Santa Cruz Biotechnology). 
2.10.11Immunofluorescence staining 
For immunofluorescence staining, paraffin embedded sections were antigen retrieved 
(as described in section 0), incubated in blocking buffer then incubated with primary antibodies 
overnight at 4°C. Sections were washed with ice cold PBS then incubated with fluorescently 
tagged species-specific secondary antibodies (anti-chicken (Alexa Fluor488 (ab150173; 
Abcam) and anti-rabbit (Alexa Fluor647) (ab150067; Abcam)) at room temperature for 1 hour. 
Sections were washed then briefly fixed for 10 minutes (0.1% formalin in PBS) and nuclei 
labelled with DAPI (300nM in PBS) for 5 minutes. Sections were mounted with ProLong Gold 
Anti-fade reagent (Invitrogen). 
Fluorescent labelling was detected using a LSM400 confocal microscope (Zeiss, 
Oberkochen, Germany). Antibodies used for IF: eYFP (ab13970; Abcam); perilipin (9349; Cell 
Signaling, MA, USA). 
2.11 Calcein labelling  
To measure bone formation in vivo, mice were subcutaneously injected with calcein at 




after the second injection, tibiaes were collected, fixed in 10% NBF then embedded in methyl 
methacrylate as previously described 270. 
Unstained, deplasticised sections of mouse tibiae were cover-slipped and used for 
dynamic measurements of bone formation. Mineral apposition rate (MAR) was evaluated as 
the mean distance between the double calcein- labelled mineralised surface (MS) and the edge 
the bone (BS), divided by 3 days (the interval between labelling and the death of the animals). 
Bone formation rate (BFR) was derived using the formula: BFR = MAR × MS/BS × 365/100.  
2.12 Gross phenotype analyses 
Total body weight was recorded immediately prior to culling the mouse. Tibial 
measurements were calculated as an average of three measurements take from the proximal 
tibial head to the fibular notch using electronic calipers. For spinal length, the distance from 
cervical 1 (C1) to lumbar 5 (L5) was measured in whole body x-ray (Faxitron LX-60, Faxitron, 
IL, USA) and quantitated using ImageJ. The liver, spleen, heart, kidney and lungs were isolated 
from mice and weighed. Weights were normalised to specimen body weight. 
2.13 µCT 
Micro architecture of whole tibiae were analysed using µ-CT (SkyScan 1076, X-ray 
Microtomograph, Bruker). Bones were scanned at 50kV/100 mA with an isometric resolution 
of 8.65 μm/pixel with a 0.5mm aluminium filter, 2 frame averaging at a magnification of 6.5 
μm. Scanned data was reconstructed using NRecon (SkyScan).  
2.13.1 Trabecular analysis by µCT 
For trabecular bone, the region of analysis was determined as an area of 150 
microtomographic slices, commencing 20 slices distal to the primary spogiosa for an 11mm 




Regions of interest (ROI) were manually defined to exclude the cortex. Quantification of bone 
volume fraction (BV/TV), bone surface fraction (BS/BV), trabecular thickness (Tb.Th.), 
trabecular number (Tb.N), trabecular spacing (Tb.Sp), structure model index (SMI) and 
trabecular pattern factor (Tb.Pf) were calculated using CTAn (SkyScan).  
2.13.2 Cortical analysis by µCT 
For cortical bone, the region of analysis was determined as the first, middle and last 
microtomographic slices utilised in the trabecular analysis (section 2.13.1). Measurements of 
cortical thickness (Ct.Th) were calculated as the average of measurement in the lateral, medial, 
caudal and cranial orientation of the three microtomographic slices. Intramedullary thickness 
was calculated as the average of measurements in the lateral-medial and caudal-cranial 
orientation of the three microtomographic slices. 
2.13.3 Growth plate analysis by µCT 
For measurement of the growth plate width, 3-dimensional (3D) re-constructions of the 
PCT data were generated using DataViewer (SkyScan). Growth plate width was calculated by 
taking an average measurement at 20 equidistant points across the central section of the 
proximal growth plate. 
2.13.4 Assessment of longitudinal growth 
Assessment of longitudinal growth was conducted on calcien-labelled sections as 
described in section 0. The rate of longitudinal growth per day, was determined by measuring 
the average width of the newly-formed primary and secondary spongiosa identified as unstained 
mineral, distal to the growth plate. Analyses were conducted in duplicate on blind-coded slides 




2.13.5 Skeletal staining and analysis of newborn mice 
Alizarin red and alcian blue staining of new born mice was performed as previously 
described 271. Briefly, newborn pup (P0) were euthanized by CO2 for 30mins. Pups were scalded 
in hot tap water (65ºC-70ºC) for 30 seconds. Skin and viscera was removed with forceps and 
pups were fixed in 95% ethanol overnight. Pups were transferred to acetone and incubated 
overnight at room temperature. Specimens were rinsed in dH2O, covered with alcian blue stain 
and incubated for 24hrs. Specimen were washed 7 times in 70% ethanol for 1hr. Specimens 
were transferred to 1% potassium hydroxide and incubated at room temperature until visibly 
cleared. Specimens were counterstained in alizarin red stain overnight. Specimens were cleared 
in 1%potassium hydroxide/20% glycerol until appropriately cleared. Specimens were stored in 
glycerol:ethanol (1:1) at room temperature. The percentage of the bone (humerus and tibia) that 
was mineralised was calculated by dividing the length of the mineralised (alizarin red) region 
of the bone by the total length of the bone using Image J 272. Images were acquired using bright 
field optics. 
2.14 Mechanical Testing 
Isolated femora were subjected to three-point bend test conducted to failure using a 
materials testing machine (Model 800LE4; Test Resources Inc., Shakopee MN, USA) based on 
previously published protocols 273 The lower span width was 5.0mm. Both the upper and lower 
contact anvils had a radius of 1.0mm. Femurs were positioned posterior side down on the 
support anvils to cause bending about the medial-lateral axis (posterior side in tension). The 
bones were centred on the supports to ideally induce failure at the mid-point along the diaphysis 
on the tension (posterior) side. A pre-load of 1N was applies and then a consistent cross-head 
displacement rate of 0.017mm/s for the bend test to failure. Compliance in the load-line and 
bend fixtures was removed from the displacement measurement by using a correction factor 




tap water at room temperature (22-24qC) and before testing, bones were kept in PBS soaked 
gauze at room temperature for 1hr. Loading displacement curves were analysed using standard 
Euler-Bernoulli theory for linear-elastic beams to obtain the flexural rigidity and the ultimate 
moment. Flexural rigidity was calculated by multiplying the measured displacement by 6/(3aL-
4a2) where L is the lower span with and is half the difference between the lower and upper span 
widths. The ultimate moment was calculated by multiplying the ultimate force by the value at 
failure. No correction for shear deformation was made.  
2.15 Calvarial imaging 
Calvariae were scanned by µCT as described previously in section 0. Images were 
acquired using Avizo® Fire (FEI Visualization Science Croup, MA, USA). 
2.16 Statistical Significance 
All data were graphed as mean±standard deviation (SD). Statistical analyses were 
performed using one-way or two-way ANOVA with the Dunnet’s post-hoc test or an unpaired 
Students t-test using GraphPad Prism (GraphPad Software Inc, CA, USA). In all cases, p<0.05 
was considered statistically significant. 
Chapter 3 - The role of mTORC1 in osteogenic and 






The ageing skeleton is characterized by a reduction in bone mineral density and an 
increase in intramedullary adiposity 3, 111. At the cellular level, these age-related changes are 
associated with an increase in bone marrow AdCs and a decrease in bone-forming OBs 2. As 
AdCs and OBs originate from a common multi-potent MSC progenitor 112-115, it has been 
postulated that the shift in the AdC:OB ratio occurs in response to increased AdC differentiation 
at the expense of OB differentiation 116, 117. In support of this, functional comparisons of MSCs 
isolated from osteoporotic and healthy individuals show that whilst they are similar in 
morphology, size and cell surface antigen expression, MSCs from osteoporotic individuals 
exhibit a reduced propensity for osteogenic differentiation 3, 4.  
In response to extracellular factors, MSCs differentiate into a range of cell types 
including AdCs, OBs, chondrocytes and myocytes 81, 112, 274, 275. MSC differentiation towards 
each cell lineage is a tightly-regulated process governed by extracellular and environmental 
cues. Osteogenic MSC differentiation is regulated by a variety of local and systemic factors, 
and proceeds through a series of distinct developmental stages that are characterised by the 
expression of specific molecular and functional markers 30, 81. BMPs, TGFE and Wnt molecules 
all play an important role in OB development and function 33, 276. BMPs stimulate bone 
formation in vitro and in vivo by activating a complex network of signalling molecules 
including SMADs, ERK1/2 and p38, culminating in the transcriptional up-regulation of key 
OB genes RUNX2 and SP7 277, 278. RUNX2 is the obligate OB transcription factor that regulates, 
and is in turn regulated by, a number of factors to control the expression of genes involved in 
OB differentiation and function. 
Similarly, adipogenic MSC differentiation is regulated by a variety of local and systemic 
factors which guide cells through a series of distinct developmental stages. Members of the 





expression of PPARγ and C/EBPα 108, 110. PPARγ and C/EBPα then form a positive feedback 
loop to maintain and enhance their expression and activate adipogenic genes required for 
function and maintenance of differentiated adipocytes and accumulation of triglycerides.  
In recent years, considerable effort has been directed toward defining the molecular 
mechanisms and signalling pathways associated with MSC commitment to both the osteogenic 
and adipogenic lineages. Several signalling pathways, including Wnt/β-catenin, BMP/SMAD, 
IHH, MAPK and Insulin/IGF1 have been shown to be involved 33, 124-127.  
Previous studies have shown that the mTOR signalling pathway plays an important role 
in the adipogenic program, as rapamycin, an allosteric mTOR inhibitor, inhibits adipogenesis 
19-23 whilst deletion of TSC2, a negative regulator of mTOR, promotes adipogenesis 23. The role 
of mTOR in osteogenic MSC commitment, however, is less clear as rapamycin-mediated 
mTOR inhibition has been shown to have both inhibitory 24-29 and stimulatory 13, 16-18 effects on 
osteogenesis, a disparity which may reflect the nature of the cell types and treatment conditions 
used in each study. Furthermore, rapamycin sequesters FKBP12 279, a negative regulator of 
TGFE1 signalling, and thus the pro-osteogenic effects of rapamycin may be the indirect result 
of TGFE1 activation.  
As outlined in Chapter 1, mTOR exists in two distinct multi-protein complexes, termed 
mTORC1 and mTORC2, which can be distinguished by their unique adaptor proteins, raptor 
and rictor, respectively. As there are currently no commercially available mTORC1- or 
mTORC2- specific inhibitors, studies are now utilising genetic approaches to delineate the roles 
of these complexes in various biological contexts. In this chapter, primary multipotent MSC 
populations were isolated from the long bones of R26eYFP-Rptorfl/fl mice and the Cre-loxP 
system was used to delete the mTORC1-specific protein raptor in these cells. The effect of 
Rptor deletion on osteogenic and adipogenic MSC differentiation was then examined using 
lineage-specific culture conditions to promote MSC differentiation into mineralised matrix-






3.2.1 Generation of primary Rptor knockout (RapKO) MSCs. 
As outlined in Figure 3.1, primary compact bone-derived MSCs were isolated from the 
humeri, femora, tibiae and iliac crests of R26eYFP-Rptorfl/fl mice (n≥6 mice per harvest), 
according to established protocols264. Following collagenase digestion, mature haematopoietic 
cells were removed from this heterogeneous cell suspension by targeting the haematopoietic 
cell antigens B220, Gr-1, CD3, CD4, CD5, CD8, CD11b and Ter-119. Following this lineage 
depletion, multipotent Lin-CD51-CD45-CD31-Sca1+ R26eYFP-Rptorfl/fl MSCs were isolated 
by fluorescence-activated cell sorting (FACS).  
Following in vitro expansion of the Lin-CD51-CD45-CD31-Sca1+ R26eYFP-Rptorfl/fl 
MSC population, these cells were infected with a lentivirus encoding a tamoxifen (TAM)-
inducible self-deleting Cre recombinase (CreERT2) or empty vector control. Infected cells 
harbouring stable integration of CreERT2 or empty vector control were subsequently isolated 
based on eGFP expression using FACS. As CreERT2 remains inactive in the cytoplasm until 
exposed to TAM 280, CreERT2-infected R26eYFP-Rptorfl/fl MSCs were cultured in the presence 
of TAM to induce Rptor deletion (herein referred to as "RapKO" MSCs). To control for any 
off-target effects related to TAM treatment in these cells, separate populations of CreERT2-
infected R26eYFP-Rptorfl/fl MSCs were treated with vehicle alone (herein referred to as "Cre-
TAM" MSCs). Furthermore, to control for off-target effects related to CreERT2 expression, 
R26eYFP-Rptorfl/fl vector control MSCs were also treated with TAM (herein referred to as 
"vector+TAM") or vehicle alone (herein referred to as "vector-TAM"), and used as additional 
control cell populations in the studies outlined below.  
  
Figure 3.1 -  Generation of primary RapKO MSC populations: (A) Compact bone MSCs 
were isolated from the fore- and hind-limbs of 6-7 week old Rptorfl/fl mice (n≥6 per harvest) 
following collagenase digestion. (B) Multipotent Lin-CD51-CD45-CD31-Sca1+ Rptorfl/fl 
MSCs were isolated from the heterogenous bone cell population via FACS and expanded in 
vitro (orange cells). (C) Multipotent R26eYFP- Rptorfl/fl MSCs were infected with a lentivirus 
encoding a tamoxifen (TAM)-inducible Cre recombinase (CreERT2) or empty vector control. 
The Lentiviral vector (LEGO-iG2) also contains a floxed eGFP cassette. (D) GFP+ MSCs 
harbouring Cre recombinase or vector control were isolated using FACS (green cells) and 
expanded in vitro. (E) Transduced GFP+ Rptorfl/fl cells were treated with TAM to induce Cre-
mediated deletion of Rptor (RapKO MSCs, blue cells). To produce control MSC cultures 
containing normal Rptor expression, CreERT2-infected cells were cultured in the absence of 
TAM (Cre –TAM) and vector control cells cultured in either the presence or absence of TAM 
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3.2.2 Confirmation of Rptor knockout in transduced MSCs. 
To confirm TAM-induced nuclear translocation of CreERT2 and subsequent Cre 
recombinase activity in transduced cells, GFP expression was monitored using flow cytometry. 
This was facilitated by the presence of a floxed GFP cassette within the CreERT2 vector, which 
upon induction of Cre activity, resulted in the loss of GFP expression. As outlined in 
Figure3.2A, GFP expression was analysed after 0, 2, 6 and 8 days of 0.5PM TAM treatment in 
CreERT2-infected RapKO MSCs, to determine the optimal length of TAM-treatment required 
for complete gene deletion. Over the 8 days of TAM treatment, a progressive decrease in GFP 
expression was observed, with a complete loss of GFP expression observed after 8 days (Figure 
3.2A). Based on this information, 8 days of TAM treatment was used to induce Cre-mediated 
gene deletion for all subsequent studies. 
To confirm successful Rptor deletion in RapKO MSCs, CreERT2-infected MSCs and 
vector control MSCs were treated for 8 days with TAM, and whole cell lysates were prepared. 
Western blot analyses were then performed using antibodies directed against raptor, rictor and 
mTOR, and downstream effectors of the mTOR signalling pathways (P-S6KT389, P-AktS473, P-
AktT308, P-IRS1S636/639, P-FOXO1/3aT24/32). As shown in Figure 3.2B, there was a significant 
reduction in levels of raptor protein expression in RapKO cells and Rptor deletion resulted in a 
decrease in the activation status of the primary mTORC1 substrate S6K.  Furthermore, deletion 
of Rptor resulted in the hyperphosphorylation of AktThr308, IRS-1 and FOXO1/3a signifying 
loss of mTORC1 mediated feedback regulation of PI3K/Akt and insulin signalling. No changes 
in the levels of mTOR or rictor protein, nor downstream mTORC2 targets (e.g. AktS473), were 
observed in RapKO MSCs (Figure 3.2B). 
3.2.3 Proliferative capacity is reduced in RapKO MSCs. 
As mTORC1 is known to regulate cell growth and proliferation, the effect of Rptor 
knockout on MSC proliferation was examined. In these studies, equal numbers of RapKO and 
Figure 3.2 - Verification of Rptor deletion in MSC in vitro: Multipotent Lin-CD51-CD45-
CD31-Sca1+ R26eYFP- Rptorfl/fl MSCs stably infected with a lentivirus encoding a TAM-
inducible Cre recombinase were treated with TAM for 8 days to induce the translocation of 
CreERT2 to the nucleus. (A) Flow cytometry was used to monitor the loss of GFP expression, 
a surrogate marker of Cre activity, over the 8 days of TAM treatment. A representative 
histogram of GFP expression following 0, 2, 6 and 8 days of TAM treatment is shown relative 
to control (Cre-TAM). (B) Lysates were prepared from control (vehicle-treated CreERT2-
infected cells) and RapKO MSCs. Western blot analyses were performed using antibodies 
directed against the proteins indicated to confirm the deletion of Rptor and determine the 
effect of Rptor deletion on downstream mTOR signalling pathways. Membranes were probed 









































control cells were seeded into 96-well plates and the relative number of metabolically active 
cells present after 1, 3, 5, and 7 days of culture was assessed using the colorimetric WST-1 
assay. As outlined in Figure 3.3A, a significant decrease in the number of viable cells was 
observed in RapKO MSCs compared to controls after 3, 5 and 7 days of culture (Figure 3.3A). 
The proliferative activity of RapKO and control cells was also examined using 
bromodeoxyuridine (BrdU), a synthetic nucleoside analogue of thymidine, that is incorporated 
into the newly-synthesised DNA of replicating cells281. In these studies, equal numbers of  
RapKO and control cells were seeded into 96 well plates and BrdU was added after 3 and 5 
days of culture to label replicating cells. As shown in Figure 3.3B, RapKO cells displayed a 
significant decrease in proliferative activity compared to controls after 3 days (RapKO: 
0.12±0.023 units vs control: 0.57±0.061 units) and 5 days (RapKO: 0.26±0.051 units vs control: 
0.57±0.093 units) of culture.  
3.2.4 The reduced proliferation of RapKO MSCs is not associated with apoptosis. 
To determine whether the reduction in proliferation in RapKO MSCs was attributable 
to an increase in the rate of apoptosis and necrosis, RapKO and control MSCs were stained with 
Annexin V and 7-aminoactinomycin D (7-AAD), markers of early- and late-stage cell death, 
respectively. These markers enable the analysis of 4 distinct cell populations: viable cells 
(AnnV-/7AAD-), cells undergoing early apoptosis (AnnV+/7AAD-), cells in late apoptosis 
(AnnV-/7AAD+) and dead cells (AnnV+/7AAD+). As shown in Figure 3.4, whilst no 
significant difference in Annexin V labelling was observed (RapKO: 9.49% vs control: 
11.04%), a 2.7-fold increase in 7-AAD incorporation was evident in RapKO MSCs (16.95%) 
compared to controls (6.36%). 
  
Figure 3.3 - The effect of Rptor deletion on MSC proliferation in vitro: RapKO and 
control MSCs were cultured for 7 days and proliferation assessed using WST-1 and BrdU 
assays. (A) Cumulative data from WST-1 analysis showing the number of metabolically 
active cells following 1, 3, 5 and 7 days of culture. (B) BrdU incorporation by proliferating 
cells following 3 days (top) and 5 days (bottom) of culture. Data are expressed as mean ± SD 
of quintuplicate wells of a representative experiment of three. **p<0.005, ***p<0.001, 









































Figure 3.4 - The effect of Rptor deletion on MSC apoptosis in vitro: RapKO and control 
MSCs were stained with Annexin V (marker of early apoptosis) and  
7-AAD (marker of necrotic cells) for 15 minutes and analysed immediately by flow 
cytometry. Representative dot plots illustrating the percentage and distribution of Annexin V 
and 7-AAD labelled cells are shown for RapKO MSCs (bottom right) and control MSCs. 

























































3.2.5 Increased osteogenic MSC differentiation in RapKO MSCs.  
To examine the role of mTORC1 in osteogenic MSC differentiation, the ability of 
RapKO MSCs and control MSCs to differentiate into bone-forming OBs was examined in vitro. 
In these studies, RapKO and control cells from three separate MSC harvests were cultured 
under osteoinductive conditions (ie. under hypoxic culture conditions [5% O2, 10% CO2, 85% 
N2] in the presence of 20% FCS, 10-8M dexamethasone, 100µM ascorbate, 4mM KH2PO4) for 
22 days and the mineral content of cultures was visualised using Alizarin Red staining. As 
shown in Figure 3.5, RapKO MSCs produced a visible increase in mineralised matrix 
deposition compared to control MSCs. In order to quantitate the amount of mineral produced, 
the mineralised matrix in replicate wells was dissolved using hydrochloric acid and the calcium 
content quantified using the cresolphthalein complexone assay. Calcium levels were normalised 
to DNA content, to correct for differences in cell numbers between MSC populations. 
Following 22 days of osteoinductive culture, a significant increase in mineral matrix deposition 
was seen in RapKO MSCs compared to all controls. Notably, when quantitated, RapKO cells 
showed a 5-fold increase in mineralised matrix production (10.79±0.77 mM/Pg DNA) 
compared Cre-TAM controls (1.93±0.36 mM/Pg DNA). 
As previously discussed, osteogenic differentiation can be characterized by the 
expression of key transcription factors and proteins which mark the various stages from initial 
osteogenic commitment through to mature OBs. To gain insight into the molecular mechanisms 
by which Rptor deletion promotes osteogenic MSC differentiation, temporal gene expression 
analyses were performed. For these studies, RapKO and control MSCs were cultured under 
osteogenic conditions for 22 days and total RNA was harvested at 0, 4, 7, 11, 14, 18 and 22 day 
time points. The mRNA levels of osteogenic genes were then examined by real time PCR and 
the data were normalized to E-actin. In these analyses, RapKO cells displayed a strong up-
regulation of genes involved in OB differentiation including the osteogenic transcription factors  
  
Figure 3.5 - The effect of Rptor deletion on osteogenic MSC differentiation in vitro: 
RapKO and control MSCs were cultured under osteoinductive culture conditions for 22 days, 
with media changed twice-weekly. After 22 days, the amount of acid-solubilised calcium was 
quantitated and normalised to cell number. Replicate wells were stained with Alizarin Red. 
Data are expressed as the mean ± SD of quadruplicate wells from a representative experiment 

























Cbfa-1 (Runx2) and osterix (Sp7), and the marker of OB function, alkaline phosphatase (Alpl) 
when compared to controls (Figure 3.6). RapKO cells also exhibited an increase in the 
expression of BMP-2 and other osteogenic TGFE superfamily members such as inhibinE A 
chain (Inhba) and inhibinE E chain (Inhbe) compared with controls (Figure 3.6). In contrast, 
expression of integrin binding sialoprotein (Ibsp) was strongly down-regulated in RapKO 
cultures compared to controls, as was the expression of noggin (Nog), a negative regulator of 
BMP signalling (Figure 3.7). 
3.2.6 Decreased adipogenic MSC differentiation in RapKO MSC 
To determine the effects of mTORC1 activity on adipogenesis, the ability of MSCs to 
differentiate into functional AdCs was examined. RapKO and control cells were cultured under 
adipogenic culture conditions (ie. under hypoxic culture conditions [5% O2, 10% CO2, 85% N2] 
in the presence of 20% FCS, 10-6M dexamethasone, 60PM indomethacin, 1Pg/mL insulin) for 
MSCs exhibited a marked decrease in lipid accumulation compared to all controls. When the 
number of lipid-laden, Nile Red-stained cells was quantitated and normalised to total cell 
number (as determined by enumeration of DAPI-stained cell nuclei), a 1.8-fold decrease in AdC 
formation was observed in RapKO MSCs (0.14±0.06 AdCs/total cells) compared to Cre-TAM 
controls (0.24±0.05 AdCs/total cells) (Figure 3.8B). 
To gain an insight into the molecular mechanisms by which Rptor deletion inhibits adipogenic 
MSC differentiation, temporal gene expression analyses were performed. RapKO and control 
cells were cultured under adipogenic culture conditions for 8 days and RNA was harvested at 
0, 2, 4, 6 and 8 day time points. The mRNA levels of adipogenic genes were examined by real-
time PCR and data were normalized to E-actin. Consistent with the marked inhibition of AdC 
formation in RapKO MSCs, the expression of Cebpa and Pparg, transcription factors essential 
for adipogenesis, and Adipoq, an adipokine, was significantly down-regulated in RapKO MSCs 
compared to controls at all time points examined (Figure 3.9).  
Figure 3.6 - The effect of Rptor deletion on osteogenic gene expression in vitro: RapKO 
and control MSCs (Cre-TAM) were cultured under osteoinductive culture conditions for 22 
days and RNA was harvested at twice-weekly time points. The mRNA levels of osteogenic 
genes was examined by real time PCR and data were normalized to  
β-actin. Data are expressed as the mean ± SD of quadruplicate wells from a representative 
experiment of three. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001, t-test. 















































* * *** **























































































Figure 3.7 - The effect of Rptor deletion on the expression of osteogenic genes in vitro: 
RapKO and control MSCs were cultured under osteoinductive culture conditions for 22 days 
and RNA was harvested at twice-weekly time points. The mRNA levels of osteogenic genes 
was examined by real time PCR and data were normalized to β-actin. Data are expressed as 
the mean ± SD of quadruplicate wells from a representative experiment of three. *p<0.05 
***p<0.001, ****p<0.0001, t-test. 
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Figure 3.8 - The effect of Rptor deletion on adipogenic MSC differentiation in vitro: 
RapKO and control MSCs were cultured under adipogenic culture conditions for 8 days.  
(A) Adipocytes were visualised using Nile Red, a fluorescent stain for intracellular lipid 
droplets. (B) The number of adipocytes was quantitated using ImageJ and normalised to cell 
number (quantitated from the number of DAPI-stained cell nuclei present). Data are 
expressed as the mean ± SD of a representative experiment of three. *p<0.05, **p<0.01, One-
way ANOVA with Tukey’s post-hoc test. 

























Figure 3.9 - The effect of Rptor deletion on adipogenic gene expression in vitro: 
RapKO and control (Cre-TAM) MSCs were cultured under adipogenic culture conditions for 
8 days and RNA was harvested at stated time points. The mRNA level of adipogenic genes 
was examined by real-time PCR and data were normalised to β-actin. Data are expressed as 
the mean ± SD of quadruplicate wells from a representative experiment of three. **p<0.005, 













































































The mTOR signalling pathway is a fundamental nutrient-sensing pathway in 
mammalian cells. Numerous studies have demonstrated a role for mTOR in directing MSC 
lineage commitment, however, many of these studies have utilised rapamycin and related 
analogues which, while they primarily target mTORC1, also target mTORC2 154. Furthermore, 
these studies have yielded conflicting results regarding the role of mTOR in osteogenesis 13, 16-
18, 24-27 and adipogenesis23, 203, 240, 282. These conflicting results are likely attributable to 
variations in cell types and stages of lineage maturity as well as culture conditions used. 162, 283. 
Therefore, to circumvent these issues, a genetic approach was employed in this study to 
specifically disrupt mTORC1 in primary murine MSCs and thus investigate the role of 
mTORC1 in MSC differentiation.  
In this study, primary MSC populations which lacked raptor were generated via Cre-
mediated deletion of exon 6 of the Rptor gene. Western blot analysis confirmed a significant 
reduction in raptor protein levels in RapKO cells, however as has been previously reported in 
other studies, low levels of residual raptor protein expression were observed 284-287. These 
Western blot analyses also confirmed a decrease in the phosphorylation of downstream targets 
of mTORC1 such as S6K, and the hyperphosphorylation of AktThr308, IRS-1 and FOXO1/3a. 
Importantly, deletion of Rptor had no effect on the protein levels of mTOR or rictor, the unique 
component of mTORC2. Furthermore, the activity of mTORC2 was not affected by Rptor 
deletion, as evidenced by the phosphorylation of downstream target of mTORC2, AktSer473. 
Whilst RapKO MSCs were viable, there was a significant reduction in their proliferative 
capacity, consistent with previous reports in other cell types including human embryonic stem 
cells 205 and murine derived pre-osteoblast cell lines25. 
The loss of mTORC1 activity in primary murine MSCs caused an increase in the 
osteogenic potential of these cells, as demonstrated by a significant increase in the production 





genes involved in OB differentiation such as the osteogenic transcription factors Runx2 and 
osterix (Sp7), and the marker of OB function, alkaline phosphatase (Alpl) observed in RapKO 
MSCs compared to controls. This was supported by an up-regulation in the expression of the 
Bmp2, which is known to be an important inducer of RUNX2 expression, OB maturation and 
mineral formation. Similar differences in osteogenic gene expression have also been noted in 
studies examining the pro-osteogenic properties of rapamycin in vitro 17, 18, 205, 288. In addition 
to BMP-2, mRNA levels of other osteogenic TGFβ superfamily members such as inhibin beta 
A chain (Inhba) and inhibin beta E chain (Inhbe) were also elevated after 14-22 days of 
osteogenic culture, which coincides with the onset of mineralised matrix production.  
The expression of Noggin, a potent BMP antagonist that inhibits osteogenesis in vitro 
and is associated with decreased bone formation in vivo 289, was also strongly down-regulated 
in RapKO cells, consistent with a BMP-mediated induction of osteogenesis. While further 
studies are required to characterise the precise mechanisms by which mTORC1 inhibition 
promotes osteogenesis, the up-regulation of multiple TGFβ superfamily members in RapKO 
MSCs suggests that it likely occurs through autocrine and/or paracrine mechanism(s) involving 
BMPs and TGFβ/activin signalling. While the role of BMPs in promoting osteogenesis is well-
established, their roles are complex and dependent on dose and receptor subtype 290. 
In this study, RapKO MSCs also displayed a decreased capacity for adipogenic 
differentiation and lipid accumulation. A significant reduction was observed in the mRNA 
expression of the adipogenic transcription factors PPARγ and C/EBPα, and the mature AdC 
marker, adiponectin, in RapKO MSCs compared to controls. The anti-adipogenic effect Rptor 
deletion in MSCs is consistent with observations in previous in vitro studies targeting mTOR 
through rapamycin administration in both mouse and human pre-AdCs 19, 20, 22, 291. It has been 
shown that insulin signalling is   essential for proper induction of PPARγ 292, with further 
observations indicating downstream mTORC1 activity is required for expression of PPARγ and 





Collectively, the data presented in this chapter demonstrates that mTORC1 activity is 
involved in directing MSC fate towards the osteogenic and adipogenic lineages. Given that 
PI3K/Akt/mTOR signalling is the primary nutrient-sensing pathway in mammalian cells, it is 
possible that mTORC1 signalling, induced by high environmental nutrient availability, guides 
MSC differentiation towards the adipogenic lineage in order to prevent lipotoxicity in other 
cells294. Conversely, when nutrient levels fall, suppression of mTORC1 signalling promotes 
MSC differentiation towards the osteogenic lineage by down-regulating adipogenic 
transcription factors and inducing the expression of osteogenic transcription factors. 
While in vitro models provide important insight into biological processes, they provide 
limited understanding of the effects of gene deletion in the context of pre-natal and post-natal 
mammalian development. To address these limitations, transgenic mouse models have been 
developed in order to gain insight into the physiological and pathophysiological role of 
candidate genes of interest. In relation to the mTORC1 pathway, global knockout of Rptor 
results in embryonic lethality 202, necessitating the use of the Cre-loxP system of targeted 
transgenesis to investigate the role of mTORC1 in the development and function of specific 
tissues such as fat 202 skeletal muscle 241, haematopoetic stem cells 295, oocytes 246 and 
embryonic mesenchyme286, among others. In the following chapters, the role of mTORC1 in 
skeletal development and homeostasis was examined in conditional knockout mice in which 
Rptor is specifically deleted in Osx-expressing pre-OB cells.  
 
 
Chapter 4 - The phenotypic characterisation of 




In Chapter 3, deletion of Rptor in compact bone derived MSCs was shown to promote 
osteogenesis and inhibit adipogenesis, suggesting that mTORC1 plays an important role in 
directing MSC fate determination. These findings are consistent with a number of previous in 
vitro studies which suggest that mTORC1 can regulate MSC differentiation 13, 16-18. 
The pro-osteogenic effects of suppressing mTORC1 function in MSCs raises the 
possibility of utilising mTORC1 inhibitors to promote bone in vivo. Rapamycin, a potent 
inhibitor of mTORC1, is used clinically as an immunosuppressant in graft-versus-host-disease 
217-222. Pre-clinical studies in animals have shown that rapamycin analogues decrease bone 
resorption 296, 297. Rapamycin is also used clinically in preventing mTORC1-mediated cancer 
cell proliferation with p70S6K and 4EBP1, direct downstream targets of mTORC1, identified as 
being over-expressed and/or constitutively activated in several cancer types 223-230. Within these 
clinical contexts, rapamycin and related analogues have been shown to have protective effects 
on the skeleton. For example, while rapamycin preserves bone mass, commonly-used 
immunosuppressive drugs, including cyclosporine A (CsA), are associated with rapid turnover 
of bone resulting in severe osteopenia 231-235. Additionally, rapamycin reduces bone loss in 
patients suffering from both osteoporosis and exacerbated bone loss as a result of chemotherapy 
236, 237. While these studies indicate a bone-sparing effect of rapamycin, these are largely due to 
reduced resorption as opposed to increased mineralisation.  
In contrast to clinical studies indicating rapamycin has bone-sparing properties, loss of 
function studies in mice suggest the PI3K/Akt/mTOR pathway is activated during skeletal 
development and bone accrual. Factors which promote bone accrual, such as insulin and IGF-
1, are known to activate PI3K/Akt/mTOR signalling 298. Insulin signaling activates mTORC1 
via inhibition of the TSC1/TSC2 complex. Homozygous mutation of genes encoding insulin-
like growth factor 1 (IGF1), IGF2 or the IGF receptor (IGF1R) all confer abnormal embryonic 
skeletal development, resulting in dwarfism 251-253. Mice in which the Igf1r is deleted in OBs, 
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using Osx-cre, also have a low bone mass phenotype 299. mTORC1 activity is elevated in mice 
harbouring Pten 262 or TSC2 300 disruption localized to mature OBs with both models conferring 
a high bone mass phenotype.  Additionally, mice lacking both Akt1 and Akt2 showed neonatal 
lethality, dwarfism 259 and delayed bone ossification 166, 260. 
Considering the findings in Chapter 3 and results from genetic studies in mice, the role 
of mTORC1 in in vivo osteogenesis remains unclear. This uncertainty is exacerbated by recent 
evidence suggesting that long-term treatment with rapamycin inhibits both mTORC1 and 
mTORC2 162. Investigation of the biological importance of mTORC1 and mTORC2 in vivo has 
been limited by the finding that global deletion of either mTOR, Rptor or Rictor is 
embryonically lethal. Of note, both mTOR-/- and Rptor-/- mice die shortly after implantation 
(E5.5 and E9.5 respectively), reflecting the absolute necessity for mTORC1 signalling during 
embryonic development 202, 238, 239. 
To overcome these issues, a conditional knockout approach utilising the Cre-loxP 
system has been developed to facilitate tissue-specific deletion of genes of interest. In recent 
years, conditional tissue-specific Rptor knockout models have been used to characterise the role 
of mTORC1 in multiple tissues including mature adipocytes 240, skeletal muscle 241 and 
mesenchyme 286. These studies have shown that the deletion of Rptor in adipose tissue caused 
leanness in mice due to an elevated energy expenditure caused by mitochondrial uncoupling 
202. Similarly, Benzinger et al (2008) reported that mice harbouring a skeletal muscle-specific 
deletion of Rptor have decreased muscle formation and a down-regulation of genes involved in 
mitochondrial biogenesis. Numerous other studies have utilised this model to assess the role or 
mTORC1 in tissues including but not limited to; neural cells 243, oligodendrocytes 244, T-cells 
245, oocytes 246, intestinal epithelial cells 247 and red blood cells 248. 
While conditional knockout models have been used to characterise the role of mTORC1 
in many other tissues, to date, the role of mTORC1 signalling in skeletal development has yet 
to be examined. To address this, the studies outlined in this chapter describe the phenotypic 
characterisation of a bone-specific Rptor knockout mouse model, using the pre-OB-specific 
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promoter Osterix to drive Cre recombinase expression. Numerous other Cre transgenic lines 
have been utilised in the analysis of bone related genes such as markers of osteo-
chondroprogenitors including Prx1 249, Sox9 301 and mature OBs including osteocalcin 250 and 
Col1A1 302. While the commitment of MSCs to the osteogenic lineage is marked by the 
expression of key transcription factors Runx2 and Osterix, Runx2 is also expressed in 
chondrogenic progenitors. Therefore, the Osterix-Cre line was utilized in this study as it allows 
for gene deletion in committed OB progenitors in both endochondral and intramembranous-





4.2.1 Generation of OB-specific Rptor knockout mice 
To examine the role of mTORC1 in skeletal development in vivo, conditional KO mice 
in which either one or both Rptor alleles were deleted in Osx-expressing cells were generated. 
To achieve this, three strains of mice were utilised: (1) Osx1-GFP::cre mice (herein referred to 
as Osx:Cre), in which Cre expression is  driven by the OB-specific Osx promoter 33;  (2)  Rptor 
floxed (Rptorfl/fl) mice, in which loxP sites have been inserted to flank exon 6 of the Rptor gene 
241; and (3) Rosa26eYFP mice, whereby eYFP expression is activated in Cre expressing cells 
via deletion of an upstream floxed STOP cassette 303. 
As outlined in Figure 4.1A, the breeding strategy used to generate heterozygous 
(Rptorob-/+) and homozygous (Rptorob-/-) OB-specific knockout mice was a multistep process. 
Firstly, Osx:Cre animals were mated with Rptorfl/fl mice to produce heterozygous Rptorfl/+ 
offspring (in which one allele of Rptor is disabled in osterix expressing cells, herein referred to 
as Rptorob-/+). From this mating, Rptorob-/+ were then backcrossed with Rptorfl/fl mice to produce 
progeny of three different genotypes:(i) Osx1-GFP::cre transgene negative Rptorfl/fl or Rptorfl/wt 
(herein referred to as Wt), (ii) heterozygous Rptorob-/+ mice and (iii) Osx-Cre-raptorfl/fl 
(homozygous OB-specific Rptor knockout mice, herein referred to as Rptorob-/-). 
For studies examining gene expression, ROSA26eYFP reporter mice were introduced 
into the breeding strategy to facilitate lineage tracing of MSC-derived cells or for the isolation 
of the cells harbouring Osx:Cre-mediated gene deletion. To achieve this, Rptorfl/fl mice were 
bred to homozygosity with Rosa26eYFPfl/fl mice, generating R26eYFPfl/fl-Rptorfl/fl mice (herein 
referred to as eYFP-Rptorfl/fl), which were mated with Osx:Cre mice in the breeding strategy as 
described above. From this breeding strategy, progeny with the following genotypes were 
generated (i) eYFP-Rptorfl/wt or eYFP-Rptorfl/fl mice (herein referred to as Wt), (ii) Osx-Cre-
R26eYFP-Rptorfl/wt (herein referred to as eYFP-Rptorob-/+) and (iii) Osx-Cre-R26eYFP-
Raptorfl/fl (herein referred to as eYFP-Rptorob-/-). 
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All progeny generated from this breeding strategy were genotyped in tail biopsies using 
PCR primers that were designed to detect (i) the presence of the Osx:Cre transgene, and (ii) the 
presence or absence of LoxP sites within the Rptor gene (Fig. 4.1B). 
4.2.2 Postnatal survival is reduced in Rptorob-/- mice 
As outlined in Figure 4.2A, animals generated from this breeding strategy were born at 
the expected Mendelian frequencies (i.e. approximately 50% Wt, 25% Rptorob-/+ and 25% 
Rptorob-/-). Postnatal survival was monitored over a 52 week period, and as shown in Figure 
4.2B, the survival of both Rptorob-/- and Rptorob-/+ mice was significantly reduced compared to 
Wt littermates after 52 weeks (68%, 72% and 97% survival respectively) (Fig. 4.2 B).  
4.2.3 Osx:Cre mice have a distinct skeletal phenotype  
To identify whether Wt littermates or Osx:Cre transgenic mice were the more suitable 
controls to use when characterising the skeletal phenotype of our Rptorob-/+ and Rptorob-/- mice, 
we performed a comparative analysis of Osx:Cre animals and Wt littermate controls at 4, 8 and 
12 weeks of age. As gender contributes to measurable differences in skeletal development 304, 
305, this study was performed on male mice only. 
At all time points examined, Osx:Cre animals were visibly smaller than Wt littermate 
controls (Fig. 4.3A), and had a significantly lower body weight than Wt controls at 4, 8 and 12 
weeks (% reduction 34.2±8.2%, 28.2±6.4% and 18.3±4%, respectively) (Fig. 4.3B, Table 4.1). 
At 4 weeks of age mice were x-rayed and spinal lengths (defined by the distance from C1 to L5 
vertebrae) quantitated using ImageJ. While no significant difference in spinal length was 
observed at any of the time points examined (Fig. 4.3C; Table 4.1), Osx:Cre animals were found 
to have significantly shorter tibial bones at 12 weeks of age, compared to Wt controls (mean 
decrease 6.3%±2.3) as measured by electronic calipers from the proximal tibial head to the 
fibular notch (Fig. 4.3D; Table 4.1).   
Figure 4.1 - Generation of OB-specific Rptor KO mice: (A) The multi-step breeding 
strategy used to generate mice with an OB-specific Rptor deletion. Osx:Cre animals were 
mated with mice harbouring two floxed Rptor alleles (Rptorfl/fl). Heterozygous Osx:Cre 
positive animals from this mating (Rptorob-/+, in which one allele of Rptor has been deleted in 
pre-OBs) were then backcrossed with Rptorfl/fl animals to produce: (i) Osx:Cre negative 
animals (Wt), (ii) heterozygous OB-specific Rptor knockouts (Rptorob-/+), and (iii) 
homozygous OB-specific Rptor knockouts (Rptorob-/-). For some studies a Rosa26eYFP 
reporter line was utilised for identification of Cre activity. The floxed "stop" cassette in 
R26eYFP- Rptorfl/fl mice becomes excised upon exposure to Cre recombinase, thus labelling 
the OB-specific Rptor knockout cells eYFP+. (B) PCR was used to detect the presence of the 
Osx:Cre transgene and the presence or absence of floxed Rptor alleles to ascertain the 




Rptorfl - floxed allele
(substituted for R26eYFP-Rptorfl/fl for some studies)








































Figure 4.2 - Frequency and survival rates of OB-specific Rptor knockout mice: (A) The 
observed frequency of wild type, heterozygous (Rptorob-/-) and homozygous (Rptorob-/-) OB-
specific Rptor knockout animals generated by our breeding strategy was consistent with 
expected Mendelian ratios (n>100 per group). (B) Kaplan-Meier survival curves were 
generated for Wt, Rptorob-/+ and Rptorob-/- animals (n≥60 per group). *p < 0.05, **p < 0.01, 











































Figure 4.3 - Osx:Cre mice display a stunted phenotype compared to Wt controls: (A) 
Representative images of male Wt and Osx:Cre animals at 4, 8 and 12 weeks of age. Bar = 
10mm. (B) Animals were weighed at 4, 8 and 12 weeks of age. (C) Animals were x-rayed at 
4, 8 and 12 weeks of age and spinal lengths (defined by the distance from C1 to L5 vertebrae) 
were quantitated using ImageJ. (D) Electronic callipers were used to measure the length of the 
tibia (from the proximal head to the fibular notch) in animals at 4, 8 and 12 weeks of age. (E) 
mCT analysis was performed on tibiae from animals at 4, 8 and 12 weeks of age, to measure 
bone volume (BV/TV) in a region of trabecular bone distal to the growth plate. (F) mCT 
analysis was performed on tibiae from animals at 4, 8 and 12 weeks of age, to measure the 
average cortical thickness (Ct.Th) in a region of trabecular bone distal to the growth plate. In 
all graphs, data are expressed as mean ± S.D, n≥8 per group. *p<0.05, **p<0.001 and 



































































































































Table 4.1 Wildtype vs Osx:cre comparison 
  Wt Osx:Cre Wt vs Osx:Cre 
  Mean St Dev1 Mean St Dev Sig.2 P value3 
Weight (g)           
4 weeks 17.52 ±0.88 11.52 ±3.23 **** < 0.0001 
8 weeks 22.87 ±2.16 16.43 ±2.47 *** 0.00010 
12 weeks 27.80 ±3.07 22.76 ±1.47 **** < 0.0001 
         
Spinal Length (cm)        
4 weeks 7.73 ±0.86 8.88 ±0.55 ns4 0.07 
8 weeks 9.27 ±0.44 8.57 ±0.43 ns 0.2 
12 weeks 9.92 ±0.47 10.17 ±0.35 ns 0.37 
         
Tibial Length (mm)        
4 weeks 9.44 ±0.46 9.04 ±0.50 ** 0.003 
8 weeks 10.62 ±0.56 10.60 ±0.50 ns  0.95 
12 weeks 11.28 ±0.38 10.57 ±0.49 ** 0.0013 
        
BV/TV5 (%)         
4 wk 9.09 ±1.65 9.81 ±1.60 ns 0.94 
8 wk 12.67 ±3.17 12.83 ±2.10 ns 0.9991 
12 wk 16.57 ±2.36 17.03 ±1.83 ns 0.59 
        
Ct.Th6 (mm)        
4 wk 0.13 ±0.01 0.10 ±0.01 ** 0.0030 
8 wk 0.15 ±0.01 0.14 ±0.01 ns 0.94 
12 wk 0.16 ±0.03 0.14 ±0.02 ns 0.45 
1St Dev = Standard deviation 
2Sig. = Significance 
3P value = Values determined using ANOVA with Tukey’s post hoc test 
4ns = No significance 
5BV/TV = Percentage of total volume comprising bone 





To examine the bone microstructure in Osx:Cre and Wt animals, high-resolution micro-
computed tomography (mCT) analyses were performed on the proximal tibiae. No significant 
difference in the percentage of trabecular bone volume to total volume (BV/TV) was observed 
at 4 and 8 weeks and 12 weeks in Osx:Cre mice compared to Wt mice (Fig. 4.3E; Table 4.1). 
Furthermore, mCT analysis of a region of trabecular bone distal to the tibial growth plate 
revealed that Osx:Cre mice have significantly thinner cortical bone compared to Wt controls at 
4 weeks of age (mean decarese 23.1±3.9%) (Fig. 4.3F; Table 4.1).  
4.2.4 Confirmation of OB-specific Rptor deletion 
To confirm the bone-specific deletion of Rptor in this mouse model, genomic DNA was 
isolated from multiple tissues (bone, liver, spleen, heart, kidney, lung) of control and knockout 
animals and PCR used to amplify a product generated by Cre-mediated recombination of the 
Rptor gene 241. A deletion-specific product was amplified from genomic DNA isolated from 
cells of the long bones of Rptorob-/+ and Rptorob-/- mice but was absent in liver, spleen, heart, 
kidney and lung samples, thus confirming that the deletion of Rptor was bone-specific in these 
mice (Fig. 4.4A).  
Further confirmation of OB-specific Rptor gene deletion was sought at the 
transcriptional level. Due to the low incidence of Osterix expressing cells harbouring the Rptor 
deletion, relative to the total cell population of the bone (which contains a heterogeneous mix 
of cells including osteoclasts, adipocytes, haematopoetic cells and bone marrow stromal cells), 
a purified population of Osterix-expressing cells was isolated from each animal cohort to 
confirm OB-specific Rptor deletion. To achieve this, the ROSA26eYFP reporter was utilised 
which, as described earlier, labels cells eYFP+ upon exposure to the Cre recombinase. Using 
this reporter, eYFP+ cells were isolated from eYFP-Osx:cre (ROSA26eYFP x Osx:Cre) and 
eYFP-Rptorob-/- mice using fluorescence activated cell sorting (FACS) and lysed for RNA. 
Using Rptor-specific primers, RT-PCR analysis of these RNA samples showed a significant 
reduction in Rptor transcript in eYFP+ cells isolated from heterozygous (eYFP-Rptorob-/+) and  
 
Figure 4.4 - Confirmation of tissue specific Rptor deletion: (A) Genomic DNA was 
isolated from the indicated tissues of 4-week old Osx:Cre,  
Rptorob-/+ and Rptorob-/- animals and PCR was used to determine the genotype (upper panel) 
and the presence of a Rptor gene deletion product (lower panel). fl, floxed; wt, wildtype; del, 
deletion. (B and C) qPCR was performed on RNA extracted from eYFP+ cells isolated from 
eYFP-Osx:cre (control), eYFP- Rptorob-/+ and eYFP- Rptorob-/- mice (n=10 per genotype) 
using Rptor exon 6-specific and b-actin primers. Amplified products were resolved on 2% 
agarose gels stained with Gel Red. Rptor transcript levels were quantitated using real-time 
PCR, and normalised to β-actin. Data are presented as mean ± S.D of quadruplicate samples. 









































































































































































homozygous (eYFP-Rptorob-/-) knockout mice relative to eYFP-Osx:Cre controls (mean 
decrease 48.6±7.4% and 86.3±0.7% respectively) (Fig. 4.4B and 4.4C). 
4.2.5 Prenatal skeletal phenotype in Rptorob-/- mice 
To determine the effect of Rptor deletion on prenatal skeletal development, 
examinations were performed on newborn (P0) Osx:Cre and Rptorob-/- mice. As shown in Figure 
4.5A, Osx:Cre and Rptorob-/- mice were phenotypically indistinguishable at birth. To investigate 
the effect of Rptor gene deletion on prenatal skeletal development, the skeletons of newborn 
(P0) Osx:Cre and Rptorob-/- mice were stained to assess the level of mineralised bone and 
cartilage using Alizarin Red and Alcian Blue, respectively. As shown in Figure 4.5B, bones of 
the pelvic cage such as the ilium, ischium and pubic bones were visibly less mineralised in 
Rptorob-/- mice compared to Osx:Cre controls. Similarly, staining of the skulls indicated that 
Rptorob-/- mice have narrower skulls and decreased mineralisation of the calvarial plates 
compared to Osx:Cre controls (Fig. 4.5C). A decrease in Alizarin Red staining was also 
observed in the mandibles of Rptorob-/- mice (Fig. 4.5D). 
Analysis of prenatal long bone development was also performed on newborn Alizarin 
Red and Alcian Blue-stained Osx:Cre and Rptorob-/- mice (Fig. 4.6A and 4.6C). As shown in 
Figure 4.6, long bones of the hind and fore limbs (ie. the femur and humerus, respectively) were 
significantly shorter in newborn Rptorob-/- mice compared to Osx:Cre controls (mean decrease 
8.5±1% for both bones), and the percentage of mineralised bone was also significantly reduced 
in newborn Rptorob-/- mice (mean decrease 17.4±2.2% for both bones) (Fig. 4.6 B and D). 
4.2.6 Rptorob-/- mice have a stunted phenotype and reduced body weight 
To characterise the effect of conditional deletion of Rptor in pre-OBs on postnatal 
skeletal development, male Osx:Cre, Rptorob-/+ and Rptorob-/- animals were examined at 4, 8 
and 12 weeks of age. These time points were selected on the basis that they represent the early, 
mid and later phases of long-bone growth in mice 306. As shown in Figure 4.7A, Rptorob-/+ and 
Rptorob-/- mice were visibly smaller than Osx:Cre control mice at 4, 8 and 12 weeks of age. At  
Figure 4.5 - Rptorob-/- mice display altered prenatal skeletal mineralisation: Newborn mice 
(P0) were stained with Alizarin Red and Alcian Blue to visualise mineralised bone (red) and 
cartilage (blue), respectively. (A) Representative images of newborn (P0) Osx:Cre and 
Rptorob-/- animals prior to staining are shown. Bar = 10mm.  
(B) Schematic of the basic anatomy of the pelvic cage (left) and representative images of 
Alizarin Red and Alcian Blue staining of the pelvic cage of newborn Osx:Cre and Rptorob-/- 
animals (right). Bar = 5mm. (C) Schematic of the basic anatomy of the skull (superior view, 
left) and representative images of Alizarin Red and Alcian Blue staining of the skull of 
newborn Osx:Cre and Rptorob-/- animals (right). Bar = 5mm. (D) Schematic of the basic 
anatomy of the skull (lateral view, left) and representative images of Alizarin Red and Alcian 



















Figure 4.6 - Rptorob-/- animals display reduced prenatal long bone length and 
mineralisation: Newborn mice (P0) were stained with Alizarin Red and Alcian Blue to 
visualise mineralised bone (red) and cartilage (blue), respectively. (A) Representative images 
of Alizarin Red and Alcian Blue staining of the forelimbs of newborn Osx:Cre and Rptorob-/- 
mice. (B) The length of the humerus (left) and the percentage of the humerus that is 
mineralised (right) were measured using ImageJ. (C) Representative images of Alizarin Red 
and Alcian Blue staining of hind-limbs of newborn Osx:Cre and Rptorob-/- mice. (D) The 
length of the femur (left) and the percentage of the femur that is mineralised (right) were 
measured using ImageJ. Bar = 5mm. Data are presented as mean ± SD, n≥8 per group. 


















































































































each of these time points, Osx:Cre, Rptorob-/+ and Rptorob-/- animals were weighed and, as 
shown in Figure 4.7B, Rptorob-/- animals were found to have a significantly lower body weight 
compared to Osx:Cre animals at both 4 and 12 weeks of age (mean decrease 22.9±7.8% and 
15.2±2.12%, respectively), whereas the Rptorob-/+ animals did not exhibit any changes in body 
weight at these time points. Additionally, Rptorob-/- animals weighed significantly less than 
Rptorob-/+ animals at 8 and 12 weeks of age (mean decrease 24.5±6.5% and 15.4±3.5%, 
respectively). However, somewhat surprisingly, Rptorob-/+ animals displayed an increase in 
body weight at 8 weeks of age compared to Osx:Cre controls (mean increase 16.43±2.43) (Fig. 
4.7B; Table 4.2). 
4.2.7 Organ development in Rptorob-/- mice 
To determine whether OB-specific Rptor deletion affects other organ systems, organ 
weights of the spleen, heart, liver and kidney were recorded for Osx:Cre controls, Rptorob-/+ 
and Rptorob-/- mice at 4, 8 and 12 weeks of age. Given that body weight is a key determinant of 
organ size, all organ weight measurements were normalised to total body weight. When 
normalised to body weight, Rptorob-/- mice were found to have a significantly smaller liver than 
Osx:Cre controls at 4 weeks of age (mean decrease 24.7±9%), but not at 8 and 12 weeks of age. 
In contrast, Rptor deletion had no effect on the spleen, heart or kidney weights at any of the 
time points examined (Fig. 4.8; Table 4.3). 
4.2.8 Spinal and tibial length are reduced in Rptorob-/- mice 
To further evaluate the macroscopic effects of OB-specific mTORC1 deletion on 
skeletal development, mice were x-rayed and spinal lengths (defined by the distance from C1 
to L5 vertebrae) quantitated using ImageJ. A significant reduction in spinal length was observed 
in Rptorob-/- animals at 4 and 12 weeks of age compared to Rptorob-/+ (mean decrease 11±2.8% 
and 10.8±2.3%, respectively) and Osx:Cre animals (mean decrease 16.8±2.5% and 14.4±2.5%, 
respectively). In contrast, no significant difference in spinal length were observed between any 
of the animal groups at 8 weeks of age (Fig. 4.9A; Table 4.2).  
 
Figure 4.7 - Rptorob-/- mice display reduced postnatal weight: (A) Representative images of 
male Osx:Cre, Rptorob-/+ and Rptorob-/- animals (L-R) at 4, 8, and 12 weeks of age. Bar = 
10mm. (B) Weights of Osx:Cre, Rptorob-/+ and Rptorob-/- animals were recorded at 4, 8, and 12 
weeks of age. Data are presented as mean ± SD, n≥8 per group. *p<0.05 and **p<0.01, two-








































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.8 - Rptorob-/- mice display reduced liver weight: Following careful dissection of the 
major organs from the surrounding tissues, the weights of the (A) spleen, (B) liver, (C) heart, 
and (D) kidney were recorded for Osx:Cre, Rptorob-/+ and Rptorob-/- animals at 4, 8 and 12 
weeks of age, and normalised to total body weight. Data are presented as mean ± SD, n≥8 per 























































































































































































































































































































































































































































































































































































































































































































































































To complement these findings, electronic calipers were used to measure the length of 
the tibia (from the proximal head to the fibular notch) in Osx:Cre, Rptorob-/+ and Rptorob-/- 
animals at 4, 8 and 12 weeks of age. As shown in Figure 4.9B, a significant decrease in tibial 
length was observed in Rptorob-/- animals at 4 weeks of age compared to both Osx:Cre and 
Rptorob-/+ animals (mean decrease 12.8±2.6% and 15.4±2.2% respectively). Additionally, at 8 
weeks Rptorob-/- animals had a significantly shorter tibia than Rptorob-/+ animals (mean decrease 
7.2±2.9%), and although also reduced compared to Osx:Cre animals, this was not statistically 
significant. Despite the reduced weight and spinal length of Rptorob-/- animals in comparison to 
the Rptorob-/+ and Osx:Cre animals, the stunted tibial growth was overcome by 12 weeks of age 
(Fig. 4.9 B; Table 4.3). 
4.2.9 Growth plate thickness is reduced in Rptorob-/- mice 
Numerous studies suggest that epiphyseal growth plate activity determines long bone 
growth 307. To determine if the reduced tibial length observed in Rptorob-/- mice was associated 
with a reduction in tibial growth plate thickness, tibiae collected from Osx:Cre, Rptorob-/+ and 
Rptorob-/- animals at 4, 8 and 12 weeks of age were analysed using high resolution mCT 
imaging. From 3-dimensional (3D) re-constructions of these µCT data, measurements of 
growth plate thickness were taken at 20 equidistant points across the central section of the 
proximal growth plate, and an average growth plate thickness calculated. At 4 weeks of age, a 
significant decrease in the thickness of the growth plate in both Rptorob-/+ and Rptorob-/- animals 
compared to Osx:Cre controls was observed (mean decrease 16.4±4.5% and 25.9±3.2%, 
respectively, Fig. 4.10C). In contrast, no significant difference in growth plate thickness was 
observed between any of the animal cohorts at 8 and 12 weeks of age (Fig. 4.10C; Table 4.4).  
4.2.10 Analysis of the trabecular bone micro-architecture in mice 
To assess the effects of OB-specific Rptor deletion on the micro-architecture of 
trabecular bone, mCT analysis was performed on tibiae from Osx:Cre, Rptorob-/+ and Rptorob-/- 
animals at 4, 8 and 12 weeks of age. For these studies, 150 slices (~0.97mm) were analysed in  
 
Figure 4.9 - Rptorob-/- mice display reduced postnatal spinal and tibial length: (A) The 
spinal lengths (defined by the distance from C1 to L5 vertebrae) of Osx:Cre, Rptorob-/+ and 
Rptorob-/- mice were measured from X-ray images taken at 4, 8 and 12 weeks of age using 
ImageJ. (B) The tibial lengths (as determined by an average of three measurements taken 
from the proximal tibial head to the fibular notch using electronic calipers) of Osx:Cre, 
Rptorob-/+ and Rptorob-/- mice were measured at 4, 8 and 12 weeks of age. Data are presented as 
mean ± SD, n≥8 per group. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, two-way 































































Figure 4.10 - Rptorob-/- mice display reduced growth plate thickness: The growth plate 
width in the proximal tibial head was analysed in male Osx:Cre,  
Rptorob-/+ and Rptorob-/- animals at 4, 8 and 12 weeks of age from high resolution mCT 
images. (A) A schematic depiction of the proximal tibial growth plate. (B) A representative 
mCT image of the proximal tibial head of a male Osx:Cre, Rptorob-/+ and Rptorob-/- animal at 4 
weeks of age. In these images, the growth plate is identified by the unmineralised area, 
between the indicated arrows). (C) Mean growth plate thickness was determined by an 
average of 20 measurements taken across the growth plate. Data are presented as mean ± SD, 








































































































































































































































































































































































a region of trabecular bone commencing 20 slices distal to the growth plate. Importantly, 
considering the differences observed in tibial length between animal cohorts (Fig. 4.9), an 
algorithm was devised to ensure the trabecular bone analyses were conducted in regions of the 
proximal tibiae in each animal. As summarised in Figure 4.11A, this algorithm ensures that (i) 
the distance from the growth plate, and (ii) the area of the region of interest (ROI) analysed for 
each animal was normalised to the length of the tibia (distance from growth plate = tibial 
length/11*20; length of ROI = tibial length/11*150). 
4.2.11 Trabecular bone volume is decreased Rptorob-/- mice 
High resolution mCT analysis of the secondary spongiosa within the proximal tibia 
revealed a visible reduction in the amount of trabecular bone in Rptorob-/- mice, compared to 
Osx:Cre controls, at 4, 8 and 12 weeks of age (Fig. 4.11B). Upon quantitation of these data, a 
significant decrease in trabecular bone volume, as a percentage of the total volume analysed 
(BV/TV), was observed in Rptorob-/- mice compared to Osx:Cre controls at 4, 8 and 12 weeks 
of age (mean decrease 29±3.5%, 31.8±11%, and 45±7%, respectively). At 12 weeks of age, a 
significant decrease in BV/TV was also observed in Rptorob-/+ mice relative to Osx:Cre controls 
(mean decrease 31±5.2%). In addition, Rptorob-/- mice displayed a significant decrease in 
BV/TV compared to Rptorob-/+ mice at 8 weeks of age (mean decrease 33.4±11.8%) (Fig. 
4.11C; Table 4.5) 
4.2.12 Trabecular number, but not thickness, is decreased in Rptorob-/- mice 
Trabecular bone volume is largely determined by the number, thickness and/or spacing 
between the individual trabeculae 308, 309. To further characterise the trabecular morphology of 
Osx:Cre, Rptorob-/+ and Rptorob-/- mice, the following  parameters were also measured from high 
resolution mCT reconstructions: (i) trabecular number (Tb.N), which analyses the number of 
individual trabeculae in the ROI, (ii) trabecular spacing (Tb.Sp), which calculates the average 
distance between each trabeculae, and (iii) trabecular thickness (Tb.Th), which calculates the 
average width of the individual trabeculae. 
 
Figure 4.11 - Rptorob-/- mice display reduced trabecular bone volume: Tibiae were isolated 
from male Osx:Cre, Rptorob-/+ and Rptorob-/- animals at 4, 8 and 12 weeks of age and µCT 
analysis was performed on a region of trabecular bone distal to the proximal tibial growth 
plate. (A) A schematic depicting the defined region of the proximal tibia that was analysed. 
To account for differences in tibial length between genotypes, the region of interest (ROI) 
was normalised to the length of the bone for each animal, and the number of slices from the 
growth plate and number of slices included in the ROI were calculated as follows:distance 
from the growth plate = tibial length (mm)/11*20 and the ROI = tibial length(mm)/11*150). 
(B) Representative 3D µCT reconstructions showing a section of the trabeculae and cortices 
on the sagittal plane distal to the proxial tibial growth plate in the ROI of Osx:Cre, Rptorob-/+ 
and Rptorob-/- animals at 4, 8 and 12 weeks of age.  
(C) Quantitation of the bone volume to total volume ratio (BV/TV) in the ROI of Osx:Cre, 
Rptorob-/+ and Rptorob-/- animals at 4, 8 and 12 weeks of age. Data are presented as mean ± SD, 

















Distance from growth plate = 
(tibial length (mm)/11*20)












































































































































































































































































































































































































































































































































































































































































































































































































































































As shown in Figure 4.12A, a significant decrease in Tb.N was observed in Rptorob-/- 
animals compared to Osx:Cre controls at 4, 8 and 12 weeks of age (mean decrease 29.4±4.2%, 
34.8±9.9%, and 35.5±5.1% at 4, 8 and 12 weeks, respectively). Whilst Tb.N was also decreased 
in Rptorob-/+ animals compared to Osx:Cre at all time points examined, this was only 
statistically significant at 4 and 12 weeks of age (mean decrease 23.65±9.8% and 24.8±5.9%, 
respectively)  (Fig. 4.12A; Table 4.5). 
Further analysis revealed that the decrease in Tb.N in Rptorob-/+ and Rptorob-/- animals 
was coupled with a significant increase in Tb.Sp at 4 weeks of age (mean increase 44.3±7.5% 
and 45.7±9.4%, respectively) (Fig. 4.13B). A significant increase in Tb.Sp was also observed 
in Rptorob-/- animals compared to Osx:Cre animals at 12 weeks (mean increase 45.25±18%), 
however at the 8 week time point no significant differences were observed between the animal 
cohorts (Fig. 4.12B; Table 4.5). In contrast to the Tb.N and Tb.Sp data, no significant difference 
in trabecular thickness (Tb.Th) was observed in Osx:Cre, Rptorob-/+ and Rptorob-/- animals at 
any of the time points examined (Fig. 4.12C; Table 4.5). 
4.2.13 Trabecular structure is altered in Rptorob-/- mice 
Structural integrity is determined by the shape and connectivity of the individual 
trabeculae within the lattice network 309. To measure differences in the connectivity of the 
trabecular network in knockout mice, trabecular pattern factor (Tb.Pf) was measured in 
Osx:Cre, Rptorob-/+ and Rptorob-/- mice using high resolution µCT. Tb.Pf is a bone-specific 
parameter enumerating the connection of trabeculae in three dimensions and provides an 
indication of the structural integrity of the trabecular network. At 4 weeks of age, there was no 
significant change in the connectivity of the trabecular micro-architecture between any of the 
animal cohorts. However, at the later 8 and 12 week time points, there was a significant decrease 
in the connectivity of the trabeculae in the KO animals, as indicated by an increase in the 
trabecular pattern factor (Fig. 4.13A). This difference was statistically significant for both 
Rptorob-/+ and Rptorob-/- KO animals at 8 weeks (mean increase 35.6±13.9% and 55.8±13.9%,  
Figure 4.12 - Rptorob-/- mice display reduced trabecular number and increased 
trabecular spacing: Tibiae were isolated from male Osx:Cre, Rptorob-/+ and Rptorob-/-animals 
at 4, 8 and 12 weeks of age and high resolution µCT analysis was performed on a region of 
trabecular bone distal to the proximal tibial growth plate (normalised to the length of the 
bone). Quantitation of (A) trabecular number (Tb.N), (B) trabecular separation (Tb.Sp), and 
(C) trabecular thickness (Tb.Th) was performed using CTAn (SkyScan). Data are presented as 
mean ± SD, n≥8 per group.  *p<0.05, **p<0.01, ****p<0.0001, two-way ANOVA with 













































































Figure 4.13 - Rptorob-/- mice display altered trabecular micro-architecture: Tibiae were 
isolated from male Osx:Cre, Rptorob-/+ and Rptorob-/- animals at 4, 8 and 12 weeks of age and 
high resolution µCT analysis was performed on a region of trabecular bone distal to the 
proximal tibial growth plate. Quantitation of (A) trabecular pattern factor (Tb.Pf), and (B) 
structure model index (SMI) was performed using CTAn (SkyScan). Data are presented as 
mean ± SD, n≥8 per group. *p<0.05, **p<0.01 and ****p<0.001, two-way ANOVA with 












































































































































































































































































































































































































































































































































respectively), and for Rptorob-/- animals at 12 weeks (mean increase 52±14%), compared to 
Osx:Cre controls (Fig. 4.13A; Table 4.6) 
In addition to the changes in trabecular connectivity, the physical structure of the 
trabeculae was also examined. The structure model index (SMI) is used to describe the three-
dimensional structure of the trabeculae, distinguishing between plate-like (SMI=0) and 
spherical (SMI=4) geometry 310. At 4 weeks of age, there was no difference in the SMI between 
the three animal groups. However, at 8 weeks of age, a statistically significant increase in SMI 
was observed in Rptorob-/+ and Rptorob-/- animals (mean increase 19.3±5.5% and 19.8±5.5%, 
respectively), suggesting a shift away from a plate-like trabecular morphology to a spherical 
morphology (Fig. 4.13B). A statistically significant difference in SMI was also seen in Rptorob-
/- animals at 12 weeks of age, compared to Osx:Cre controls (mean change 23.6±5.3%) (Fig. 
4.13B; Table 4.6). 
4.2.14 Reduced cortical bone in Rptorob-/- mice  
The shaft, or diaphyses of the long bones are composed of cortical bone surrounding 
the intramedullary cavity. To assess the effects of OB-specific Rptor deletion on the micro-
architecture of cortical bone, mCT analysis was performed on tibiae from Osx:Cre, Rptorob-/+ 
and Rptorob-/- animals at 4, 8 and 12 weeks of age. As previously described for the trabecular 
bone analyses (see Section 4.2.11), the ROI for cortical bone analysis was normalised to the 
length of the tibia for each animal, to account for differences in the tibiae lengths between 
animal groups (Fig. 4.11A). 
As shown in Figure 4.14A, cross-sectional mCT images demonstrate a visible thinning 
of the cortical bone in Rptorob-/- animals compared to Osx:Cre controls. Quantitation of these 
data confirmed that the average thickness of the cortical bone (Ct.Th) was decreased at 4, 8 and 
12 weeks in Rptorob-/- animals relative to both Osx:Cre controls (mean decrease 31±7.8%, 
28.5±7.3% and 28.6±6%,respectively) and Rptorob-/+ mice (mean decrease 25.8±8.6%, 
28.6±6.9% and 23.08±7.8%, respectively)  (Fig. 4.14B; Table 4.7). Furthermore, at 8 and 12 
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weeks of age, the average intramedullary diameter of the ROI analysed was significantly 
increased in Rptorob-/- animals compared to Osx:Cre controls (mean increase 18.2%±7.2 and 
5.1%±4.4 respectively). Rptorob-/+ animals also displayed a significant increase 
inintramedullary diameter compared to Osx:Cre controls at 12 weeks of age (mean increase 
8.8%±4.8)   (Fig. 4.14C; Table 4.7). 
4.2.15  Reduced rigidity and strength of bone Rptorob-/- mice 
In order to investigate changes in the mechanical properties of the long bones of OB-
specific Rptor KO mice, dynamic three-point bending flexural tests were conducted on femurs 
isolated from 4 week old Osx:Cre, Rptorob-/+ and Rptorob-/- animals. Three-point bending 
analyses test the stiffness and flexibility of the bones. Considering the association between body 
weight and the mechanical properties of bone, animal bodyweight was introduced as a covariate 
during statistical analyses (ANCOVA) of these data. The flexural rigidity (i.e. bending 
stiffness) was calculated from the load-displacement curves using basic beam theory 311. As 
shown in Figure 4.15A (Table 4.8), a significant decrease in the flexural rigidity of long bones 
from Rptorob-/+ and Rptorob-/- animals was observed, compared to Osx:Cre controls (mean 
decrease 71.9%±0.2 and 74.8%±10.1 respectively). Furthermore, a decrease in the amount of 
force the bone was able to withstand before breaking (ultimate load) was also observed in the 
long bones of Rptorob-/- animals compared to Osx:Cre controls (mean decrease 56.3%±10) (Fig. 
4.15B; Table 4.8). 
4.2.16  Altered cranial and facial morphology in Rptorob-/- mice 
While tibial development is facilitated by endochondral ossification, intramembranous 
ossification facilitates the development of the flat bones including the cranial plates. To assess 
the effect of OB-specific Rptor deletion on intramembranous ossification, cranial mCT scans 
were performed on 4-week-old mice and 3D re-constructions of the data were generated using 
Avizo® Fire. As shown in Fig. 4.16B, the skulls of Rptorob-/- animals were visibly malformed 
compared to Osx:Cre controls. Regions of the skull of Rptorob-/- animals appeared incompletely 
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mineralised, especially in the frontal region adjacent to the coronal suture line and in the nasal 
region. Incomplete mineralization was also observed in the lambdoidal and sagittal sutures of 
Rptorob-/- animals. Lateral images derived from 3D reconstructions of the mCT data also 
indicated a change in morphology of the facial structure of Rptorob-/- animals compared to 
Osx:Cre controls (Fig. 4.16D). Of note, incomplete mineralization of the temporal and 
zygomatic bones was evident in Rptorob-/- animals compared to Osx:Cre controls, and their 
mandibles were smaller and displayed an altered morphology (Fig. 4.16 D). 
 
Figure 4.14 - Rptorob-/- mice display reduced cortical thickness and increased 
intramedullary diameter: Tibiae were isolated from male Osx:Cre, Rptorob-/+ and Rptorob-/- 
animals at 4, 8 and 12 weeks of age and µCT analysis of cortical bone distal was analysed in 
the ROI proximal tibial growth plate (ROI as outlined in Figure 4.11). (A) Representative 3D 
mCT reconstructions showing a section of the cortices on the sagittal plane distal to the 
proximal tibial growth plate in the ROI of Osx:Cre, Rptorob-/+ and Rptorob-/-animals at 4, 8 and 
12 weeks of age. Quantitation of (B) cortical thickness (Ct.Th), and (C) intramedullary 
diameter (Im.Dm) was performed using CTAn (SkyScan). Data are presented as mean ± SD, 










































































































































































































































































































































































































































































































































































Figure 4.15 - Reduced long bone strength and flexibility in Rptorob-/- mice : Femurs were 
isolated from male Osx:Cre, Rptorob-/+and Rptorob-/- animals at 4 weeks of age and subjected 
to 3-point load testing using using a materials testing machine (Model 800LE4; 
TestResources Inc, Shakopee MN, USA). Femurs were placed posterior side down on the test 
anvils, which where immersed in a bath of distilled water to keep the bones hydrated. The 
lower span of the anvils was 5.2 mm and the upper and lower contact radii were 1.0 mm. A 
pre-load of 0.5 N was applied to the bones before ramp loading to failure with a constant 
displacement rate of 0.017 mm/s. Compliance in the load-line and bend fixtures was removed 
from the displacement measurement by using a correction factor obtained from tests with an 
aluminium calibration specimen. (A) Flexural rigidity was calculated from the load-
displacement curves using basic beam theory. (B) Ultimate load was taken directly as the 
peak load during the tests. Data are presented as mean ± SD, n≥5 per group. *p<0.05, 
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Figure 4.16 - Rptorob-/- mice display altered craniofacial development: Three-dimensional 
reconstructions of the skull were generated for 4 week old Rptorob-/- and Osx:Cre animals 
using high resolution mCT imaging. (A) A schematic of the basic anatomy of the superior 
view of the skull. (B) Representative 3D mCT images of the skull (superior view) of a 
representative 4 week old Osx:Cre and Rptorob-/- mouse. (C) A schematic of the basic anatomy 
of the lateral view of the skull. (D) Representative 3D mCT images of the skull (lateral view) 
































In this chapter, the role of mTORC1 in skeletal development was assessed by generating 
an OB-specific Rptor knockout mouse model. Following confirmation that the knockout of 
Rptor was specific to the skeleton in these animals, comparative analyses were performed to 
examine the whole body and skeletal consequences of OB-specific Rptor deletion in vivo. 
While global deletion of Rptor confers embryonic lethality, OB-specific Rptor knockout 
mice were viable and born at the expected Mendelian ratios. However, the survival rates of both 
Rptorob-/+ and Rptorob-/- mice were significantly lower than wild type littermates after 52 weeks. 
While the precise reasons this reduction in long term survival remain to be determined, 
abnormal OB function has been associated with a variety of pathological conditions in humans 
including osteogenesis imperfecta, van Buchem Disease and osteoporosis, which require 
therapeutic intervention for extended survival and disease management 312-314.  
As the skeletal phenotype of Osx:Cre embryos has been reported as indistinguishable 
from wild type animals, wildtype littermates have been the standard comparative control in 
Osx:Cre-driven conditional knockout studies 33. However, shortly after the commencement of 
this study, Davey et al. (2011) 315 published a contrasting study reporting that Osx:Cre mice 
have a decrease in body weight and reduced bone acquisition at 6 weeks of age, compared to 
wildtype littermate controls. Therefore, to investigate this further and ascertain which control 
group was the most suitable for this study, a series of comparative studies was performed 
between Osx:Cre mice and wild type controls. These analyses showed that Osx:Cre mice have 
significantly lower body weights than wild type animals at 4, 8 and 12 weeks of age and thinner 
cortical bone compared to wild type littermates at 4 weeks. While these findings were consistent 
with the study by Davey et al 315, intriguingly we did not observe the ‘lag-phase’ in Osx:Cre 
development that they described, whereby the significant differences present during early 
development (6 weeks of age) are overcome by adulthood (12 weeks of age). While the reason 
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for these discrepancies remain unclear, variations could be a result of differences in housing 
conditions and/or the respective breeding colonies. 
More recently, additional studies have emerged detailing a defect in early craniofacial 
bone development 316, delayed calvarial ossification 317 and delayed fracture callus development 
317 in Osx:Cre animals compared to wild type littermates. Collectively, these findings confirm 
the importance of using the correct control to eliminate inaccuracies when reporting the 
phenotype of knockout animals. As the presence of the tTA:OSX:Cre transgene clearly has an 
effect on skeletal development in mice, Osx:Cre animals were deemed to be the most suitable 
control group when characterising the skeletal phenotype of Rptorob-/+ and Rptorob-/- mice and 
were used for all subsequent studies.  
During normal murine embryonic development, the first evidence of skeletal formation 
appears at day E9.5. By day E14.5, the skeletal system has been fully formed and is primarily 
composed of cartilage. This cartilaginous skeleton then undergoes progressive mineralisation 
prior to birth at day E19 35, 318. Osterix expression is detected in utero at E12.5, immediately 
prior to mineralization of the limb buds 90. At birth, whilst the gross morphology of Osx:Cre 
and Rptorob-/- mice were indistinguishable, the cartilage and mineral deposition in bones of 
newborn Rptorob-/- mice showed perturbed skeletal development as evidenced by incomplete 
mineralisation in the ilium and cranium. Furthermore, there was a decrease in both length and 
proportion of mineral in the long bones of newborn Rptorob-/- mice compared to Osx:Cre 
controls. While the exact mechanisms for this observation are currently unknown, IGF 
signalling upstream of mTORC1 may be a contributor. Mice with disruption of IGF1, IGF2 or 
IGF-1R exhibit a similar reduction in body weight and abnormal skeletal development 
consistent with the Rptorob-/- mice 251-253. Furthermore, deletion of IGF-1R in pre-OBs using the 
Osx:Cre driver produced mice that exhibited the same low bone mass and reduced mineral 
deposition rates as seen in Rptorob-/- mice 319.  Finally, recent studies have shown that deletion 
of Rptor in mesenchymal progenitors results in a dramatic decrease in animal size and decreased 
long bone mineralization with a deficit in protein synthesis in chondrocytes leading to a 
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reduction in long bone length 286. These results indicate that while mTORC1 activity in Osx-
expressing cells is not necessary for embryonic survival, it is necessary for proper skeletal 
development in utero. 
To characterise the postnatal skeletal phenotype of OB-specific knockout mice, Rptorob-
/+ and Rptorob-/- mice and Osx:Cre controls were examined at 4, 8 and 12 weeks of age in order 
to assess early, mid and late-stages of bone development and remodelling, respectively. A 
decrease in body weight was observed in Rptorob-/- mice compared to Osx:Cre mice at 4 and 12 
weeks of age, and in Rptorob-/+ mice at both 8 and 12 weeks of age. These data suggest the 
expression of a single Rptor allele in pre-OBs can overcome some of the systemic abnormalities 
associated with Rptorob-/- mice. However, it should be noted that Rptorob-/+ mice have a 
significantly higher body weight compared to Osx:Cre mice at 8 weeks, with no difference 
observed at other time points. While mechanisms for this are unknown, the differences in 
Rptorob-/+ mice could be attributed to phenotypic consequences associated with the gene dose 
effect and gene dosage compensation 320, 321. To date, none of the published studies describing 
conditional Rptor knockouts have reported a heterozygous knockout animal phenotype and 
therefore further studies are required to determine the effects of heterozygous Rptor expression 
in other tissues 240, 241, 322. 
To determine if conditional Rptor deletion caused any major systemic effects, major 
organs including heart, liver, kidneys and spleen were collected and weighed at 4, 8 and 12 
week time points. The analysis of organ weight largely indicated no effects of conditional Rptor 
knockout. However, at 4 weeks Rptorob-/- animals had smaller livers, normalised to total body 
weight, compared to Osx:Cre mice. This reduction was seemingly rectified by 8 weeks and was 
most likely associated with the relative increase in Rptorob-/- animal weight at this time.  
The rate of long bone growth is at its greatest during the period between weaning and 
sexual maturation (approximately week 4 in mice), with growth slowing thereafter and ceasing 
in early adulthood (approximately week 12 in mice) 306. Long bone growth, which occurs via 
endochondral ossification, is facilitated via the chondrocyte-dense epiphyseal growth plates 
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which remain active throughout elongation prior to thinning and fusing following the cessation 
of growth. Previous studies have shown the major downstream mTORC1 substrate, p70S6K to 
be phosphorylated in growth plate chondrocytes suggesting mTORC1 activity during this 
process 286, 323. Additionally, Osx expression in differentiating chondrocytes within the growth 
plate has been identified both pre-natally and post-natally in mice as early as E13.5 324 and Osx 
expression has been shown to overlap with p70S6K activation within the growth plate in E16.5 
– E18.5 embryos 323, 325. As growth plate activity is the principle driving force of longitudinal 
bone growth, differences in thickness were examined in the proximal tibial growth plates of 
Rptorob-/+ and Rptorob-/- mice. Analyses revealed the thickness of the tibial growth plate in 
Rptorob-/- mice was significantly thinner than that of both Rptorob-/+ and Osx:Cre controls at 4 
weeks.  In similar studies, chondrocyte-specific deletion of the negative regulator of mTORC1, 
liver kinase b1 (Lkb1) led to an increase in growth plate thickness 323. Therefore, loss of 
mTORC1 function reduces growth plate thickness which likely contributes to the reduced tibial 
length observed in Rptorob-/- mice relative to Osx:Cre controls. These findings also suggest that 
while the reduced long bone growth is evident at 4 and 8 weeks, this can be overcome by 12 
weeks of age, suggesting an important role for anabolic mTORC1 signalling in rapid phases of 
endochondral ossification. While vertebral growth also occurs via endochondral ossification, 
the formation is less-rapid occurring over a longer period compared to long bone growth. The 
prolonged growth rate of the vertebrae may account for the decreased spinal length in Rptorob-
/- mice, relative to both Osx:Cre and Rptorob-/+ mice, that was evident at 12 weeks whereas tibial 
length had normalized by this time 326. 
Recently, a study by Chen et. al., (2015) was published suggesting that genetic ablation 
of Rptor in osterix-expressing cells led to osteopenia in mice 327. While this initial 
characterisation of OB-specific Rptor-null mice gives insight into a role of mTORC1 in the 
osteogenic program, the results presented are brief and are limited to the assessment of 
homozygous Rptorob-/- knockout mice (i.e. heterozygous Rptor KO mice were not examined), 
and data was presented for only one postnatal time point (i.e. 6 weeks of age). The studies 
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presented in this thesis describe a much more detailed investigation into the phenotypic 
characterizations of OB specific Rptor KO mice. These data presented here indicate that 
trabecular mineralisation in Rptorob-/- mice is reduced in the tibia, as indicated by a decrease in 
the percentage of bone volume (BV/TV), compared to Osx:Cre controls at 4, 8 and 12 weeks 
of age. Decreased BV/TV was also observed in Rptorob-/+ mice in comparison to Osx:Cre at 12 
weeks. Further investigations showed that the decrease in BV/TV in Rptorob-/- mice could be 
attributed to a decrease in the number of trabeculae (Tb.N), coupled with an increase in the 
spacing between the trabeculae (Tb.Sp). This reduction in Tb.N and increase in Tb.Sp is 
consistent with the 6 week findings from Chen et al., 327. However, in contrast to the findings 
published by Chen et al., 327, decreased BV/TV observed at 4, 8 and 12 week time points was 
not attributable to a reduction trabecular thickness (Tb.Th). While trabecular structure was 
consistent between all genotypes at 4 weeks, there was a decrease in trabecular connectivity at 
8 and 12 weeks, as indicated by (i) an increase in Tb.Pf, and (ii) a shift away from a plate-like 
morphology to a spherical morphology at 8 weeks in Rptorob-/+ mice compared to Osx:Cre. 
These results suggest that in OBs, mTORC1 is involved in the formation and maintenance of 
structural integrity of the trabecular micro-architecture. An unexpected observation was made 
at 8 weeks of age, with a significant decrease in BV/TV observed in Rptorob-/- mice compared 
to Rptorob-/+ mice, which was not associated with any differences in structural parameters. 
Furthermore, despite no differences in BV/TV, the structure of the trabeculae in Rptorob-/+ mice 
differed to Osx:Cre mice represented as a decrease in Tb.N at 4 and 12 weeks and an increase 
in Tb.Sp at 4 weeks.  
mCT analysis of the cortical bone within the proximal tibia also revealed a decrease in 
bone formation in Rptorob-/- mice. In addition to the reduced BV/TV of the trabeculae, tibiae of 
Rptorob-/- mice had significantly reduced cortical thickness at all time points examined, 
compared to both Rptorob-/+ and Osx:Cre mice. This was accompanied by an increase in 
intramedullary diameter compared to Osx:Cre at 8 and 12 weeks and Rptorob-/+ mice at 12 
weeks. Riddle et al., (2014) showed that deletion of TSC2 (a negative regulator of mTORC1) 
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caused a progressive increase in postnatal cortical thickness. Furthermore, this excess bone 
phenotype was partially restored in compound mice in which one allele of mTOR was also 
deleted. These data suggest that mTORC1 function in osteoblasts is essential for the 
development and maintenance of long bone diaphyses. Ablation of one allele of Rptor resulted 
in less severe defects than those presented in the double mutation cohort. Nonetheless, the 
skeletal abnormalities in Rptorob-/+ mice reflect the important role mTORC1 plays in these 
processes. 
OB-specific Rptor knockout mice also displayed changes in the biomechanical 
dynamics of the long bones. Three-point bending analyses confirmed that Rptorob-/+ and 
Rptorob-/- mice have more brittle and weak bones compared with Osx:Cre controls. These 
findings are characteristic of an osteoporotic phenotype found in humans which includes a 
decrease in bone mineral content as well as an increase in the rate of fracture caused by brittle 
and inflexible bones 328.  
As indicated by representative 3D-reconstructions of mCT images of the skull, deletion 
of Rptor in pre-osteoblasts resulted in incomplete mineralization of the cranial plates, temporal 
and zygomatic bones and mandiles. Distinct from endochondral ossification, cranial bones 
develop through the process of intramembranous ossification arising without the production of 
a cartilage scaffold through the condensation and osteogenic differentiation of MSCs. OB 
clusters begin synthesizing osteoid which is subsequently mineralized forming spicules that 
grow and fuse to create interconnecting woven bone. Incomplete and reduced mineral was 
observed particularly around the calvarial sutures indicating mTORC1 activity is required for 
normal formation of bones during intramembranous ossification and proper suture fusion. In 
humans, it has been shown that increased IGF signalling in osteoblasts results in 
craniosynostosis, the premature fusion of the cranial plates 329, 330. IGF is a potent activator of 
mTORC1 signalling in bone 319 suggesting the reduction in suture fusion in Rptorob-/- mice may 
be attributable to attenuated IGF-1 signalling in these processes. During the development of the 
jaw, Osx expression is evident in odontoblasts which are responsible for the formation of the 
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teeth 331. While the incidence of malocclusion was similar in Osx:cre and Rptorob-/- mice (data 
not shown), further investigation onto the micro-architecture of the jaw may reveal a role for 
mTORC1 in tooth development.. 
Although results from Chapter 3 indicated that loss of mTORC1 function in primary 
MSCs had a pro-osteogenic effect, the deletion of Rptor in pre-OBs did not reflect this 
observation. Indeed, the low bone mass phenotype of Rptorob-/- mice suggests mTORC1 plays 
an important role in skeletal development. In support of this, mice harbouring a deletion of 
Pten, a negative regulator of PI3kinase, exhibit increased bone mineral density that is associated 
with constitutive mTORC1 activation. Furthermore, Osx:Cre-mediated deletion of Akt1 and 
Akt2 (proteins required for suppression of Tsc1/Tsc2, negative regulators of mTORC1) results 
in delayed bone ossification 166, 260 and shorter lone bones 259. Additionally, OB-specific 
hyperactivity of mTORC1 via both Osx:Cre mediated TSC1 deletion and Ocn:Cre mediated 
TSC2 deletion presented increased bone production 300, 332. Collectively, these studies indicate 
signalling via mTORC1 mediates skeletal formation and bone accrual. While the discrepancies 
between pro-osteogenic effect of Rptor deletion in MSC and the low bone mass phenotype in 
Rptorob-/- mice are not readily apparent, it is possible that this difference is due to mTORC1 
activation during different stages of OB differentiation.  
In summary, the data presented in this chapter shows that OB-specific deletion of Rptor 
in mice results in incomplete mineralisation and altered skeletal formation. Furthermore, a 
significant reduction in the length of long bones and in the level of mineralization in the long 
bones of newborn mice demonstrates an important role for mTORC1 in pre-natal skeletal 
development. Additionally, these data show that deletion of Rptor in pre-OBs leads to defective 
intramembranous and endochondral ossification and a low bone mass phenotype. Collectively, 
these findings highlight an important role for mTORC1 in pre- and post-natal skeletal 
development.  
In the following chapter, changes in the cellular components of bone, which likely 
contribute to the morphological changes evident in Rptorob-/+ and Rptorob-/- mice, were 
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examined. These studies were performed to ascertain whether the low bone mass phenotype of 
OB-specific Rptor knockout animals is due to (i) a decrease in the number of osteoblasts, (ii) a 
reduction in the synthetic potential of osteoblasts (iii) stalled differentiation of pre-osteoblasts 
or (iv) uncoupling of the balance between osteoblast-mediated bone-formation and osteoclast-
mediated bone resorption. 
 
Chapter 5 - Defining the mechanisms leading to 






A key determinant of skeletal integrity is the homeostatic balance between the actions 
of bone-resorbing OCs and bone-forming OBs. This tightly-coupled process is maintained by 
the coordinated actions and cross-talk between OBs and OCs. OBs secrete a number of proteins 
that regulate bone resorption activities of OCs, including M-CSF, RANKL and OPG while 
factors which activate OBs,  including IGF-1, are sequestered in the bone matrix and released 
during OC-mediated bone resorption 55-58. Uncoupling of normal bone remodelling results in 
pathological changes to the skeleton. In osteoporosis, bone mineral density is reduced as the 
result of an imbalance between the rate of resorption and the rate of formation and can be 
accounted for byreduced OB number and activity and increased OC number and activity 3, 4. In 
Paget’s disease, abnormal bone growth occurs as a result of increased bone resorption due to 
increased OC numbers 55, 59. The increase in OC activity increases bone activating factors which 
signal the limited numbers of OBs to rapidly form bone and results in the synthesis of bone 
with poor structural integrity that lacks the strength and shape of normal bone 59.  
In addition to the regulation of OC-mediated bone resorption, bone mass is determined 
by OB maturation and function. Multipotent MSCs within the BM undergo osteogenic 
differentiation in response to various local and systemic factors, which induce the expression 
of transcription factors promoting OB maturation. As discussed previously, osteogenesis 
requires the initial expression of the transcription factor Runx2 which in turn regulates the 
expression of Osterix (Sp7) 87, 90. Furthermore, mature OBs are marked by their synthesis of 
integrin-binding sialoprotein (Ibsp), osteopontin (Spp1) and osteonectin (Sparc) and 
osteocalcin (Bglap) which collectively contribute to both the ECM and mineralised matrices of 
bone. The coordinated and temporal expression of these key markers can be used in the 





mTORC1 is activated by several extracellular factors that control skeletal development. 
Insulin and IGF-1, activators of PI3K/Akt/mTOR signalling indirectly regulate Runx2 by 
down-regulating Twist1 and Twist2, negative regulators of Runx2 that bind and inhibit Runx2 
activity 256, 333. Additionally, insulin signalling inhibits Foxo1-mediated suppression of Runx2 
128, 334. Deletion of the insulin receptor or insulin-like growth factor receptor 1 (Igflr) in OBs 
leads to the development of a post-natal low bone phenotype 319, 335. Furthermore,  studies 
indicate that these pro-osteogenic effects are mediated through mTORC1, as rapamycin 
administration in vitro has been shown to block IGF-1-stimulated osteogenesis 299, 335. BMPs 
including BMP-2 and BMP-4 positively regulate both Runx2 and Osx expression and activity 
via activation of SMAD signalling molecules7, 336, 337 Following stimulation by BMP-2 and 
BMP-7, PI3K/Akt/mTOR signalling is also activated in OBs during osteogenesis in vitro 338, 
339. 
As discussed previously, endochondral ossification facilitates longitudinal growth of 
the long bones via the proliferation and hypertrophy of chondrocytes within the growth plate 36, 
47, 96, 318. During this process, chondrocytes align in a vertical arrangement stratified into 
horizontal layers termed the resting, proliferative and hypertrophic zones 35, 318. During growth, 
anabolic factors stimulate the resting chondrocytes to proliferate in an organised column 
formation in the direction of bone growth. Proliferating chondrocytes then mature into 
hypertrophic chondrocytes which undergo enlargement via both dry mass and liquid uptake. 
Chondrocyte maturation can be marked by the expression lineage specific genes including 
Col2A1, Sox9 as early lineage markers and Mmp13 and Col10A1 as mature markers. As osterix 
expression has been identified within the growth plate in differentiating chondrocytes 324, the 
potential deletion of Rptor in osterix expressing chondrocytes may account for the reduction in 





In Chapter 4, the characterisation of OB-specific raptor KO mice showed that mTORC1 
plays an important role in pre- and post-natal skeletal development. These mice displayed 
perturbed intramembranous and endochondral ossification, skeletal fragility, and reduced long 
bone length. In this Chapter, the mechanisms by which this skeletal phenotype is caused were 
investigated by undertaking prospective histological and immunohistochemical analyses and 






As outlined in Chapter 4, Rptorob-/+ and Rptorob-/- mice display reduced bone volume 
and increased skeletal fragility. As BMD is mediated by the relative contribution of OBs and 
OCs, this low bone mass phenotype is likely indicative of either: (i) a decrease in the number 
and/or activity of bone-forming OBs, or (ii) an increase in the number and/or activity of bone-
resorbing OCs.  
5.2.1 Deletion of Rptor in pre-OBs does not affect OB morphology or OB number. 
To determine whether the low bone mass phenotype of Rptorob-/+ and Rptorob-/- mice is 
due to a change in OB number, histomorphometric analyses were performed on tibiae isolated 
from Osx:Cre, Rptorob-/+ and Rptorob-/- animals 4, 8 and 12 weeks of age. For this, undecalcified, 
formalin-fixed tibiae were embedded in methyl methacrylate and sections stained with 
Toluidine blue. OBs were identified based on their anatomical location on the bone surface and 
their distinct cuboidal morphology. As shown in Figure 5.1A, a visual assessment of OB 
morphology, in a defined region of the secondary spongiosa, revealed no distinct morphological 
differences in OBs in Osx:Cre, Rptorob-/+ and Rptorob-/- mice. Quantitation of the number of 
OBs per bone perimeter (N.Ob/B.Pm) and the number of OBs per intramedullary area 
(N.Ob/M.Ar) was conducted using the OsteoMeasure XP (OsteoMetrics Inc) 
histomorphometric analysis system. These analyses revealed no significant difference in the 
number of OBs lining the bone surface (Fig. 5.1B; Table 5.1) or in the number of OBs per area 
of intramedullary bone surface analysed (Fig. 5.1C; Table 5.1) in Rptorob-/+ and Rptorob-/- 
knockout mice compared to Osx:Cre controls at any of the time points examined. 
5.2.2 Deletion of Rptor in pre-OBs does not affect OC morphology, OC number or 
OC activity 
To determine whether the low bone mass phenotype of Rptorob-/+ and Rptorob-/- mice is 





in tibial specimens from Osx:Cre, Rptorob-/+ and Rptorob-/- animals 4, 8 and 12 weeks of age. 
OCs were identified in a defined region of secondary spongiosa, in toluidine blue-stained tibial 
sections, based on their anatomical location on the bone surface and their multi-nucleated 
morphology (Fig. 5.2A). Quantitative histomorphometric analyses revealed no significant 
difference in the number of OCs lining the bone perimeter (N.OC/B.Pm), nor any significant 
difference in the number of OCs present per intramedullary area (N.OC/M.Ar) in Rptorob-/+ and 
Rptorob-/- mice, compared to Osx:Cre controls, at any of the time points examined (Fig.s 5.2B 
and C; Table 5.2). 
To examine whether OC activity is altered in OB-specific Rptor knockout mice, serum 
levels of tartrate-resistant acid phosphatase (TRAcP5), an established biomarker of OC activity, 
were measured. For this, serum samples were collected from Osx:Cre, Rptorob-/+ and Rptorob-/- 
mice at 4, 8 and 12 weeks of age by cardiac puncture and assayed using a commercial ELISA 
kit. As shown in Figure 5.2D, highly variable TRAcP5 levels were observed within each of the 
animal cohorts, and no statistically significant differences in TRAcP5 levels were observed 
Rptorob-/+ and Rptorob-/- mice compared to Osx:Cre controls at any of the time points examined 
(Fig. 5.2 D). 
5.2.3 OB activity is reduced in Rptorob-/- mice 
As outlined in Sections 5.2.1 and 5.2.2, histological analyses suggest that the low bone 
mass of the OB-specific Rptor knockout animals was not attributable to a change in the number 
of OBs and OCs, nor a change in OC activity. These findings raised the possibility that the low 
bone mass phenotype of these animals was due to changes in OB activity. 
5.2.3.1 The rate of bone formation is reduced Rptorob-/- mice 
To measure OB activity and bone formation during rapid phases of bone growth, 4 week 
old Osx:Cre, Rptorob-/+ and Rptorob-/- mice were subcutaneously injected with calcein  
Figure 5.1 - OB-specific Rptor deletion does not affect OB numbers: Tibiae isolated from 
male Osx:Cre, Rptorob-/+ and Rptorob-/- mice at 4, 8 and 12 weeks of age were embedded in 
methyl methacrylate and 5µm sections were stained with toluidine blue. Osteoblasts were 
identified based on their anatomical location on the bone surface and their distinct cuboidal 
morphology. (A) Representative images of toluidine blue-stained bone sections from 4 week 
old mice highlighting osteoblasts (red arrows) on a section of bone surface (green arrows). 
Bar = 50µm.  (B) Number of osteoblasts per bone perimeter (N.OB/B.Pm). (C) Number of 
osteoblasts per intramedullary area (N.OB/M.Ar). Data represented as mean ± SD, n≥8 per 





































































































































































































































































































































































































































































































































































































Figure 5.2 - OB-specific Rptor deletion does not affect OC number or OC activity: Tibiae 
isolated from male Osx:Cre, Rptorob-/+ and Rptorob-/- mice at 4, 8 and 12 weeks of age were 
embedded in methyl methacrylate and 5µm sections were stained with toluidine blue. 
Osteoclasts were identified based on their location on the bone surface and their morphology. 
(A) Representative images of toluidine blue-stained bone sections highlighting osteoclasts 
(red arrows) on a section of bone surface (green arrows).  Bar = 50µm. (B) Number of 
osteoclasts per bone perimeter (N.OC/B.Pm). (C) Number of osteoclasts per intramedullary 
area (N.OC/M.Ar). Data represented as mean ± SD, n≥8 per group in duplicate. (D) Serum 
levels of the marker of osteoclast activity TRAcP5 (tartrate-resistant acid phosphatase) were 
measured in end-of-study blood samples collected at 4, 8 and 12 weeks of age. Data 






































































































































































































































































































































































































































































































































































































(20mg/gram body weight) at 4 days and 24 hours prior to harvest, to label the exposed bone 
surface. One day after the second injection, tibiae were collected, fixed in 10% formalin and 
embedded in methyl methacrylate. Dynamic measurements of bone formation were then 
conducted on a defined area of the secondary spongiosa using the Osteomeasure XP system. 
As shown in Figure 5.3A, the calcein inter-label distance was visibly thinner in 
Rptorob-/- mice, compared to both Rptorob-/+ and Osx:Cre controls (Fig. 5.3A). Mineral 
apposition rate (MAR), which provides an indication of OB activity, was calculated by 
quantitating the distance between the two calcein-labelled mineralisation fronts and dividing 
this by the time interval between calcein injections. A significant reduction in MAR was 
observed in Rptorob-/- mice compared to both Rptorob-/+ and Osx:Cre controls at 4 weeks of 
age (mean decrease 38.8±8.1% and 36.3±8.3% respectively) (Fig. 5.3B; Table 5.3). The 
reduced MAR in Rptorob-/- mice was associated with a significant reduction in the bone 
formation rate (BFR), the volume of mineralized bone formed per unit time and per unit bone 
surface. BFR was significantly reduced in Rptorob-/- mice relative to both Rptorob-/+ and 
Osx:Cre controls (36.9±5.9% and 39.3±5.7% respectively) at 4 weeks of age (Fig. 5.3C; 
Table 5.3). Newly mineralised bone surface to bone surface ratio (MS/BS) showed no 
significant difference between all genotypes (Fig. 5.3D; Table 5.3). 
To examine the rate of activity of mature OBs in knockout mice, serum levels of 
established biomarkers of bone formation were assessed targeting the OB specific protein 
OCN and P1NP which indicates levels of collagen type 1 synthesis. Serum samples were 
collected from Osx:Cre, Rptorob-/+ and Rptorob-/- mice at 4 weeks of age by cardiac puncture 
and assayed using commercial ELISA kits. As shown in Figure 5.3E, a significant reduction 
in serum OCN levels was observed in both Rptorob-/+ and Rptorob-/- mice compared to Osx:Cre 
controls (mean decrease 49.7±18% and 56.5±16.7% respectively) (Fig. 5.3E). In contrast, no 
statistically significant difference in P1NP levels were observed in Rptorob-/+ and Rptorob-/- 
mice compared to Osx:Cre controls (Fig. 5.3F). 
 
 
Figure 5.3 OB-specific Rptor deletion reduces OB function 
Osx:Cre, Rptorob-/+ and Rptorob-/- animals were analysed for dynamic markers of bone 
formation at 4 weeks of age. Calcein was injected into mice 4 days and 24 hours prior to 
harvest. Undecalcified tibiae were embedded in methyl methacrylate and 5µm sections were 
analysed using fluorescence microscopy. (A) Representative images of calcein double 
labelling in Osx:Cre, Rptorob-/+ and Rptorob-/- mice. The inter-label distance is indicated by red 
arrows. Bar = 30µm. (B) Mineral apposition rate was quantitated from the calcein inter-label 
distance relative to time. (C) Bone formation rate was quantitated from the calcein inter-label 
distance. (D) Mineralised surface to bone surface ratio was quantitated from the calcein inter-
label distance. (E) Serum levels of total osteocalcin were measured in samples collected from 
4 week old Osx:Cre, Rptorob-/- and Rptorob-/+ mice using a commercial ELISA kit. (F) Serum 
levels of P1NP were measured in samples collected from Osx:Cre, Rptorob-/- and Rptorob-/+  
mice at 4 weeks of age using a commercial ELISA kit. Data are presented as mean ± SD, n≥5 













































































































































































































































































































































































































































































































5.2.3.2 OB differentiation marker expression is reduced in Rptorob-/- mouse 
tibia 
To determine whether the reduction in OB function observed in Rptorob-/- mice was due 
to a block in OB differentiation, the expression of markers of OB differentiation was examined 
in tibial sections from Osx:Cre, Rptorob-/+ and Rptorob-/- mice at 4 weeks of age. As shown in  
Figure 5.4A, osterix expression was clearly evident in cells of the primary spongiosa 
immediately adjacent to the zone of hypertrophic chondrocytes in the growth plate of Osx:Cre 
controls, but was not evident in Rptorob-/- sections (Fig. 5.4A). Similarly, osteocalcin 
expression, a marker of mature OBs, was evident in cells of the primary spongiosa in Osx:Cre 
controls but was absent in Rptorob-/- mice (Fig. 5.4A). 
5.2.3.3 OBs derived form Rptorob-/- mice have an immature osteogenic 
transcriptional profile  
To gain further insight into the osteoblastic phenotype of Rptor knockout cells, the 
transcript level of genes associated with different stages of osteogenesis was assessed in eYFP+ 
cells isolated from the long bones of eYFP-Osx:Cre and eYFP-Rptorob-/- mice using real time-
PCR. Expression of Runx2 and Sp7 (osterix), transcription factors essential for the initial stages 
of osteogenesis, were significantly elevated in eYFP+ cells isolated from eYFP-Rptorob-/- mice 
relative to eYFP-Osx:Cre controls (mean fold increase 2.73±0.71 and 2.0±0.27, respectively) 
(Fig. 5.4B). In contrast, mRNA expression of late OB markers such as osteocalcin (Bglap), 
integrin-binding sialoprotein (Ibsp), osteopontin (Spp1), and osteonectin (Sparc) was 
significantly down-regulated in eYFP-Rptorob-/- mice relative to eYFP-Osx:Cre  controls (mean 
decrease:  Bglap: 79±1.5%, Ibsp: 81±4%, Spp1: 60.8± 1.8% and Sparc: 87.9±6%)(Fig. 5.4B). 
5.2.3.4 OBs derived form Rptorob-/- mice have reduced osteogenic potential  
To further assess OB function, calvarial MSCs isolated from Osx:Cre, Rptorob-/+ and 





matrix was assessed. As shown in Figure 5.5A, deletion of Rptor caused a significant reduction 
in mineralised matrix production, as evidenced by reduced alizarin red staining of calcium 
deposits in OBs from Rptorob-/+ and Rptorob-/- mice compared to Osx:Cre controls. Furthermore, 
the level of acid-solubilised calcium and alizarin red staining of calcium deposits in OBs from 
Rptorob-/+ and Rptorob-/- mice was decreased compared to Osx:Cre controls (mean decrease 
41.5±8.5% and 72.8±4.1% respectively). 
In order to gain further insight into the biochemical mechanisms by which mTORC1 
facilitates OB maturation and function, the responsiveness of knockout and control calvarial 
OBs to anabolic factors known to activate mTORC1 340 was assessed. Insulin signalling which 
stimulates osteogenesis, has been shown to signal upstream of mTORC1. Addition of insulin 
to osteogenic cultures of calvarial MSCs from Osx:Cre, Rptorob-/+ and Rptorob-/- mice resulted 
in a significant increase in the amount of mineralised matrix production by Osx:Cre cells 
relative to unstimulated cultures (mean increase 35.8±2.7%). However, no significant 
differences were observed in response to insulin in cells isolated from Rptorob-/+ and Rptorob-/- 
mice (Fig. 5.5B).  
An organotypic culture system was also used to assess bone growth. In this assay, whole 
calvarias isolated from 4-day old control and knockout mice were cultured at the air-liquid 
interface ex vivo in the presence or absence of BMP-2, a potent anabolic factor. After 10 days 
of culture, calvarias were fixed in formalin, decalcified and embedded in paraffin. Quantitation 
of new bone growth in H&E-stained sections cut parallel to the midline suture showed that 
BMP-2 stimulated a significant increase in new bone formation in calvarias isolated from 
Osx:Cre controls (mean increase 37±7.7%), however, no significant anabolic effect was 
observed in calvarias isolated from Rptorob-/+ and Rptorob-/- mice (Fig. 5.5C).  
  
 
Figure 5.4 - Rptor null osteoblasts have an immature osteogenic transcriptional profile : 
(A) Tibiae were isolated from male Osx:Cre and Rptorob-/- mice at 4 weeks of age and 
immunohistological analyses performed on a region of primary spongiosa distal to the 
proximal growth plate. Formalin-fixed tibiae were decalcified, embedded in paraffin, and 
5µm sections were stained with Haematoxylin and Eosin (H&E), and antibodies directed 
against osterix and osteocalcin. Bar = 50µm. (B) eYFP+ cells were isolated from 6 week old 
eYFP-Osx:cre and eYFP-Rptorob-/- mice (n=11 per genotype, pooled) and lysed for total 
RNA. qPCR analyses were performed to measure levels of Runx2, osterix (Sp7), osteocalcin 
(Bglap), integrin-binding sialoprotein (Ibsp), osteopontin (Spp1) and osteonectin (Sparc), and 
data were normalised to β-actin. Data are presented as mean ± SD. *p<0.05, **p<0.01, 











































































































































































Figure 5.5 - Rptor null MSCs have a reduced osteogenic potential: (A) Calvarial MSCs 
isolated from 4 week old male Osx:Cre, Rptorob-/+ and Rptorob-/- mice were cultured under 
osteogenic conditions for 21 days and the amount of acid-solubilised calcium was quantitated 
and normalised to cell number. Data are expressed as the mean ± SD of quadruplicate wells 
from a representative experiment of three. Representative images of Alizarin Red-stained 
wells are shown below the graph. *p<0.05; ***p<0.001, one-way ANOVA with Tukey's post-
hoc test. (B) Cavarial MSCs isolated from Osx:Cre, Rptorob-/+ and Rptorob-/- animals were 
cultured under osteogenic conditions for 21 days in the presence or absence of 10nM insulin, 
and the amount of acid-solubilised calcium was quantitated and normalised to cell number. 
Data are expressed as the mean ± SD of quadruplicate wells from a representative experiment 
of three. *p<0.05 ***p<0.001, one-way ANOVA with Tukey's post-hoc test. (C) Neonatal 
calvariae isolated from 4 day old Osx:Cre, Rptorob-/+  and Rptorob-/- mice were cultured ex 
vivo in the presence or absence of recombinant human BMP-2 (50ng/mL) for 10 days. The 
width of newly-formed bone per bone perimeter (Ir.L.Th/B.Pm) was quantitated using 
histomorphometry. Data are presented as mean ± SD of three independent experiments each 


































































5.2.4 Growth plate analysis 
Longitudinal bone growth is primarily driven by the coordinated proliferation and 
differentiation of chondrocytes. At the growth plate, chondrogenic cells are arranged into 
vertical columns that can be stratified into horizontal layers (zones) corresponding to different 
phases of chondrocyte differentiation 35, 318. These zones are termed the resting zone (RZ), 
proliferative zone (PZ) and hypertropic zone (HZ). 
5.2.4.1 Osx is expressed in growth plate chondrocytes 
Osterix expression has previously been observed in pre-hypertrophic chondrocytes of 
the embryonic 90, 341 and postnatal 342 skeleton. Therefore, the reduction in both growth plate 
thickness and long bone growth could be associated with Rptor deletion in Osx expressing 
chondrocytes.  To confirm OSX expression in chondrocytes of the growth plate, tibiae from 
R26eYFP-Osx:Cre and R26eYFP-Rptorob-/- mice were analysed using confocal microscopy. 
Osx expression was assessed using the ROSA26eYFP reporter gene, whereby eYFP expression 
is activated through Cre mediated deletion of an upstream floxed STOP cassette303. As shown 
in Figure 5.6A, eYFP-labelled chondrogenic cells were detected within the proximal tibial 
growth plate in both eYFP-Osx:Cre control and eYFP-Rptorob-/- mice. 
5.2.4.2 Proliferative- and hypertrophic- zones are smaller in the growth 
plate of Rptorob-/- mice 
To investigate whether the deletion of Rptor in chondrogenic cells could contribute to 
the reduction in limb length observed in Rptorob-/- mice, the morphology of the tibial growth 
plate was analysed using sections in which acidic proteoglycan, present in cartilage tissues, was 
stained red with Safranin O (Fig. 5.6B). In Rptorob-/- mice, chondrocytes within the proliferating 
zone were disorganised with fewer cells arranged into vertical columns relative to Osx:Cre 
controls (Fig. 5.6B). To quantitate any changes in the growth plate of OB-specific KO mice, 
the width of the three chondrocyte zones within the growth plate were measured using  
 
Figure 5.6 - OB-specific Rptor deletion results in decreased thickness of the proliferative 
zone in the growth plate: Tibiae from male Osx:Cre, Rptorob-/+ and Rptorob-/- animals were 
isolated at 4 weeks of age for analysis of the proximal growth plate. (A) Formalin-fixed tibiae 
from eYFP-Osx-cre and eYFP- Rptorob-/- mice were embedded in OCT compound and 5µm 
sections stained with an anti-eYFP antibody. Cell nuclei were stained with DAPI. Confocal 
microscopy was used to detect eYFP expression in the growth plate. Representative images of 
eYFP-labelled cells (green) within the proliferative zone (PZ), hypertrophic zone (HZ), and 
primary spongiosa (PS) of the epiphyseal growth plate are shown. Bar = 50mm. (B) Tibiae 
from male Osx:Cre, Rptorob-/+ and Rptorob-/- mice at 4, 8 and 12 weeks of age were embedded 
in methyl methacrylate and stained with Safranin O and Fast Green. Representative images of 
the growth plate of 4 week old Osx:Cre, Rptorob-/+ and Rptorob-/- mice indicating the resting 
zone (RZ), proliferative zone (PZ), hypertrophic zone (HZ),. Bar = 200mm.  The widths of 
the (C) proliferative zone, (D) resting zone and (E) hypertrophic zone of  the growth plate 
were quantitated using histomorphometry, based on chondrocyte morphology  Data are 
presented as mean ± S.D, n≥6 per group. *p<0.05; **p<0.01; ****p<0.001. One-way 
ANOVA with Tukey's post-hoc test.  
A
C




















































































histomorphometric analysis. At 4 weeks of age, the width of the proliferating zone was 
significantly reduced in both Rptorob-/+ and Rptorob-/- mice (mean decrease 15.7±4% and 
30.3±5% respectively) compared to Osx:Cre controls, however no statistically significant 
differences were observed at the 8 and 12 week time points (Fig. 5.6C; Table 5.4). Furthermore, 
no significant difference in the width of the resting zone (which contains precursor cells which,  
when activated, proliferate and synthesise a cartilagenous matrix) was observed at any of the 
time points examined (Fig. 5.6D). Whilst the width of the hypertrophic zone was significantly 
reduced in both Rptorob-/+ and Rptorob-/- mice (mean decrease 21.6±9.4% and 27.4±5% 
respectively) compared to Osx:Cre controls at 4 weeks of age,  no significant differences were 
observed at the 8 and 12 week time points (Fig. 5.6E). 
5.2.4.3 Deletion of Rptor reduces the proliferation and maturation of 
growth plate chondrocytes in Rptorob-/- mice 
To examine whether the marked reduction in the width of the proliferating and 
hypertrophic zones of the growth plate was attributable to a decrease in chondrocyte 
proliferation, PCNA expression, a nuclear marker of proliferating cells 343 was assessed in 4 
week old Rptorob-/- mice. As shown in Figure 5.7A, PCNA expression was clearly evident in 
chondrocytes within the growth plate of Osx:Cre controls but was otherwise absent in 
chondrocytes in the growth plate of Rptorob-/-  mice.  
To determine if Rptor deletion in osterix-expressing chondrocytes affects chondrocyte 
differentiation, transcript levels of immature and mature chondrocyte markers were assessed in 
RNA isolated from eYFP+ cells recovered from the long bones of control eYFP-Osx:Cre and 
knockout eYFP-Rptorob-/- mice. As shown in Figure 5.7B, no significant difference in the 
expression of early chondrocyte markers Sox9 and Col2a1 (isoform 2) was observed in Rptorob-
/- mice relative to Osx:Cre controls. However, transcript levels of Mmp13 and Col10a1, markers 
of mature and terminally differentiated chondrocytes, were significantly reduced in Rptorob-/-  
 
Figure 5.7 - OB-specific Rptor deletion reduces chondrocyte proliferation and 
maturation: Tibiae from age-matched male Osx:Cre and Rptorob-/- mice at 4 weeks of age 
were isolated for immunohistological and histological analysis of the chondrocytes within the 
proximal growth plate. (A) Representative image of immune-histochemical staining of 
proliferating cell nuclear antigen (PCNA) in the growth plates of Osx:Cre and Rptorob-/- mice. 
The proliferative zone (PZ), hypertrophic zone (HZ), and primary spongiosa (PS) of the 
epiphyseal growth plate are shown. Bar = 50mm. (B) qPCR was performed on RNA extracted 
from eYFP+ cells isolated from control eYFP-Osx:cre and eYFP- Rptorob-/- mice at 4 weeks of 
age using primers specific to the indicated genes. Relative transcript levels were normalised to 
β-actin. *p<0.05, one-way ANOVA with Tukey's post-hoc test. (C) Osx:Cre, Rptorob-/+ and 
Rptorob-/- animals were injected with calcein 4 days and 24 hours prior to harvest at 4 weeks of 
age. Tibiae were embedded in methyl methacrylate and 5µm sections were analysed using 
fluorescence microscopy. The rate of endochondral bone growth was quantitated from the 
average distance between the growth plate and newly-deposited mineral. Data are presented 









































































































































































































































































































































































mice compared to Osx:Cre controls (fold decrease: Mmp13, 3.0±0.55; Col10a1, 
1.4±0.07) (Fig. 5.7B). 
Given the decreased proliferative zone width in the proximal tibial growth plate, the 
effect of OB-specific Rptor deletion on the rate of long bone growth was next assessed in 4 
week old mice. To achieve this, Osx:Cre, Rptorob-/+ and Rptorob-/- mice were subcutaneously 
injected with calcein (20Pg/gram body weight) at 4 days and 24 hours prior to harvest at 4  
weeks of age, to label the exposed bone surface. Using histomorphometric analysis, the rate of 
longitudinal growth per day was determined by measuring the average width of the newly-
formed primary and secondary spongiosa, identified as unstained mineral, distal to the growth 
plate. As shown in Figure 5.7C, a significant reduction in longitudinal growth per day was 
observed in Rptorob-/- mice compared to Osx:Cre controls (mean decrease 43.3±15.4%; Table 
5.5). 
5.2.5 Intramedullary adiposity is increased in Rptorob-/- mice 
During histological assessments of the tibia and femur of Rptorob-/-  mice, it was noted 
that long bones of Rptorob-/- mice contain high levels of intramedullary adipose (as defined by 
the circular, unstained spaces within the intramedullary space) (Fig. 5.8A). To examine this 
further, histological analyses were carried out to quantitate AdC numbers and adipose volume 
in Osx:Cre, Rptorob-/+ and Rptorob-/- mice. For these studies, the number of AdCs as a percentage 
of the intramedullary area (N.AdC/M.Ar) and the area of adipose tissue as a percentage of the 
intramedullary area (AdC.Ar/M.Ar) were quantified in a defined region of secondary spongiosa 
in toluidine blue-stained tibial sections from male Osx:Cre, Rptorob-/+ and Rptorob-/- animals at 
4, 8 and 12 weeks of age. As shown in Figure 5.8B, the number of AdCs as a percentage of the 
intramedullary area was significantly higher in Rptorob-/-  mice relative to both Rptorob-/+ and 
Osx:Cre controls at 4 weeks of age (mean fold increase 1.18±0.46 and 6.64±1.52, respectively) 
(Fig. 5.8B; Table 5.6). Whilst there was a trend towards a higher N.AdC/M.Ar in Rptorob-/+ and  
 
Figure 5.8 - OB-specific Rptor deletion is associated with increased intramedullary 
adipose: Tibiae isolated from male Osx:Cre, Rptorob-/+ and Rptorob-/- mice at 4, 8 and 12 
weeks of age were embedded in methyl methacrylate and 5µm sections were stained with 
toluidine blue. Adipocytes were identified based on their morphology. (A) Representative 
images of toluidine blue-stained bone sections from 4 week old mice highlighting the 
unstained zones representing lipid vacuoles of adipocytes cleared during the fixation process 
(red arrows). Bar = 250mm.  (B) The number of adipocytes per area of intramedullary space 
(N.Adc/M.Ar), (C) the area occupied by adipocyes per number of adipocytes 
(AdC.Ar/N.AdC), and (D) the average adipocyte area (AdC.Ar/AdC.N) was quantified.  Data 
are presented as mean ± S.D, n≥8 per group in duplicate. *p<0.05; **p<0.01 and 










































































































































































































































































































































































































































































































































































































































































































































































































Rptorob-/- animals compared to Osx:Cre controls at 8 weeks, this was not statistically significant 
(Table 5.4). However, at 12 weeks, there was significantly more AdCs in Rptorob-/- animals 
relative to Rptorob-/+ mice (mean fold increase 3.59±1.38) (Fig. 5.8B; Table 5.6). Similarly, the 
area of adipose tissue as a percentage of the intramedullary area was significantly higher in 
Rptorob-/-  mice relative to Rptorob-/+ and Osx:Cre controls at both 4 weeks (mean fold increase 
1.29±0.34 and 6.09±0.99, respectively) and 12 weeks of age (mean fold increase 3.78±1.05 and 
2.14±0.66 respectively) (Fig. 5.8C; Table 5.6).  
To examine whether the increase in intramedullary adiposity was due to an increase in 
the relative size of the AdCs present, the average AdC size was calculated by dividing the total 
AdC area measured by the number of AdCs enumerated (AdC.Ar/AdC.N). As shown in Figure 
5.8D, there was no difference in relative AdC size observed at any of the time points examined 
Intramedullary AdCs in Rptorob-/- mice are not derived from rptor null pre-OBs 
The observed increase in intramedullary adipose in Rptorob-/-  mice suggests that OB-
specific deletion of Rptor either (i) affects the differentiation potential of the MSC pool toward 
the adipogenic lineage, or (ii) that the AdCs arose from trans- or de-differentiation of Rptor 
knock-out cells. To investigate the latter, the origin of the intramedullary AdCs was examined 
using mice bred with the eYFP reporter. Tibial sections from control eYFP-Osx:Cre and eYFP-
Rptorob-/- mice were stained for eYFP and perilipin (an adipocyte integral membrane protein) 
and overlapping signals assessed using 2-colour confocal microscopy. As shown in Figure 
5.9A, only a small proportion of AdCs in the bone marrow of eYFP-Rptorob-/- mice were 
eYFP+perilipin+, suggesting that most of the AdCs did not arise from trans- or de- 
differentiation of Rptor null cells. Of note, eYFP+perilipin+ AdCs were also evident in eYFP-
Osx:Cre controls (data not shown) suggesting osterix expression in an AdC precursor may 





The effect of OB-specific Rptor deletion on the intramedullary MSC pool was next 
assessed by measuring the number of colony unit-fibroblastic (CFU-F) in cell populations 
isolated from the long bones of 4 week old Rptorob-/+, Rptorob-/- and Osx:Cre control mice. CFU-
F assays asses the number of clonogenic cells as an indirect measure of the size of the pool of 
immature MSCs. As shown in Figure 5.9B, there was a visible increase in the number of 
fibroblastic colonies formed from Rptorob-/- MSCs, and enumeration of the number of 
morphologically discreet fibroblastic colonies in serially-diluted cell populations revealed a 
significant increase in CFU-F in Rptorob-/- mice relative to Osx:Cre controls and Rptorob-/+ mice 
(mean fold increase 9.6±4.8 and 5.2±9, respectively)(Fig. 5.9C). 
Figure 5.9 - Increased intramedullary adipose is not caused by transdifferentiation of 
Rptor null pre-osteoblasts: (A) Two-colour confocal microscopy was used to detect 
overlapping eYFP (green) and perilipin (red) staining in frozen tibial sections isolated from 4-
week-old eYFP- Rptorob-/- mice. Nuclei were stained with DAPI . Bar = 20mm. (B) Compact 
bone MSCs were isolated from the long bones of 4 week old Osx:Cre, Rptorob-/+ and Rptorob-/- 
mice and plated at concentrations of 1, 3 and 6 x 105 cells/well in duplicate in 6 well plates 
for CFU-F assays. After 9 days, colonies were stained with toluidine blue. Representative 
images of toluidine blue-stained colonies are shown. (C) The frequency of CFU-F colonies 
per 105 cells plated was enumerated. Data are presented as mean ± S.D. n≥6 per group 
****p<0.0001. one-way ANOVA with Tukey's post-hoc test. 
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5.1 Discussion  
As previously discussed, bone remodelling is tightly-coupled process mediated by two 
specialised cell types; OCs which resorb mineralized bone, and OBs which synthesise new 
bone 30. In diseases, such as osteoporosis, which are characterised by a low bone mass 
phenotype and increased skeletal fragility, this tightly-coupled balance between OBs and OCs 
becomes skewed to favour bone resorption over bone synthesis. Somewhat surprisingly, when 
the number of OBs and OCs were enumerated in the long bones of Osx:Cre, Rptorob-/+ and 
Rptorob-/- mice at 4, 8 and 12 weeks of age, no statistically significant differences were 
observed. Thus, the low bone mass phenotype of OB-specific Rptor KO mice was not 
attributable to a change in the number of OBs or OCs. 
Further examinations also revealed no significant difference in OC activity, as 
evidenced by unchanged TRAcP5 serum levels, suggesting that the low bone mass phenotype 
of OB-specific Rptor KO mice was not caused by an increase in OC-mediated bone 
resorption. In contrast, calcein labelling studies showed that both the mineral apposition rate 
(MAR) and bone formation rate (BFR) were significantly reduced in Rptorob-/- mice relative to 
both Osx:Cre controls and heterozygous KO mice while the percentage of newly mineralised 
surface (MS/BS) was unaffected, demonstrating that deletion of Rptor in pre-OB cells had no 
effect on OB numbers, but significantly affected OB function. This could be associated with 
either a functional defect in the mineralisation capacity of mature OBs and/or a defect in the 
osteogenic differentiation program hindering maturation and subsequent bone synthesis. 
While circulating levels of the early marker of bone formation P1NP 346, a measure of OB-
produced circulating type 1 collagen, were unchanged between the KO mice and Osx:Cre 
controls, both Rptorob-/+ and Rptorob-/- mice had reduced serum levels of OCN 347. This 







have a reduced capacity for the deposition of hydroxyapatite which manifests as a low bone 
mass phenotype due to a stall in OB lineage progression.  
While the precise mechanism leading to the decrease in bone accrual in Rptorob-/- mice 
remains to be determined, suppression of insulin and IGF-1 signalling is likely to play an 
important role. IGF-1 activates the PI3kinase/Akt/mTOR pathway and induces osteogenic 
differentiation in Sca-1+ MSC progenitor cells, which is blocked by rapamycin 319. This 
suggests that the low bone mass phenotype in Rptorob-/- mice could be due in part to impaired 
IGF-1 signalling. In support of this view, addition of insulin to osteogenic cultures derived 
from the calvaria of Rptorob-/- mice failed to promote osteogenesis suggesting that Rptor-
deletion leads to impaired insulin signalling. Similarly, mice in which the insulin receptor is 
deleted in OBs using Ocn:Cre fail to accumulate trabecular bone, however, unlike the present 
study this was due in part to a reduction in OB number and not OB function 256. In addition, 
mice in which the insulin-like growth factor receptor (Igf1r) is deleted in OBs using Osx:Cre 
also have a low bone mass phenotype 319. This low bone mass was not attributable to reduced 
OB numbers but rather a failure of Igf1r null OBs to fully differentiate into mature 
osteocalcin-positive cells.  
In Rptorob-/- mice, OB differentiation appears to be stalled at an early stage of the 
osteogenic program, as evidenced by decreased expression of late OB markers and increased 
expression of Runx2 and Sp7 in eYFP+ cells isolated from eYFP-Rptorob-/- mice compared to 
controls. Runx2 controls OB differentiation by regulating the expression of key OB genes 
including osterix (Sp7) 90, integrin-binding saloprotein (Ibsp), osteopontin (Spp1), osteonectin 
(Sparc) and osteocalcin (Bglap) 91, 92. How the OB differentiation pathway is stalled is 
currently unclear, however, it is likely related to the role played by mTORC1 in controlling 
important cellular functions such as protein translation 348. Suppression of translation in OBs 







program after osterix expression is initiated by Runx2. In support of this, the significant 
reduction in protein synthesis observed in chondrocytes lacking Rptor is thought to account 
for the severe prenatal skeletal phenotype of Prx-1-cre:mTOR and Prx-1-cre:Rptor knockout 
animals 286. 
Recent evidence suggests that correct regulation of mTORC1 activity during 
chondrogenesis is essential for the normal progression of pre-hypertrophic chondrocytes to a 
terminal hypertrophic fate. Deletion of Lkb1, a negative regulator of mTORC1 349, in 
immature chondrocytes using Col2α1-Cre, caused a rapamycin-sensitive expansion of 
immature chondrocytes and formation of enchondroma-like tumors 323. Deletion of mTOR or 
Rptor in the developing head and limb mesenchyme at E9.0, prior to skeletogenesis, using 
Prx-1-cre mice has also been shown to profoundly affect chondrogenesis 286. Most notably, 
mTORC1 is important for the transition of chondrocytes to the hypertrophic program and may 
be involved in the phases of hypertrophy that drive the increase in dry cell mass 50, 286. Given 
the importance of mTORC1 activity in chondrogenesis, deletion of Rptor in osterix-
expressing prehypertrophic chondrocytes may have affected chondrocyte differentiation by 
prematurely terminating mTORC1 activity. Col10a1 and Mmp13 expression was reduced in 
eYFP+ chondrocytes isolated from the long bones of eYFP-Rptorob-/- mice, suggesting fewer 
terminally differentiated chondrocytes are present in Rptorob-/- mice. It was also evident that 
deletion of Rptor in osterix-expressing hypertrophic chondrocytes caused an overall reduction 
in chondrocyte proliferation as measured by a decrease in PCNA expression. Further 
investigation of the role of mTORC1 in chondrogenesis, following the deletion of Rptor in 
immature chondrocytes using Col2α1-Cre mice, would provide important insight into the role 
of Rptor in chondrogenesis. 
Somewhat surprisingly, pre-OB-specific deletion of Rptor caused a significant 







increase in fat deposits was observed at other sites (data not shown). Histological analyses 
revealed an increase in both the of area of adipose tissue and an increase in the number of 
AdCs per intramedullary area in Rptorob-/- mice compared to both Osx:Cre and Rptorob-/+ at 4 
weeks and 12 weeks. Studies have demonstrated factors secreted from AdCs, such as 
adiponectin, leptin and fatty acids, modify the function and proliferation of neighbouring cells 
350-352. It has previously been suggested that the increase in medullary adiposity within the 
osteoporotic skeleton is due to adipogenic factors limiting the commitment of MSC to the OB 
lineage 353. However, due to the stall in OB maturation observed in Rptorob-/- mice, it is also 
probable that these same adipogenic factors result in trans-differentiation of Rptor null pre-
OBs to the adipogenic lineage 354, 355. Immunofluorescence staining of intramedullary AdCs in 
long bone sections from eYFP-Rptorob-/- mice revealed eYFP labelling of only a small 
proportion of AdCs, suggesting that the majority of the AdCs did not arise from trans-
differentiation of eYFP+ cells. Furthermore, eYFP+perilipin+ AdCs were also evident in 
eYFP-Osx:Cre controls (data not shown), suggesting that osterix expression in an AdC 
precursor may account for the dual labelling 344, 345. Furthermore, the frequency of CFU-F was 
increased in the long bones of Rptorob-/- mice, which suggests that loss of mTORC1 function 
in pre-OBs affects the MSC pool. While it remains to be determined, these MSCs maybe a 
source of the increased bone marrow AdCs seen in the Rptorob-/- mice. 
Taken together, these findings suggest that mTORC1 signalling is essential for proper 
skeletal development by driving the differentiation and maturation of OBs. Whilst the exact 
mechanisms by which this occurs remain to be determined, IGF signalling through mTORC1 
is a likely contributor to the maturation and function of both OBs and chondrocytes. Thus, the 
loss of mTORC1 reduces the capacity for these cells to undergo differentiation to become 
mature functioning OBs. 




6.1 General discussion 
Ageing, genetics and environmental factors influence the development and homeostasis 
of bone. These factors contribute to numerous bone-related diseases and co-morbidities, such 
as osteoporosis and osteogeneis imperfecta (OI), resulting in detrimental effects on patient 
health and placing a heavy financial burden on the Australian healthcare system1. While 
numerous studies from the last half century have identified the processes which govern skeletal 
development and homeostasis, therapeutics for bone disease remain limited.  
Commitment of MSCs to the OB lineage is the critical first step in bone formation, and 
is followed by the step-wise maturation of these committed pre-OBs into mature, bone-forming 
OBs. mTORC1 is a key intracellular regulator of skeletal formation and transduces signals from 
extracellular factors such as insulin128, 256, 333, BMPs7, 337 and Wnt ligands 33, 136 to regulate stem 
cell function356-358, MSC commitment, OB differentiation and OB function18, 24, 205, 359. 
However, delineating how mTORC1 regulates these complicated cellular processes has 
remained poorly understood due to limitations in previous investigative methods. The studies 
presented in this thesis provides clear insight into the role of mTORC1 in these processes via 
the utilisation of a novel genetic approach to analyse the role of mTORC1 in MSC commitment 
in vitro as well as the role of mTORC1 in OB maturation and skeletal development in vivo.  
Identifying the role of mTORC1 in MSC function and commitment was achieved via 
the generation of primary MSC populations harbouring deletion of the essential mTORC1 
adaptor protein, raptor. As mTORC1 is a known mediator of cellular proliferation 189, it was 
not surprising that deletion of Rptor reduced in vitro proliferation of MSCs. When cultured 
under adipogenic conditions, RapKO MSCs showed reduced adipogenic potential and reduced 
expression of the essential AdC transcription factor, PPARγ108, 110. These findings support 
previous in vitro studies showing that mTORC1 is essential for adipogenic MSC differentiation 




increased osteogenic capacity and an upregulation of both Runx2 and osterix, both essential 
transcription factors in OB commitment of MSCs. While the pro-osteogenic effect of mTORC1 
inhibition presented in this thesis is supported by several studies 17, 18, 205, over the past two 
decades, evidence has emerged to suggest that inhibition of mTORC1 has an anti-osteogenic 
effect 24, 25, 27. However, the novel in vitro approach applied in this study, via the genetic deletion 
of Rptor in primary MSC populations, overcome many of the deficiencies in the methodologies 
used in previous studies. For the first time, this study provides compelling evidence that 
inhibition of mTORC1 signalling promotes osteogenic MSC commitment, a theory previously 
considered inconclusive (Figure 6.1). 
In keeping with the long-standing theory of a mutually exclusive relationship between 
OB and AdC commitment 121, 123, 360 studies presented in Chapter 3 of this thesis show that 
mTORC1 plays a role in MSC lineage commitment. As shown in this study, and confirmed by 
others, loss of mTORC1 reduces expression of PPARγ in MSC under adipogenic conditions 21, 
23, 203, 293. As expression of PPARγ has been shown to inhibit Runx2 expression and OB 
differentiation 108, 121-123, reduced PPARγ expression, due to loss of mTORC1, could allow for 
upregulation of Runx2-mediated commitment of MSCs toward the osteogenic lineage (Fig. 
6.1).  
In addition, age-related metabolic changes in MSCs are known to negatively influence 
their osteogenic differentiation potential. Previous studies have demonstrated that mTORC1 
inhibition attenuates stem cell aging and mTORC1 activation promotes MSC proliferation and 
cell cycle progression 119, 356-358. Increased cell cycle progression and proliferation results in 
loss of MSC quiescence and stem-ness, which reduces their osteogenic potential 117. Therefore, 
it is likely that loss of mTORC1 serves to retain MSC quiescence, and serves to prime the MSC 
to be responsive to osteogenic induction (Fig 6.1). 
  
Figure 6.1 - mTORC1 regulates MSC lineage commitment: (A) Activation of mTORC1 in 
MSCs sitmulates the upregulation of PPARg driving adipogenic commitment at the expense 
of osteogenic commitment. mTORC1 stimulation promotes cell cycle progression and loss of 
MSC quiescence. (B) Inhibition of mTORC1 in MSCs increases osteogenic commitment 
through downregulation of PPARg resulting in the upregulation of RUNX2. Inhibition of 
mTORC1 possibly increases quiescence and stem-ness of MSCs reducing age-related loss of 





























































































































































































Based on the results from Chapter 3, which showed that loss of mTORC1 in primary 
MSCs mediates an increase in osteogenesis in vitro, it was expected that the OB-specific 
deletion of mTORC1 in a conditional knockout mouse model would show increased 
mineralised bone accrual. However, somewhat surprisingly, the number of mature OBs in 
Rptorob-/- mice was indistinguishable from controls and bone accrual was significantly 
reduced. Consistent with the pro-osteogenic transcriptional profile of RapKO MSCs presented 
in Chapter 3, the levels of Runx2 and Osx expression were elevated in Rptor knockout OBs 
isolated from Rptorob-/- mice. However, these OBs had reduced expression of late stage 
osteogenic markers (including Col1a1, BSP, OPN and OCN), indicating that the reduction in 
bone accrual was due to a stall in OB differentiation and maturation. Mechanistically, 
mTORC1 regulates translation and ribosomal biogenesis, therefore it is likely that suppression 
of translation prevents the translation of essential stage-dependant OB genes stalling pre-OB 
maturation following Osx expression (Figure 6.2).  
Insulin and IGF-1 are established as regulators of OB differentiation via activation of 
the PI3K/AKT/mTOR signalling cascade 164, 198, 256, 340. In established in vitro assays, OBs 
isolated from Rptorob-/- mice failed to respond to insulin, which suggests that disruption of this 
signalling pathway is a likely contributor to the low bone mass phenotype observed in 
Rptorob-/- mice. In support of this theory, mice harbouring a bone-specific deletion of the 
insulin receptor (OB-ΔIR) 319 or global deletion of insulin like growth factor receptor (Igflr-/-
)252 also display a low bone mass phenotype. While this phenotype was attributed to reduced 
OB numbers in OB-ΔIR mice, the low bone phenotype observed in Igflr-/- mice was attributed 
to an inhibition of OB maturation. Furthermore, in vitro analyses indicate that IGF-1-induced 
osteogenesis is lost in MSCs with the addition of rapamycin. These findings indicate the loss 
of mTORC1 disrupts extracellular insulin and IGF-1 cues, which activate the 




bone accrual. Collectively, these findings highlight the essential role of mTORC1 in 
transducing bone-anabolic signals for the progression of pre-OBs to mature OBs. 
Since the commencement of this study, additional insight into the role of mTORC1 
during OB differentiation has emerged from mTORC1 gain-of-function mouse models in both 
pre- OBs332 and mature OBs300. Huang et al.332 employed Osx:Cre mediated deletion of the 
upstream negative regulator of mTORC1, TSC1 (ΔTSC1), which resulted in the 
hyperactivation of mTORC1. Interestingly, the reduced body weight and immature OB 
phenotype observed in Rptorob-/- mice was also present in ΔTSC1 mice. However, several key 
differences between the activation and inhibition models indicate mTORC1 serves to 
modulate the progression of osteogenic differentiation. In support of findings from this thesis, 
Huang et al. concluded that mTORC1 is activated during proliferation in pre-OBs and is 
suppressed during their differentiation. The increase in proliferative capacity was also 
reflected in ΔTSC1 mice, which had increased numbers of OB progenitors, however they 
lacked the proper morphology of mature OBs. Expression of Osx was also reduced, which 
was attributed to the activation of Notch signalling, a negative regulator of Runx2. As 
mentioned previously in Section 1.4.1, commitment of OB progenitors coincides with the 
upregulation of Runx2 and Osx and a conformational progression from the long, thin MSC 
morphology, to the cuboidal OB morphology regardless of functionality. Together, these data 
suggest that mTORC1 remains inactive in early OB differentiation promoting OB lineage 
commitment of MSCs through to the morphological change towards the pre-OB phenotype 
(Fig 6.3). 
As outlined in Chapter 4, a stunted skeletal phenotype and improper skeletal 
patterning was observed in Rptorob-/- mice, compared to controls. This manifested as a 
reduction in trabecular number, which has been subsequently reported by Chen et al 327, and 
reduced cortical thickness. Notably a reduction in OCN levels, the necessary component of 
mineral matrix synthesis, was also observed in Rptorob-/- mice. However, in contrast to  
Figure 6.2 - mTORC1 regulates pre-OB maturation and function: (A) Activation of 
mTORC1 through stimulation of PI3K/Akt signaling cascade regulates the translation of 
osteogenic proteins driving the differential stages required for the maturation of pre-OBs to 
mature, mineral matrix forming OBs. (B) inhibition of mTORC1 in pre-OBs stalls OB 


















































































































































Rptorob-/- mice, observations in ΔTSC1 mice suggest that while displaying low levels 
of OCN, these mice display increased cortical thickness and trabecular number, which was 
attributed to stalled OB maturity. Additionally, while not defined in this study, ΔTSC1 mice 
showed hyperactivation of mTORC1 resulted in more porous bone of poor quality attributed 
to the marked increase in osteoid thickness 332. While not investigated in this study, it is 
possible that mTORC1 is an essential regulator of osteoid synthesis by OBs. Following pre-
OB maturation and prior to mineral matrix deposition, both pre-OBs and mature OBs 
synthesise osteoid providing the scaffold for which bone mineral is formed. Reduced osteoid 
synthesis reduces appositional bone growth of the cortices and reduces trabecular number as 
thinner trabeculae are more readily resorbed by osteoclasts. However, determination of the 
requirement for mTORC1 function in relation to osteoid synthesis remains to be elucidated. 
Due to the prevalence of cells of an immature OB phenotype, the findings from this 
study cannot draw definitive conclusions for the exact role of mTORC1 in mineralised bone 
accrual by mature OBs. However, additional studies published during the course of the PhD 
studies described herein, suggest that mTORC1 is essential for both proper bone formation by 
mature OBs. Notably, deletion of TSC2 (ΔTSC2) in mature osteoblasts (using OCN:Cre), 
which leads to hyperactivation of mTORC1, resulted in increased post-natal cortical thickness 
and trabecular number300 similar to ΔTSC1 mice. ΔTSC2 mice also displayed an 
accumulation of disorganised bone, attributable to increased OB numbers and increased 
osteoid synthesis. However, while the bone formation rate and OCN levels were elevated, 
mineral apposition was not affected in ΔTSC2 mice. Rapamycin administration to ΔTSC1 and 
ΔTSC2 OBs in vitro and to ΔTSC1 mice were shown to rescue impaired OB function, 
suggesting that mTORC1 activation can lead to increased bone accrual. In contrast, Riddle et 
al. showed that mice  
Figure 6.3 - mTORC1 activity during osteogenesis: mTORC1 activity is reduced in MSC 
resulting in increased RUNX2 expression resulting in commitment to the OB lineage. 
mTORC1 remains inactive during early OB differentiation increasing OSX and ALPL 
expression and facilitating conformational changes resulting in cuboidal OB morphology. 
Activation of mTORC1 is required for the maturation of pre-OBs capable of synthesising 
osteoid coinciding with upregulation of BSP and COL1A1. The role of mTORC1 in mature 




















































































































































































































harbouring loss of mTOR in mature OBs (ΔmTOR), through OCN:Cre mediated deletion, 
have reduced trabecular number and bone volume, similar to Rptorob-/- mice300. While ΔmTOR 
targets both mTORC1 and mTORC2, the trabecular bone phenotype of ΔmTOR mice can be 
attributed directly to mTORC1, as subsequent studies have shown that deletion of Rictor in 
mature OBs does not contribute to the tibial bone phenotype 361. Taken together, these 
findings suggest that mTORC1 is essential in normal skeletal development, most likely via 
regulation of osteoid synthesis; while the mechanisms that regulate bone mineralisation 
remain to be elucidated. 
As mentioned in section 1.4, osteocytes are the terminal differentiation stage of OBs and 
play an integral role in the mediation of cues governing bone development and remodelling 62-
65. While not investigated in this study, stalled pre-OB maturation likely affects the presence 
and activity of osteocytes contributing to the distinct Rptorob-/- phenotype. Histological 
assessment of mineral-sequestered osteocytes372 and analyses of markers of mature osteocytes 
(including Dentin matrix protein 1 (DMP-1)373, sclerostin374 and matrix extracellular 
phosphoglycoprotein375) would give further insight into the role of mTORC1 in pre-OB 
maturation contributing to observations presented in Rptorob-/- mice. Furthermore, recent 
studies by Joeng et al (2017)376 have revealed a role for mTORC1 in osteocyte activity via 
Wnt signaling. Utilising Cre-mediated targeting of osteocytes, via Dentin matrix acidic 
protein 1 (Dmp-1:Cre), over-expression of Wnt1 stimulated bone formation and an increase in 
mature OB numbers.  These findings were attributed to activation of mTORC1, as  rapamycin 
administration was able to reverse this effect. Furthermore,  as mTORC1 regulates protein 
translation, Osx:Cre mediated Rptor deletion may affect the production of osteocyte-derived 
factors, such as IGF-1 and nitric oxide, during bone growth and homeostasis62-65. These 
findings highlight the complex role of mTORC1 in multiple aspects of skeletal development 




It should also be noted Osx expression was detected in growth plate chondrocytes of 
Rptorob-/- mice. As a regulator of endochondral ossification, it was concluded that the reduced 
longitudinal tibial growth in Rptorob-/- mice is attributed to the loss of mTORC1 through 
reduced growth plate chondrocyte proliferation. Additionally, reduced MMP13 levels and 
hypertrophic zone width were observed in Rptorob-/- mice, indicating that mTORC1 is 
essential in the normal progression of pre-hypertrophic chondrocytes to a terminal 
hypertrophic fate. In support of these findings, deletion of Lkb1, a negative regulator of 
mTORC1 349, in immature chondrocytes using Col2α1-Cre causes a rapamycin-sensitive 
overgrowth of the proliferative zone 323. Additionally, using Prx-1-cre mice to delete mTOR 
or Rptor in the developing head and limb mesenchyme at E9.0, prior to skeletogenesis, results 
in severe delays chondrocyte hypertrophy 286. In addition to mediating chondrocyte 
proliferation and hypertrophy, evidence shows mTORC1 is essential for the synthesis of 
cartilage matrices. In chapter 5, transcriptional profiling indicated that collagen synthesis was 
reduced in Rptorob-/- cells cultured ex vivo. Notably, a low collagen matrix phenotype was also 
reported by Chen et al. (2014) 286. Moreover, while the growth plate was not specifically 
examined, recent studies examining the effects of chondrocyte-specific deletion of TSC1 in 
the ΔTSC1 mouse model362, showed that mTORC1 activity is necessary for type 1 collagen 
expression in chondrocytes. Yan et. al (2016) showed that hyperactivation of mTORC1 in 
chondrocytes, via Col2a1-cre deletion TSC1 in vivo, resulted in the uncoupling of normal 
chondrocyte proliferation and differentiation. Taken together, these findings indicate that 
mTORC1 is essential in the regulation of chondrocyte activity during endochondral growth. 
Findings from this study, together with others detailed above, indicate that mTORC1 is 
essential in the synthesis of type I collagen. While still speculative, these data provide 
evidence that the low bone mass phenotype is as a result of the requirement for mTORC1 
during osteoid synthesis. While further confirmation is required, this could contribute to the 




and 4 of this thesis. In vivo findings from this study show mTORC1 deletion in pre-OBs 
reduces both trabecular bone formation and cortical thickness. These processes require the 
three-dimensional synthesis of osteoid and mineral accrual which are regulated by systemic 
cues during both development and remodelling. Conversely, in vitro loss of mTORC1 in 
multipotent MSCs promotes osteogenic commitment and increased mineral matrix production 
However, in vitro mineralisation assays are unable to mimic both three-dimensional nature of 
the in vivo environment, or the various systemic cues. Additionally, the adherent nature of 
MSCs and OBs to in vitro culture plates, could negate the necessity for osteoid synthesis. The 
disparities between the in vitro and in vivo results in this thesis, contrast the results of Riddle 
et al300 who showed that deletion of TSC2, reduced the osteogenic potential of MSCs in vitro 
while deletion of TSC2 (ΔTSC2) in mature OBs (using OCN:Cre) resulted in increased post-
natal bone formation, but not mineral apposition300. Riddle et. al concluded that while 
activation of mTORC1 caused increased proliferation, a stall in OB maturation led to a 
reduction in mineralised matrix production in vitro. Collectively, these findings suggest that 
the skeletal phenotype presented in Rptorob-/- mice is a result of mTORC1 activity in the 
synthesis of osteoid. In support of this theory, several subtypes OI in humans, and their 
corresponding mouse models, present a similar bone phenotype to that of Rptorob-/- mice 
caused by mutations to collagen genes313, 363, 364. While this theory remains speculative and 
awaits further investigation, it is tempting to speculate that mTORC1 is an essential 
component in the formation and regulation of osteoid through the synthesis of essential 
collagens. 
6.2 Clinical Significance 
MSC therapies have emerged at the forefront of regenerative medicine, with numerous 
clinical studies described examining their efficacy in the therapies directed at repairing bone 




clinical standards and government regulations required for their use in regenerative medicine, 
remain ill-defined and this in some way due to limitations in current knowledge of 
biochemical regulators that maintain stem-ness and/or promote tissue-specific differentiation. 
The identification of mTORC1 as a regulator of MSC proliferation and differentiation is 
invaluable to developing established protocols for manipulation of MSC populations ex vivo.  
As discussed previously, diseases of the skeleton have detrimental impacts on a 
patient’s physical and mental health and are a significant burden on healthcare systems 
globally. While there are countless effectors of skeletal health, including genetics, age and 
lifestyle; therapies aimed at improving skeletal health are limited. Identifying the role of 
mTORC1 in mediating skeletal formation and health may provide novel drug targets for 
skeletal-related therapies. Furthermore, by identifying mechanisms by which mTORC1 
regulates extracellular signals, insight into mechanisms regulating current bone therapies, 
such as IGF-1 utilised for treatment of paediatric growth failure 368, will allow for further 
regulation of dosage, efficacy and patient suitability for current therapies. 
The identification of mTORC1 as a regulator of both OB and chondrocyte function in 
this study highlights the requirement for caution in the administration of mTORC1 inhibitors. 
Currently, rapamycin (Sirolimus) and the related analogue (Everolimus) are used clinically in 
the treatment of a variety of cancers and as an immunosuppressant to prevent organ transplant 
rejection369. While studies have identified bone sparing effects in rapamycin administration, 
this has been attributed to a reduction in OC bone resorption as opposed to increased bone 
formation236, 370. Nevertheless, additional care should be taken when administering mTORC1 
inhibitors due to the possible bone-related side effects. 
6.3 Future directions 
These studies show that mTORC1 is an essential regulator of MSC lineage commitment 




associated transcription factors and lineage-restricted proteins. More recently, mTORC1 has 
been identified in the regulation of stem cell quiescence and aging 356-358. Loss of MSC stem-
ness, due to aging, results in a reduced capacity for osteogenesis, a known contributor to age-
related bone loss and osteoporosis 3, 4. To examine whether mTORC1 is involved in this 
process and how it regulates MSC commitment by modulating stem cell aging, will require 
the establishment of long-term culture studies in which MSC self-renewal and multi-lineage 
differentiation potential could be measured as a function of the age of the cell.  
Findings presented in this thesis, together with studies that have been published during the 
course of these studies, demonstrate that mTORC1 is a key regulator of collagen synthesis 286, 
371. As speculated in section 6.1, the bone phenotype of Rptorob-/- mice may be attributable to 
the abnormal synthesis of collagens during both endochondral growth and osteoid 
synthesis313, 363, 364. Genetic disorders such, as OI, manifest in abnormal skeletal phenotypes in 
patients. The classification of genetic mutations in COL1A1 are known to attribute to 
improper collagen synthesis in several OI subtypes. Patients harbouring these mutations, and 
the corresponding mouse models, present similar skeletal phenotypes to that seen in the 
Rptorob-/- mice. However, the contribution of genetic mutations in several subtypes of OI have 
yet to be established. This raises the possibility that mutations in mTORC1-related genes may 
contribute to these disorders. Genomic profiling of OI patients would reveal whether the 
skeletal phenotype of OI can, in some way, be attributed to genetic mutations in mTORC1-
related components. Together these findings could provide valuable insight into the diagnoses 
and treatment of OI. 
It remains to be determined whether the low bone mass phenotype observed in Rptorob-/- 
mice is the result of the contribution that mTORC1 makes during mineral matrix synthesis 
and/or related to the stall in OB maturation. Recent gain of function studies 300, 332, are yet to 
resolve whether stalled OB maturation and/or OB function is the cause the low bone mass 




during mineral matrix synthesis, future studies utilising OCN-Cre-mediated deletion of 
Raptor (ie. in which deletion of Rptor is restricted to mature OBs only) would provide vital 
insight into these outstanding questions. Furthermore, future studies utilising Dmp1-Cre-
mediated deletion of Raptor (ie. in which deletion of Rptor is restricted to differentiated 
osteocytes only) to determine the role of mTORC1 in osteocyte-stimulated osteogenesis. 
6.4  Concluding Remarks 
In summary, this study has revealed a novel role for mTORC1 in both MSC fate 
determination and osteogenesis, in that mTORC1 function must be switched off to allow for 
MSC commitment to the osteogenic lineage but is subsequently required for the progression 
of the osteogenic program from the pre-osteoblast stage to the mature osteoblast stage. As 
outlined in Figure 6.1, loss of mTORC1 signalling in MSC increases OB differentiation 
potential, at the expense of AdC differentiation, via both suppression of PPARγ expression 
and maintenance of MSC stem-like properties. Furthermore, while deletion of Rptor in pre-
OBs allows for a shift in the OB morphology, OBs are unable to mature and function 
resulting in abnormal skeletal development (fig 6.3). 
Together, these findings give new insight into the role of mTORC1 in MSCs and skeletal 
development. This knowledge will assist in the development of future therapeutic strategies 
and diagnostic approaches to improve patient outcome through the identification of new drug 
targets and the understanding of possible side effects of current mTORC1 inhibition therapies. 
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